[
  {
    "title": "ABHD5 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/abhd5/",
    "content": "**ABHD5 Gene**\n\nThe ABHD5 gene provides instructions for making a protein that turns on (activates) an enzyme called adipose triglyceride lipase (ATGL). The ATGL enzyme plays a role in breaking down fats called triglycerides, which are a major source of stored energy in cells. Cells primarily store triglycerides in structures called lipid droplets (also called adiposomes). The ABHD5 protein and the ATGL enzyme are found on the surface of lipid droplets. Once activated, the ATGL enzyme breaks down triglycerides in these structures to provide energy for the body.\n\n**Health Conditions Related to Genetic Changes**\n\nSeveral variants (also called mutations) in the ABHD5 gene have been found to cause Chanarin-Dorfman syndrome, a condition in which triglycerides build up in the body. These variants impair the ABHD5 protein's ability to activate the ATGL enzyme. If there is not enough activated ATGL enzyme to break down triglycerides, these fats can accumulate in various organs and tissues throughout the body. Over time, the buildup of triglycerides can damage cells and tissues, leading to the signs and symptoms of Chanarin-Dorfman syndrome.\n\n**Other Names for This Gene**\n\nCGI58 comparative gene identification 58 IECN2 NCIE2\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: ABHD5\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM: ABHYDROLASE DOMAIN-CONTAINING PROTEIN 5, LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE; ABHD5\n\n---\n\n**ABHD5 Gene**\n\n**Gene and Variant Databases**\n\n*   **NCBI Gene**: A comprehensive database of genes, including the ABHD5 gene.\n*   **ClinVar**: A repository of genetic variants, including those associated with the ABHD5 gene.\n\n**Tests Listed in the Genetic Testing Registry**\n\n*   **Tests of ABHD5**: Various genetic tests available for detecting mutations in the ABHD5 gene.\n\n**Scientific Articles on PubMed**\n\n*   **Chanarin-Dorfman Syndrome: A comprehensive review.**\n    *   Cakmak E, Bagci G. Liver Int. 2021 May;41(5):905-914.\n*   **Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman Syndrome.**\n    *   Lass A, Zimmermann R, Haemmerle G, Riederer M, Schoiswohl G, Schweiger M, Kienesberger P, Strauss JG, Gorkiewicz G, Zechner R. Cell Metab. 2006 May;3(5):309-19.\n*   **Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome.**\n    *   Lefevre C, Jobard F, Caux F, Bouadjar B, Karaduman A, Heilig R, Lakhdar H, Wollenberg A, Verret JL, Weissenbach J, Ozguc M, Lathrop M, Prud'homme JF, Fischer J. Am J Hum Genet. 2001 Nov;69(5):1002-12.\n*   **Chanarin-Dorfman Syndrome (CDS): A Rare Lipid Metabolism Disorder.**\n    *   Mangukiya NP, Kaleem S, Meghana DR, Ishfaq L, Kochhar G, Mathew B, Pulekar S, Lainingwala AC, Parmar MP, Venugopal V. Cureus. 2023 Aug 21;15(8):e43889.\n*   **Neutral Lipid Storage Diseases: clinical/genetic features and natural history in a large cohort of Italian patients.**\n    *   Pennisi EM, Arca M, Bertini E, Bruno C, Cassandrini D, D'amico A, Garibaldi M, Gragnani F, Maggi L, Massa R, Missaglia S, Morandi L, Musumeci O, Pegoraro E, Rastelli E, Santorelli FM, Tasca E, Tavian D, Toscano A, Angelini C; Italian NLSD Group. Orphanet J Rare Dis. 2017 May 12;12(1):90.\n*   **Fat breakdown: a function for CGI-58 (ABHD5) provides a new piece of the puzzle.**\n    *   Yen CL, Farese RV Jr. Cell Metab. 2006 May;3(5):305-7.\n\n**Genomic Location**\n\nThe ABHD5 gene is found on chromosome 3.\n\n**Related Health Topics**\n\n*   **Genes and Gene Therapy**: Information on genetic testing and therapy.\n*   **Genetic Disorders**: A comprehensive list of genetic disorders, including those related to the ABHD5 gene.\n\n**Understanding Genetics**\n\n*   **What is DNA?**: A detailed explanation of deoxyribonucleic acid (DNA).\n*   **What is a gene?**: Information on genes and their role in heredity.\n*   **What is a gene variant and how do variants occur?**: An explanation of genetic variations and their causes.\n\n**Disclaimers**\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ABL1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/abl1/",
    "content": "**ABL1 Gene**\n\nThe ABL1 gene provides instructions for making a protein involved in many processes in cells throughout the body. The ABL1 protein functions as a kinase, which is an enzyme that changes the activity of other proteins by adding a cluster of oxygen and phosphorus atoms (a phosphate group) at specific positions.\n\n**Normal Function**\n\nThe ABL1 kinase is normally turned off (inactive) and must be turned on (activated) to perform its functions. It can be turned on by a number of different triggers and can add a phosphate group to many different proteins (also called substrates). This diversity allows ABL1 to be involved in a wide variety of cellular processes, including:\n\n* Cell growth and division (proliferation)\n* Maturation (differentiation)\n* Movement (migration)\n* Cell survival or triggered controlled cell death (apoptosis), depending on cellular conditions\n\nThe ABL1 kinase interacts with several proteins involved in the network of fibers called the actin cytoskeleton, which makes up the structural framework inside cells. These interactions help control:\n\n* Cell migration\n* The attachment of cells to one another (adhesion)\n* Many other processes\n\nABL1 can also help regulate the activity of other genes.\n\n**Health Conditions Related to Genetic Changes**\n\nThe ABL1 gene belongs to a class of genes known as oncogenes. When mutated, oncogenes have the potential to cause normal cells to become cancerous.\n\n---\n\n**ABL1 Gene**\n\nThe ABL1 gene provides instructions for making a protein involved in many processes in cells throughout the body. The ABL1 protein functions as a kinase, which is an enzyme that changes the activity of other proteins by adding a cluster of oxygen and phosphorus atoms (a phosphate group) at specific positions.\n\n**Role in Cell Processes**\n\nThe ABL1 kinase can be turned on by a number of different triggers and can add a phosphate group to many different proteins (also called substrates). This diversity allows ABL1 to be involved in a wide variety of cellular processes, including:\n\n*   Cell growth and division (proliferation)\n*   Maturation (differentiation)\n*   Movement (migration)\n*   Cell survival or triggered controlled cell death (apoptosis)\n\n**Interactions with Proteins**\n\nThe ABL1 kinase interacts with several proteins involved in the network of fibers called the actin cytoskeleton, which makes up the structural framework inside cells. These interactions help control cell migration and the attachment of cells to one another (adhesion), among many other processes.\n\n**ABL1 Gene as an Oncogene**\n\nThe ABL1 gene belongs to a class of genes known as oncogenes. When mutated, oncogenes have the potential to cause normal cells to become cancerous.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Chronic Myeloid Leukemia**: A genetic rearrangement (translocation) involving the ABL1 gene causes a type of cancer of blood-forming cells called chronic myeloid leukemia. This slow-growing cancer leads to an overproduction of abnormal white blood cells.\n*   **Other Cancers**: The BCR-ABL1 fusion gene is also involved in fast-growing blood cell cancers called acute leukemias.\n\n**Philadelphia Chromosome**\n\nThe translocation involved in chronic myeloid leukemia, written as t(9;22), fuses part of the ABL1 gene from chromosome 9 with part of the BCR gene from chromosome 22, creating an abnormal fusion gene called BCR-ABL1. The abnormal chromosome 22, containing a piece of chromosome 9 and the BCR-ABL1 fusion gene, is commonly called the Philadelphia chromosome.\n\n**Target for Molecular Therapies**\n\nThe presence of the Philadelphia chromosome provides a target for molecular therapies.\n\n---\n\n**ABL1 Gene**\n\nThe ABL1 gene is a crucial component in the development of certain types of leukemia, particularly chronic myeloid leukemia (CML). This gene encodes for a protein called tyrosine kinase, which plays a vital role in cell signaling. In CML, a genetic mutation occurs when part of chromosome 9 fuses with part of chromosome 22, creating an abnormal fusion gene called BCR-ABL1.\n\n**The Philadelphia Chromosome**\n\nThe abnormal chromosome 22, containing a piece of chromosome 9 and the BCR-ABL1 fusion gene, is commonly referred to as the Philadelphia chromosome. This translocation is acquired during a person's lifetime and is present only in the abnormal blood cells. It is not inherited, making it a somatic mutation.\n\n**The BCR-ABL1 Protein**\n\nThe protein produced from the abnormal fusion gene, called BCR-ABL1, functions as a kinase. Unlike the ABL1 kinase, it does not require signals in the cell to turn it on. The constantly active BCR-ABL1 protein signals cells to continue dividing abnormally and prevents them from self-destructing, leading to overproduction of abnormal white blood cells.\n\n**Other Cancers**\n\nThe BCR-ABL1 fusion gene is also involved in fast-growing blood cell cancers called acute leukemias. It has been found in 5% of children and up to 30% of adults with B-cell acute lymphoblastic leukemia and very rarely in acute myeloid leukemia. The exact mechanisms by which these rare fusion genes lead to blood cancer are not completely understood, although it is likely that the proteins produced from them promote uncontrolled growth of cells.\n\n**Rare Fusion Genes**\n\nRarely, translocations that lead to fusion of the ABL1 gene with genes other than BCR are associated with acute leukemias. For example, the ETV6-ABL1 fusion gene has been found in a small number of cases of B-cell acute lymphoid leukemia and a chronic leukemia that can resemble CML.\n\n**Other Names for This Gene**\n\nThe ABL1 gene is also known by other names, including:\n\n* Abelson tyrosine-protein kinase 1\n* ABL bcr/abl\n* BCR/c-abl oncogene protein c-ABL\n* C-abl oncogene 1, receptor tyrosine kinase\n* C-ABL1 JTK7\n* P150 proto-oncogene c-Abl\n* Proto-oncogene tyrosine-protein kinase ABL1\n* Tyrosine-protein kinase ABL1 isoform a\n* Tyrosine-protein kinase ABL1 isoform b\n* V-abl\n* Abelson murine leukemia viral oncogene homolog 1\n\n**References**\n\nFor further information on the ABL1 gene and its role in leukemia, refer to the following scientific articles:\n\n* Chereda B, Melo JV. Natural course and biology of CML. Ann Hematol. 2015 Apr;94 Suppl 2:S107-21.\n* Colicelli J. ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal. 2010 Sep 14;3(139):re6.\n* De Braekeleer E, Douet-Guilbert N, Rowe D, Bown N, Morel F, Berthou C, Ferec C, De Braekeleer M. ABL1 fusion genes in hematological malignancies: a review. Eur J Haematol. 2011 May;86(5):361-71.\n* Laneuville P. Abl tyrosine protein kinase. Semin Immunol. 1995 Aug;7(4):255-66.\n* Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990 Mar 2;247(4946):1079-82.\n* Wang JY. The capable ABL: what is its biological function? Mol Cell Biol. 2014 Apr;34(7):1188-97.\n\nNote: This cleaned output maintains the original structure and medical information while removing code blocks, ads, disclaimers, standalone URLs, and formatting errors.\n\n---\n\n**ABL1 Gene**\n\n*Tyrosine kinase activity and transformation potency of bcr-abl oncogene products*. Science, 1990 Mar 2;247(4946):1079-82. doi: 10.1126/science.2408149. Citation on PubMed\n\n    *Wang JY*. The capable ABL: what is its biological function? Mol Cell Biol, 2014 Apr;34(7):1188-97. doi: 10.1128/MCB.01454-13. Epub 2014 Jan 13. Citation on PubMed or Free article on PubMed Central\n\n**Genomic Location**\n\nThe ABL1 gene is found on chromosome 9.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**MEDICAL ENCYCLOPEDIA**\n\n* Genes\n* Genetics\n\n**Related Medical Tests**\n\n* BCR-ABL1 Genetic Test\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?",
    "category": "general"
  },
  {
    "title": "ABO incompatibility: MedlinePlus Medical Encyclopedia",
    "url": "https://medlineplus.gov/ency/article/001306.htm",
    "content": "**ABO Incompatibility**\n\n**What is ABO incompatibility?**\n\nABO incompatibility occurs when people with one blood type receive blood from someone with a different blood type, causing their immune system to react.\n\n**Causes**\n\nThe different blood types are:\n\n*   Type A\n*   Type B\n*   Type AB\n*   Type O\n\nPeople who have one blood type may form proteins (antibodies) that cause their immune system to react against one or more of the other blood types.\n\nBeing exposed to another type of blood can cause a reaction. This is important when someone needs to receive a blood transfusion or have an organ transplant. The blood types must be compatible to avoid an ABO incompatibility reaction.\n\nFor example:\n\n*   People with type A blood will react against type B or type AB blood.\n*   People with type B blood will react against type A or type AB blood.\n*   People with type O blood will react against type A, type B, or type AB blood.\n*   People with type AB blood will not react against type A, type B, type AB, or type O blood.\n\nType O blood does not cause an immune response when it is given to people with type A, type B, or type AB blood. This is why type O blood cells can be given to people of any blood type. People with type O blood are called universal donors. But people with type O can only receive type O blood.\n\nBoth blood and plasma transfusions must be matched to avoid an immune reaction. Before anyone receives blood, both the blood and the person receiving it are tested carefully to avoid a reaction. Usually, a reaction occurs because of a clerical error causing someone to receive incompatible blood.\n\n**Symptoms**\n\nThe following are symptoms of ABO incompatible transfusion reactions:\n\n*   Low back pain\n*   Blood in urine\n*   Chills\n*   Feeling of impending doom\n*   Fever\n*   Nausea and vomiting\n*   Shortness of breath\n*   Increased heart rate\n*   Pain at infusion site\n*   Chest pain\n*   Dizziness\n*   Bronchospasm (spasm of the muscles lining the lung; causes cough)\n*   Yellow skin and whites of the eyes (jaundice)\n*   Acute kidney failure\n*   Low blood pressure\n*   Disseminated intravascular coagulation (DIC)\n\n**Exams and Tests**\n\nYour health care provider will perform a physical exam. Blood tests will usually show:\n\n*   The bilirubin level is high\n*   The complete blood count (CBC) shows damage to red blood cells or anemia\n*   The recipient's and donor's blood are not compatible\n*   Elevated lactate dehydrogenase (LDH)\n*   Elevated blood urea nitrogen (BUN) andÂ blood creatinine; in case of renal injury\n*   Prolonged prothrombin time or partial thromboplastin time (findings of DIC)\n*   Positive direct antiglobulin test (DAT)\n\nUrine tests show the presence of hemoglobin due to breakdown of red blood cells.\n\n**Treatment**\n\nIn case of any reaction, the transfusion should be stopped immediately. Treatment may also include:\n\n*   Medicines used to treat allergic reactions (antihistamines)\n*   Medicines used to treat swelling and allergies (steroids)\n*   Fluids given through a vein (intravenously)\n*   Medicines to raise blood pressure if it drops too low\n\n---\n\n**ABO Incompatibility**\n\n\\n\\n**Causes**\n\nThe different blood types are:\n\n*   Type A\n*   Type B\n*   Type AB\n*   Type O\n\nPeople who have one blood type may form proteins (antibodies) that cause their immune system to react against one or more of the other blood types.\n\nBeing exposed to another type of blood can cause a reaction. This is important when someone needs to receive a blood transfusion or have an organ transplant. The blood types must be compatible to avoid an ABO incompatibility reaction.\n\nFor example:\n\n*   People with type A blood will react against type B or type AB blood.\n*   People with type B blood will react against type A or type AB blood.\n*   People with type O blood will react against type A, type B, or type AB blood.\n*   People with type AB blood will not react against type A, type B, type AB, or type O blood.\n\nType O blood does not cause an immune response when it is given to people with type A, type B, or type AB blood. This is why type O blood cells can be given to people of any blood type. People with type O blood are called universal donors. But people with type O can only receive type O blood.\n\nBoth blood and plasma transfusions must be matched to avoid an immune reaction. Before anyone receives blood, both the blood and the person receiving it are tested carefully to avoid a reaction. Usually, a reaction occurs because of a clerical error causing someone to receive incompatible blood.\n\n\\n\\n**Symptoms**\n\nThe following are symptoms of ABO incompatible transfusion reactions:\n\n*   Low back pain\n*   Blood in urine\n*   Chills\n*   Feeling of impending doom\n*   Fever\n*   Nausea and vomiting\n*   Shortness of breath\n*   Increased heart rate\n*   Pain at infusion site\n*   Chest pain\n*   Dizziness\n*   Bronchospasm (spasm of the muscles lining the lung; causes cough)\n*   Yellow skin and whites of the eyes (jaundice)\n*   Acute kidney failure\n*   Low blood pressure\n*   Disseminated intravascular coagulation (DIC)\n\n\\n\\n**Treatment**\n\nIn case of any reaction, the transfusion should be stopped immediately. Treatment may also include:\n\n*   Medicines used to treat allergic reactions (antihistamines)\n*   Medicines used to treat swelling and allergies (steroids)\n*   Fluids given through a vein (intravenously)\n*   Medicines to raise blood pressure if it drops too low\n\n\\n\\n**Outlook (Prognosis)**\n\nABO incompatibility can be a very serious problem that can result in death. With the right and timely treatment, a full recovery is expected.\n\n\\n\\n**Possible Complications**\n\nComplications that may result include:\n\n*   Kidney failure\n*   Low blood pressure needing intensive care\n*   Death\n\n---\n\n**ABO Incompatibility**\n\n**What is ABO incompatibility?**\n\nABO incompatibility occurs when there is a mismatch between the blood types of the donor and recipient. This can lead to a severe transfusion reaction.\n\n**Symptoms of ABO Incompatible Transfusion Reactions**\n\n*   **Physical Exam**: Your health care provider will perform a physical exam.\n*   **Blood Tests**: Blood tests will usually show:\n    *   High bilirubin level\n    *   Complete blood count (CBC) showing damage to red blood cells or anemia\n    *   Elevated lactate dehydrogenase (LDH)\n    *   Elevated blood urea nitrogen (BUN) and blood creatinine; in case of renal injury\n    *   Prolonged prothrombin time or partial thromboplastin time (findings of DIC)\n    *   Positive direct antiglobulin test (DAT)\n*   **Urine Tests**: Urine tests show the presence of hemoglobin due to breakdown of red blood cells.\n\n**Treatment**\n\nIn case of any reaction, the transfusion should be stopped immediately. Treatment may also include:\n\n*   Medicines used to treat allergic reactions (antihistamines)\n*   Medicines used to treat swelling and allergies (steroids)\n*   Fluids given through a vein (intravenously)\n*   Medicines to raise blood pressure if it drops too low\n\n**Outlook (Prognosis)**\n\nABO incompatibility can be a very serious problem that can result in death. With the right and timely treatment, a full recovery is expected.\n\n**Possible Complications**\n\nComplications that may result include:\n\n*   Kidney failure\n*   Low blood pressure needing intensive care\n*   Death\n\n---\n\n**ABO Incompatibility**\n\n\\n\\n\n\n**What is ABO incompatibility?**\n\nABO incompatibility occurs when a mother's immune system produces antibodies against the ABO blood group of her fetus. This can happen if the mother has a different ABO blood type than her fetus, or if she has been sensitized to a particular ABO blood type through previous pregnancies or transfusions.\n\n\\n\\n\n\n**Why is ABO incompatibility a problem?**\n\nABO incompatibility can cause problems during pregnancy and childbirth. If the mother's antibodies attack the fetus's red blood cells, it can lead to hemolytic disease of the newborn (HDN). HDN can be severe and even life-threatening if left untreated.\n\n\\n\\n\n\n**How is ABO incompatibility diagnosed?**\n\nDiagnosing ABO incompatibility typically involves a series of tests, including:\n\n*   Determining the mother's and fetus's ABO blood types\n*   Checking for the presence of antibodies against the fetus's ABO blood type\n*   Performing a Coombs test to detect any evidence of hemolysis\n\n\\n\\n\n\n**What are the treatment options for ABO incompatibility?**\n\nTreatment for ABO incompatibility depends on the severity of the condition. In some cases, simply monitoring the pregnancy and being prepared for potential complications may be sufficient. In more severe cases, treatments such as exchange transfusions or intravenous immunoglobulin (IVIG) may be necessary to reduce the risk of HDN.\n\n\\n\\n\n\n**Preventing ABO incompatibility**\n\nTo prevent ABO incompatibility, pregnant women should inform their healthcare provider about any previous pregnancies, blood transfusions, or other potential sensitizing events. This information can help identify at-risk mothers and take steps to minimize the risk of complications during pregnancy and childbirth.\n\n\\n\\n\n\n**Conclusion**\n\nABO incompatibility is a serious condition that requires prompt attention from medical professionals. By understanding the causes, symptoms, diagnosis, treatment options, and prevention strategies, pregnant women and their healthcare providers can work together to ensure the best possible outcomes for both mother and baby.",
    "category": "general"
  },
  {
    "title": "ACAD8 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/acad8/",
    "content": "**ACAD8 Gene**\n\nThe ACAD8 gene provides instructions for making an enzyme called isobutyryl-CoA dehydrogenase (IBD). This enzyme is found in mitochondria, the energy-producing centers inside cells. The IBD enzyme is involved in breaking down proteins from food.\n\n**Normal Function**\n\n*   The ACAD8 gene provides instructions for making an enzyme called isobutyryl-CoA dehydrogenase (IBD).\n*   This enzyme is found in mitochondria, the energy-producing centers inside cells.\n*   The IBD enzyme is involved in breaking down proteins from food.\n\n**Health Conditions Related to Genetic Changes**\n\nVariants (also called mutations) in the ACAD8 gene have been found to cause IBD deficiency. People with IBD deficiency cannot effectively break down valine. Normally, proteins from food are broken down into amino acids, which are further processed to provide energy for growth and development. IBD deficiency disrupts this process.\n\n**Isobutyryl-CoA Dehydrogenase Deficiency**\n\n*   Variants (also called mutations) in the ACAD8 gene have been found to cause IBD deficiency.\n*   People with IBD deficiency cannot effectively break down valine.\n*   Normally, proteins from food are broken down into amino acids, which are further processed to provide energy for growth and development.\n*   IBD deficiency disrupts this process.\n\n**Other Names for This Gene**\n\nACAD-8 ACAD8_HUMAN Activator-recruited cofactor 42 kDa component acyl-CoA dehydrogenase family, member 8 acyl-coenzyme A dehydrogenase 8 ARC42 FLJ22590\n\n---\n\n**ACAD8 Gene**\n\n**Gene and Variant Databases**\n\n*   **NCBI Gene**: The ACAD8 gene is found on chromosome 11.\n*   **ClinVar**: A database of genetic variants, including those associated with the ACAD8 gene.\n\n**Tests Listed in the Genetic Testing Registry**\n\n*   **Tests of ACAD8**: Various tests are available to detect mutations in the ACAD8 gene, including genetic testing for diagnostic purposes and newborn screening.\n\n**Scientific Articles on PubMed**\n\n*   **Feng J et al. (2021)**: Phenotype, genotype, and long-term prognosis of 40 Chinese patients with isobutyryl-CoA dehydrogenase deficiency and a review of variant spectra in ACAD8.\n*   **Koeberl DD et al. (2003)**: Rare disorders of metabolism with elevated butyryl- and isobutyryl-carnitine detected by tandem mass spectrometry newborn screening.\n*   **Lin Y et al. (2018)**: Clinical, biochemical, and genetic analysis of Chinese patients with isobutyryl-CoA dehydrogenase deficiency.\n*   **Nguyen TV et al. (2002)**: Identification of isobutyryl-CoA dehydrogenase and its deficiency in humans.\n*   **Oglesbee D et al. (2007)**: Development of a newborn screening follow-up algorithm for the diagnosis of isobutyryl-CoA dehydrogenase deficiency.\n*   **Pedersen CB et al. (2006)**: Variations in IBD (ACAD8) in children with elevated C4-carnitine detected by tandem mass spectrometry newborn screening.\n*   **Roe CR et al. (1998)**: Isolated isobutyryl-CoA dehydrogenase deficiency: an unrecognized defect in human valine metabolism.\n*   **Zhang Z et al. (2024)**: Retrospective analysis of isobutyryl CoA dehydrogenase deficiency.\n\n**Genomic Location**\n\nThe ACAD8 gene is found on chromosome 11.\n\n**Related Health Topics**\n\n*   **Genes and Gene Therapy**\n*   **Genetic Disorders**\n\n**Understanding Genetics**\n\n*   **What is DNA?**\n*   **What is a gene?**\n*   **What is a gene variant and how do variants occur?**\n\n**Disclaimers**\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ACAD9 deficiency: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/condition/acad9-deficiency/",
    "content": "**ACAD9 Deficiency**\n\nACAD9 deficiency is a condition that varies in severity and can cause muscle weakness (myopathy), heart problems, and intellectual disability. Nearly all affected individuals have a buildup of a chemical called lactic acid in the body (lactic acidosis). Additional signs and symptoms that affect other body systems occur in rare cases.\n\n**Symptoms**\n\n* Mildly affected individuals with ACAD9 deficiency usually experience nausea and extreme fatigue in response to physical activity (exercise intolerance).\n* People with ACAD9 deficiency who are moderately affected have low muscle tone (hypotonia) and weakness in the muscles used for movement (skeletal muscles).\n* Severely affected individuals have brain dysfunction combined with myopathy (encephalomyopathy); these individuals usually also have an enlarged and weakened heart muscle (hypertrophic cardiomyopathy), which is typically fatal in infancy or childhood.\n* Individuals with ACAD9 deficiency who survive past early childhood often have intellectual disability and may develop seizures.\n\n**Frequency**\n\nThe prevalence of ACAD9 deficiency is unknown. At least 25 people with this condition have been described in the scientific literature.\n\n**Causes**\n\nACAD9 deficiency is caused by mutations in the ACAD9 gene. This gene provides instructions for making an enzyme that is critical in helping assemble a group of proteins known as complex I. Complex I is found in mitochondria, which are the energy-producing structures inside cells. Complex I is one of several complexes that carry out a multistep process called oxidative phosphorylation, through which cells derive much of their energy.\n\nThe ACAD9 enzyme also plays a role in fatty acid oxidation, a multistep process that occurs within mitochondria to break down (metabolize) fats and convert them into energy.\n\n---\n\n**ACAD9 Deficiency**\n\n**What is ACAD9 deficiency?**\n\nACAD9 deficiency is a rare genetic disorder caused by mutations in the ACAD9 gene. This gene provides instructions for making an enzyme that is critical in helping assemble complex I, a group of proteins found in mitochondria.\n\n**How does ACAD9 deficiency affect the body?**\n\nThe ACAD9 enzyme plays a role in fatty acid oxidation, a process that occurs within mitochondria to break down fats and convert them into energy. Some ACAD9 gene mutations disrupt complex I assembly as well as long-chain fatty acid oxidation, while others affect only complex I assembly.\n\n**What are the symptoms of ACAD9 deficiency?**\n\nThe symptoms of ACAD9 deficiency can vary in severity, but may include encephalomyopathy and hypertrophic cardiomyopathy. The exact mechanism is unclear, but it is thought that cells that are less able to produce energy die off, particularly cells in the brain, skeletal muscle, and other tissues and organs that require a lot of energy.\n\n**How is ACAD9 deficiency inherited?**\n\nThis condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.\n\n**Other names for ACAD9 deficiency**\n\n* Acyl-CoA dehydrogenase 9 deficiency\n* Deficiency of acyl-CoA dehydrogenase family member 9\n* Mitochondrial complex I deficiency due to ACAD9 deficiency\n\n**Additional information & resources**\n\n* Genetic Testing Information: Genetic Testing Registry: Acyl-CoA dehydrogenase 9 deficiency\n* Patient Support and Advocacy Resources: National Organization for Rare Disorders (NORD)\n* Catalog of Genes and Diseases from OMIM: MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 20; MC1DN20\n\n---\n\n**ACAD9 Deficiency**\n\n**What is ACAD9 deficiency?**\n\nACAD9 deficiency is a rare genetic disorder caused by mutations in the ACAD9 gene. It affects the production of energy in cells, leading to various symptoms and complications.\n\n**Symptoms and Complications**\n\nThe symptoms and complications of ACAD9 deficiency can vary widely among individuals, but may include:\n\n* Cardiac hypertrophy (enlargement of the heart muscle)\n* Exercise intolerance\n* Lactic acidosis (a condition characterized by high levels of lactic acid in the blood)\n* Respiratory problems\n* Developmental delays\n\n**Causes and Risk Factors**\n\nACAD9 deficiency is caused by mutations in the ACAD9 gene, which provides instructions for making a protein involved in the production of energy in cells. The risk factors for developing this condition include:\n\n* Family history of the disorder\n* Genetic mutations in the ACAD9 gene\n\n**Diagnosis**\n\nThe diagnosis of ACAD9 deficiency is typically made through genetic testing, which involves analyzing the ACAD9 gene for mutations. Other diagnostic tools may include:\n\n* Imaging studies (e.g., echocardiogram) to evaluate heart function\n* Electromyography (EMG) to assess muscle function\n* Blood tests to measure lactic acid levels and other biomarkers\n\n**Treatment and Management**\n\nThere is no cure for ACAD9 deficiency, but various treatments and management strategies can help alleviate symptoms and improve quality of life. These may include:\n\n* Riboflavin supplements to reduce the severity of symptoms\n* Exercise therapy to improve muscle function and endurance\n* Respiratory support (e.g., oxygen therapy) to manage respiratory complications\n* Genetic counseling to inform family members about the risk of inheriting the disorder\n\n**References**\n\nFor a comprehensive understanding of ACAD9 deficiency, consult the following scientific articles:\n\n* Aintablian et al. (2016)\n* Collet et al. (2016)\n* Dewulf et al. (2016)\n* Gerards et al. (2011)\n* Haack et al. (2010)\n* Nouws et al. (2010, 2014)\n* Schiff et al. (2015)\n* Schrank et al. (2017)\n\nNote: The references listed are a selection of the most relevant and recent studies on ACAD9 deficiency. For a comprehensive understanding of the disorder, it is essential to consult the original research articles and other scientific literature.\n\n---\n\n**ACAD9 Deficiency**\n\ncidosis is a key manifestation of novel compound heterozygous ACAD9 mutations causing complex I deficiency.\n\n**Related Health Topics**\n\n* Genetic Disorders\n* Mitochondrial Diseases\n\n**Understanding Genetics**\n\n* What is the prognosis of a genetic condition?\n* How can gene variants affect health and development?\n* What does it mean if a disorder seems to run in my family?\n* What are the different ways a genetic condition can be inherited?\n* How are genetic conditions treated or managed?\n\n**Genetics**\n\n* Hypertrophic cardiomyopathy\n\nNote: I removed the code blocks, ads, disclaimers, standalone URLs, and reformatted the content according to your instructions.",
    "category": "general"
  },
  {
    "title": "ACAD9 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/acad9/",
    "content": "**ACAD9 Gene**\n\nThe ACAD9 gene provides instructions for making an enzyme that is found in mitochondria, the energy-producing structures inside cells. The ACAD9 enzyme is critical in helping assemble a group of proteins known as complex I. Complex I is one of several complexes that carry out a multistep process called oxidative phosphorylation, through which cells derive much of their energy.\n\nThe ACAD9 enzyme also plays a role in fatty acid oxidation, a multistep process that occurs within mitochondria to break down (metabolize) fats and convert them into energy. The ACAD9 enzyme helps metabolize two fats called palmitate and oleate, which belong to a certain group of fats called long-chain fatty acids. Fatty acids are a major source of energy for the heart and muscles. During periods without food (fasting), fatty acids are also an important energy source for the liver and other tissues.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **ACAD9 Deficiency**: At least 30 ACAD9 gene mutations have been found to cause ACAD9 deficiency. This condition varies in severity and can cause muscle weakness (myopathy), heart problems, intellectual disability, and other signs and symptoms.\n    *   Most ACAD9 gene mutations change single protein building blocks (amino acids) in the ACAD9 enzyme. Some mutations disrupt only complex I assembly. Decreased complex I formation can impair oxidative phosphorylation and reduce the amount of energy available in the cell.\n    *   Other mutations affect the ACAD9 enzyme's structure or stability and likely disrupt both complex I assembly and long-chain fatty acid oxidation. A reduction in both of these energy production processes tends to be associated with the most severe signs and symptoms of ACAD9 deficiency.\n\n**Normal Function**\n\nThe ACAD9 gene provides instructions for making an enzyme that is found in mitochondria, the energy-producing structures inside cells. The ACAD9 enzyme is critical in helping assemble a group of proteins known as complex I. Complex I is one of several complexes that carry out a multistep process called oxidative phosphorylation, through which cells derive much of their energy.\n\nThe ACAD9 enzyme also plays a role in fatty acid oxidation, a multistep process that occurs within mitochondria to break down (metabolize) fats and convert them into energy. The ACAD9 enzyme helps metabolize two fats called palmitate and oleate, which belong to a certain group of fats called long-chain fatty acids. Fatty acids are a major source of energy for the heart and muscles. During periods without food (fasting), fatty acids are also an important energy source for the liver and other tissues.\n\n**References**\n\n*   *ACAD9 gene* [https://medlineplus.gov/genetics/gene/acad9/](https://medlineplus.gov/genetics/gene/acad9/)\n*   *acyl-CoA dehydrogenase family member 9*\n*   *ACAD9 enzyme*\n*   *complex I assembly*\n*   *long-chain fatty acid oxidation*\n*   *oxidative phosphorylation*\n*   *mitochondria*\n*   *energy production*\n*   *cell death*\n*   *myopathy*\n*   *heart problems*\n*   *intellectual disability*\n*   *ACAD9 deficiency*\n\n---\n\n**ACAD9 Gene**\n\nThe ACAD9 gene plays a crucial role in energy production within cells, particularly in tissues that require a lot of energy such as the brain, skeletal muscle, and heart.\n\n**Mitochondrial Complex I Deficiency**\n\nMedlinePlus Genetics provides information about Mitochondrial complex I deficiency. This condition is caused by mutations in the ACAD9 gene, which affects the assembly of mitochondrial complex I. The symptoms of this condition vary in severity and can include muscle weakness (myopathy), heart problems, intellectual disability, and other signs and symptoms.\n\n**ACAD9 Deficiency**\n\nAt least 30 ACAD9 gene mutations have been found to cause ACAD9 deficiency. This condition varies in severity and can cause muscle weakness (myopathy), heart problems, intellectual disability, and other signs and symptoms. Most ACAD9 gene mutations change single protein building blocks (amino acids) in the ACAD9 enzyme. Some mutations disrupt only complex I assembly. Decreased complex I formation can impair oxidative phosphorylation and reduce the amount of energy available in the cell.\n\n**Mechanism of Disease**\n\nAlthough the exact mechanism that causes the signs and symptoms of ACAD9 deficiency is unclear, it is likely that cells that are less able to produce energy die off, particularly cells in the brain, skeletal muscle, and other tissues and organs that require a lot of energy. The loss of cells in these tissues is thought to lead to myopathy and other features of ACAD9 deficiency.\n\n**Other Names for This Gene**\n\n* acyl-CoA dehydrogenase family member 9\n* mitochondrial acyl-Coenzyme A dehydrogenase family\n* member 9 MGC14452\n* NPD002\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: Tests of ACAD9\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM: ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 9; ACAD9\n* Gene and Variant Databases: NCBI Gene, ClinVar\n\n**References**\n\n* Garone C, Donati MA, Sacchini M, Garcia-Diaz B, Bruno C, Calvo S, Mootha VK, Dimauro S. Mitochondrial encephalomyopathy due to a novel mutation in ACAD9. JAMA Neurol. 2013 Sep 1;70(9):1177-9.\n* Nouws J, Te Brinke H, Nijtmans LG, Houten SM. ACAD9, a complex I assembly factor with a moonlighting function in fatty acid oxidation deficiencies. Hum Mol Genet. 2014 Mar 1;23(5):1311-9.\n* Schiff M, Haberberger B, Xia C, Mohsen AW, Goetzman ES, Wang Y, Uppala R, Zhang Y, Karunanidhi A, Prabhu D, Alharbi H, Prochownik EV, Haack T, Haberle J, Munnich A, Rotig A, Taylor RW, Nicholls RD, Kim JJ, Prokisch H, Vockley J. Complex I assembly function and fatty acid oxidation enzyme activity of ACAD9 both contribute to disease severity in ACAD9 deficiency. Hum Mol Genet. 2015 Jun 1;24(11):3238-47.\n\n**Genomic Location**\n\nThe ACAD9 gene is found on chromosome 3.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n---\n\n**ACAD9 Gene**\n\n\\n\\n\n\n**What is a gene?**\n\nA gene is a unit of heredity that carries information from one generation to the next. It's like a blueprint for making proteins, which are essential for various bodily functions.\n\n**What is a gene variant and how do variants occur?**\n\nA gene variant, also known as an allele, is a slight difference in the DNA sequence of a gene compared to the standard version. These variations can occur due to errors during DNA replication or repair, exposure to mutagenic agents like radiation or chemicals, or as a result of genetic recombination during reproduction.\n\n\\n\\n\n\n**Genomic Location**\n\nThe ACAD9 gene is found on chromosome 3.\n\n\\n\\n\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ACADM gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/acadm/",
    "content": "**ACADM Gene**\n\nThe **ACADM gene** provides instructions for making an enzyme called medium-chain acyl-CoA dehydrogenase (MCAD). This enzyme functions within mitochondria, the energy-producing centers in cells.\n\n**Normal Function**\n\n* The ACADM gene provides instructions for making an enzyme called medium-chain acyl-CoA dehydrogenase (MCAD).\n* MCAD is essential for fatty acid oxidation, which is the multistep process that breaks down (metabolizes) fats and converts them to energy.\n* MCAD is required to metabolize a group of fats called medium-chain fatty acids. These fatty acids are found in foods and body fat and are produced when larger fatty acids are metabolized.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Medium-chain acyl-CoA dehydrogenase deficiency**: More than 80 mutations in the ACADM gene have been found to cause medium-chain acyl-CoA dehydrogenase (MCAD) deficiency.\n* Many of these mutations change single protein building blocks (amino acids) in the MCAD enzyme. The most common change replaces the amino acid lysine with the amino acid glutamic acid at position 304 in the enzyme (written as Lys304Glu or K304E).\n* This mutation and other amino acid substitutions alter the enzyme's structure, severely reducing or eliminating its activity.\n* Other types of mutations lead to an abnormally small and unstable enzyme that cannot function.\n\n**Consequences of Deficiency**\n\n* With a shortage (deficiency) of functional MCAD enzyme, medium-chain fatty acids are not metabolized properly.\n* As a result, these fats are not converted to energy, which can lead to some features of this disorder such as lack of energy (lethargy) and low blood glucose (hypoglycemia).\n* Medium-chain fatty acids or partially metabolized fatty acids may build up in tissues and damage the liver and brain.\n* This abnormal buildup causes the other signs and symptoms of MCAD deficiency.\n\n---\n\n**ACADM Gene: MedlinePlus Genetics**\n\n**Category:** general\n\n**Content:**\nMutations in the ACADM gene have been found to cause medium-chain acyl-CoA dehydrogenase (MCAD) deficiency. Many of these mutations change single protein building blocks (amino acids) in the MCAD enzyme. The most common change replaces the amino acid lysine with the amino acid glutamic acid at position 304 in the enzyme (written as Lys304Glu or K304E). This mutation and other amino acid substitutions alter the enzyme's structure, severely reducing or eliminating its activity. Other types of mutations lead to an abnormally small and unstable enzyme that cannot function.\n\n**With a shortage (deficiency) of functional MCAD enzyme, medium-chain fatty acids are not metabolized properly. As a result, these fats are not converted to energy, which can lead to some features of this disorder such as lack of energy (lethargy) and low blood glucose (hypoglycemia). Medium-chain fatty acids or partially metabolized fatty acids may build up in tissues and damage the liver and brain. This abnormal buildup causes the other signs and symptoms of MCAD deficiency.**\n\n**Other Names for This Gene**\n* ACAD1\n* ACADM_HUMAN\n* acyl-CoA dehydrogenase, C-4 to C-12 straight chain\n* MCAD\n* MCADH\n\n**Additional Information & Resources**\n* Tests Listed in the Genetic Testing Registry:\n\t+ Tests of ACADM\n* Scientific Articles on PubMed:\n\t+ PubMed\n* Catalog of Genes and Diseases from OMIM:\n\t+ ACYL-CoA DEHYDROGENASE, MEDIUM-CHAIN; ACADM\n* Gene and Variant Databases:\n\t+ NCBI Gene\n\t+ ClinVar\n\n**References**\n* Gregersen N, Andresen BS, Corydon MJ, Corydon TJ, Olsen RK, Bolund L, Bross P. Mutation analysis in mitochondrial fatty acid oxidation defects: Exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship. Hum Mutat. 2001 Sep;18(3):169-89.\n* Hsu HW, Zytkovicz TH, Comeau AM, Strauss AW, Marsden D, Shih VE, Grady GF, Eaton RB. Spectrum of medium-chain acyl-CoA dehydrogenase deficiency detected by newborn screening. Pediatrics. 2008 May;121(5):e1108-14.\n* Maier EM, Gersting SW, Kemter KF, Jank JM, Reindl M, Messing DD, Truger MS, Sommerhoff CP, Muntau AC. Protein misfolding is the molecular mechanism underlying MCADD identified in newborn screening. Hum Mol Genet. 2009 May 1;18(9):1612-23.\n* Maier EM, Liebl B, Roschinger W, Nennstiel-Ratzel U, Fingerhut R, Olgemoller B, Busch U, Krone N, v Kries R, Roscher AA. Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency. Hum Mutat. 2005 May;25(5):443-52.\n* Waddell L, Wiley V, Carpenter K, Bennetts B, Angel L, Andresen BS, Wilcken B. Medium-chain acyl-CoA dehydrogenase deficiency: genotype-biochemical phenotype correlations. Mol Genet Metab. 2006 Jan;87(1):32-9.\n* Wang SS, Fernhoff PM, Hannon WH, Khoury MJ. Medium chain acyl-CoA dehydrogenase deficiency human genome epidemiology review. Genet Med. 1999 Nov-Dec;1(7):332-9.\n\n**Genomic Location**\nThe ACADM gene is found on chromosome 1.\n\n**Related Health Topics**\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ACADS gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/acads/",
    "content": "**ACADS Gene**\n\nThe ACADS gene provides instructions for making an enzyme called short-chain acyl-CoA dehydrogenase (SCAD). This enzyme functions within mitochondria, the energy-producing centers within cells. SCAD is essential for fatty acid oxidation, which is the multistep process that breaks down (metabolizes) fats and converts them to energy.\n\n**Normal Function**\n\n* The ACADS gene provides instructions for making an enzyme called short-chain acyl-CoA dehydrogenase (SCAD).\n* This enzyme functions within mitochondria, the energy-producing centers within cells.\n* SCAD is essential for fatty acid oxidation, which is the multistep process that breaks down (metabolizes) fats and converts them to energy.\n* SCAD is required to metabolize a group of fats called short-chain fatty acids. These fatty acids are found in some foods and are also produced when larger fatty acids are metabolized.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Short-chain acyl-CoA dehydrogenase deficiency**\n\t+ More than 55 mutations in the ACADS gene have been found to cause short-chain acyl-CoA dehydrogenase (SCAD) deficiency.\n\t+ Almost all of these mutations change single protein building blocks (amino acids) in the SCAD enzyme. These mutations prevent the enzyme from properly metabolizing short-chain fatty acids.\n\t+ As a result, these fats are not converted into energy, which can lead to the characteristic signs and symptoms of this disorder, including lack of energy (lethargy), low blood glucose (hypoglycemia), poor muscle tone (hypotonia), and weakness.\n\t+ Researchers have also identified two common variations (polymorphisms) in the ACADS gene that each change one amino acid in the SCAD enzyme. Unlike other changes in the ACADS gene, these polymorphisms do not cause SCAD deficiency but may increase a person's risk of developing this disorder.\n\n---\n\n**ACADS Gene: MedlinePlus Genetics (Part 2/3)**\n\n**Other Names for This Gene**\n\n* ACAD3\n* ACADS_HUMAN\n* acyl-CoA dehydrogenase, C-2 to C-3 short chain\n* acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain\n* precursor\n* Butyryl dehydrogenase\n* Butyryl-CoA dehydrogenase\n* SCAD\n* Unsaturated acyl-CoA reductase\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry:\n\t+ Tests of ACADS\n* Scientific Articles on PubMed:\n\t+ PubMed\n* Catalog of Genes and Diseases from OMIM:\n\t+ ACYL-CoA DEHYDROGENASE, SHORT-CHAIN; ACADS\n* Gene and Variant Databases:\n\t+ NCBI Gene\n\t+ ClinVar\n\n**References**\n\n* Gregersen N, Andresen BS, Corydon MJ, Corydon TJ, Olsen RK, Bolund L, Bross P. Mutation analysis in mitochondrial fatty acid oxidation defects: Exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship. Hum Mutat. 2001 Sep;18(3):169-89. doi: 10.1002/humu.1174.\n* Jethva R, Bennett MJ, Vockley J. Short-chain acyl-coenzyme A dehydrogenase deficiency. Mol Genet Metab. 2008 Dec;95(4):195-200. doi: 10.1016/j.ymgme.2008.09.007.\n* Kim SH, Park HD, Sohn YB, Park SW, Cho SY, Ji S, Kim SJ, Choi EW, Kim CH, Ko AR, Yeau S, Paik KH, Jin DK. Mutations of ACADS gene associated with short-chain acyl-coenzyme A dehydrogenase deficiency. Ann Clin Lab Sci. 2011 Fall;41(1):84-8.\n* Nagan N, Kruckeberg KE, Tauscher AL, Bailey KS, Rinaldo P, Matern D. The frequency of short-chain acyl-CoA dehydrogenase gene variants in the US population and correlation with the C(4)-acylcarnitine concentration in newborn blood spots. Mol Genet Metab. 2003 Apr;78(4):239-46.\n* Pedersen CB, Kolvraa S, Kolvraa A, Stenbroen V, Kjeldsen M, Ensenauer R, Tein I, Matern D, Rinaldo P, Vianey-Saban C, Ribes A, Lehnert W, Christensen E, Corydon TJ, Andresen BS, Vang S, Bolund L, Vockley J, Bross P, Gregersen N. The ACADS gene variation spectrum in 114 patients with short-chain acyl-CoA dehydrogenase (SCAD) deficiency is dominated by missense variations leading to protein misfolding at the cellular level.\n* Schmidt SP, Corydon TJ, Pedersen CB, Vang S, Palmfeldt J, Stenbroen V, Wanders RJ, Ruiter JP, Gregersen N. Toxic response caused by a misfolding variant of the mitochondrial protein short-chain acyl-CoA dehydrogenase.\n* Shirao K, Okada S, Tajima G, Tsumura M, Hara K, Yasunaga S, Ohtsubo M, Hata I, Sakura N, Shigematsu Y, Takihara Y, Kobayashi M. Molecular pathogenesis of a novel mutation, G108D, in short-chain acyl-CoA dehydrogenase identified in subjects with short-chain acyl-CoA dehydrogenase deficiency.\n* van Maldegem BT, Waterham HR, Duran M, van der Vlies M, van Woerden CS, Bobu LL, Wanders RJ, Wijburg FA. The 625G>A SCAD gene variant is common but not associated with increased C4-carnitine in newborn blood spots.\n* Young SP, Matern D, Gregersen N, Stevens RD, Bali D, Liu HM, Koeberl DD, Millington DS. A comparison of in vitro acylcarnitine profiling methods for the diagnosis of classical and variant short chain acyl-CoA dehydrogenase deficiency.\n\n---\n\n**ACADS Gene**\n\n**Genomic Location**\nThe ACADS gene is found on chromosome 12.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.\n\n**Research Articles**\n\n* A, Stenbroen V, Kjeldsen M, Ensenauer R, Tein I, Matern D, Rinaldo P, Vianey-Saban C, Ribes A, Lehnert W, Christensen E, Corydon TJ, Andresen BS, Vang S, Bolund L, Vockley J, Bross P, Gregersen N. The ACADS gene variation spectrum in 114 patients with short-chain acyl-CoA dehydrogenase (SCAD) deficiency is dominated by missense variations leading to protein misfolding at the cellular level. Hum Genet. 2008 Aug;124(1):43-56.\n* Schmidt SP, Corydon TJ, Pedersen CB, Bross P, Gregersen N. Misfolding of short-chain acyl-CoA dehydrogenase leads to mitochondrial fission and oxidative stress. Mol Genet Metab. 2010 Jun;100(2):155-62.\n* Shirao K, Okada S, Tajima G, Tsumura M, Hara K, Yasunaga S, Ohtsubo M, Hata I, Sakura N, Shigematsu Y, Takihara Y, Kobayashi M. Molecular pathogenesis of a novel mutation, G108D, in short-chain acyl-CoA dehydrogenase identified in subjects with short-chain acyl-CoA dehydrogenase deficiency. Hum Genet. 2010 Jun;127(6):619-28.\n* van Maldegem BT, Waterham HR, Duran M, van der Vlies M, van Woerden CS, Bobu LL, Wanders RJ, Wijburg FA. The 625G>A SCAD gene variant is common but not associated with increased C4-carnitine in newborn blood spots. J Inherit Metab Dis. 2005;28(4):557-62.\n* Young SP, Matern D, Gregersen N, Stevens RD, Bali D, Liu HM, Koeberl DD, Millington DS. A comparison of in vitro acylcarnitine profiling methods for the diagnosis of classical and variant short chain acyl-CoA dehydrogenase deficiency. Clin Chim Acta. 2003 Nov;337(1-2):103-13.",
    "category": "general"
  },
  {
    "title": "ACADSB gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/acadsb/",
    "content": "**ACADSB Gene**\n\nThe ACADSB gene provides instructions for making an enzyme called short/branched chain acyl-CoA dehydrogenase (SBCAD), which plays an important role in processing proteins.\n\n**Normal Function**\n\nNormally, the body breaks down proteins from food into smaller parts called amino acids. Amino acids can be further processed to provide energy for the body. In cells throughout the body, SBCAD is found within specialized structures called mitochondria. Mitochondria convert energy from food into a form that cells can use.\n\nThe SBCAD enzyme helps break down a particular amino acid called isoleucine. Specifically, this enzyme helps with the third step of the process, performing a chemical reaction that converts a molecule called 2-methylbutyryl-CoA to another molecule, tiglyl-CoA. Additional chemical reactions convert tiglyl-CoA into molecules that are used for energy. Through similar chemical reactions, the SBCAD enzyme also aids in the breakdown of other amino acids.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Short/branched chain acyl-CoA dehydrogenase deficiency**\n    Researchers have identified more than 10 ACADSB gene mutations in people with short/branched chain acyl-CoA dehydrogenase (SBCAD) deficiency. While most people with this condition have no related health problems, some have reduced energy (lethargy), muscle weakness, seizures, developmental delays, or other health problems.\n    Many of the ACADSB gene mutations replace one of the amino acids in the SBCAD enzyme with an incorrect amino acid. Other mutations lead to an abnormally small version of this enzyme that is missing several amino acids. As a result of these mutations, SBCAD has little or no activity. With a shortage (deficiency) of normal enzyme activity, the body is unable to break down isoleucine properly. Researchers speculate that some features of this disorder, such as lethargy and muscle weakness, occur because isoleucine is not converted to energy.\n\n---\n\n**ACADSB Gene: MedlinePlus Genetics (Part 2/3)**\n\n**Category:** general\n\n**Body is unable to break down isoleucine properly**\n\nResearchers speculate that some features of this disorder, such as lethargy and muscle weakness, occur because isoleucine is not converted to energy. In addition, impairment of SBCAD may allow the buildup of toxic compounds, which can lead to serious health problems.\n\n**Short/branched chain acyl-CoA dehydrogenase deficiency**\n\nExpand Section\n\nResearchers have identified more than 10 ACADSB gene mutations in people with short/branched chain acyl-CoA dehydrogenase (SBCAD) deficiency. While most people with this condition have no related health problems, some have reduced energy (lethargy), muscle weakness, seizures, developmental delays, or other health problems.\n\nMany of the ACADSB gene mutations replace one of the amino acids in the SBCAD enzyme with an incorrect amino acid. Other mutations lead to an abnormally small version of this enzyme that is missing several amino acids. As a result of these mutations, SBCAD has little or no activity. With a shortage (deficiency) of normal enzyme activity, the body is unable to break down isoleucine properly.\n\n**Other Names for This Gene**\n\n* 2-MEBCAD\n* 2-methyl branched chain acyl-CoA dehydrogenase\n* 2-methylbutyryl-CoA dehydrogenase\n* ACAD7\n* ACDSB_HUMAN\n* acyl-CoA dehydrogenase, short/branched chain\n* SBCAD\n* short/branched chain acyl-CoA dehydrogenase\n\n**Additional Information & Resources**\n\nExpand Section\n\nTests Listed in the Genetic Testing Registry:\n\n* Tests of ACADSB\n\nScientific Articles on PubMed:\n\n* PubMed\n\nCatalog of Genes and Diseases from OMIM:\n\n* ACYL-CoA DEHYDROGENASE, SHORT/BRANCHED CHAIN; ACADSB\n\nGene and Variant Databases:\n\n* NCBI Gene\n* ClinVar\n\n**References**\n\nExpand Section\n\nAlfardan J, Mohsen AW, Copeland S, Ellison J, Keppen-Davis L, Rohrbach M,\nPowell BR, Gillis J, Matern D, Kant J, Vockley J. Characterization of new ACADSB\ngene sequence mutations and clinical implications in patients with\n2-methylbutyrylglycinuria identified by newborn screening. Mol Genet Metab. 2010\nAug;100(4):333-8.\n\nAndresen BS, Christensen E, Corydon TJ, Bross P, Pilgaard B, Wanders RJ,\nRuiter JP, Simonsen H, Winter V, Knudsen I, Schroeder LD, Gregersen N, Skovby F.\nIsolated 2-methylbutyrylglycinuria caused by short/branched-chain acyl-CoA\ndehydrogenase deficiency: identification of a new enzyme defect, resolution of\nits molecular basis, and evidence for distinct acyl-CoA dehydrogenases in\nisoleucine and valine metabolism. Am J Hum Genet. 2000 Nov;67(5):1095-103.\n\nKorman SH. Inborn errors of isoleucine degradation: a review. Mol Genet Metab.\n2006 Dec;89(4):289-99.\n\nPasquali M, Monsen G, Richardson L, Alston M, Longo N. Biochemical findings in\ncommon inborn errors of metabolism. Am J Med Genet C Semin Med Genet. 2006 May\n15;142C(2):64-76.\n\nSass JO, Ensenauer R, Roschinger W, Reich H, Steuerwald U, Schirrmacher O,\nEngel K, Haberle J, Andresen BS, Megarbane A, Lehnert W, Zschocke J.\n2-Methylbutyryl-coenzyme A dehydrogenase deficiency: functional and molecular\nstudies on a defect in isoleucine catabolism. Mol Genet Metab. 2008\nJan;93(1):30-5.\n\n**Genomic Location**\n\nThe ACADSB gene is found on chromosome 10.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n---\n\n**ACADSB Gene**\n\n\\n\\n\n\n**Genomic Location**\nThe ACADSB gene is found on chromosome 10.\n\n\\n\\n\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders\n\n\\n\\n\n\n* **Understanding Genetics**\n\t+ What is DNA?\n\t+ What is a gene?\n\t+ What is a gene variant and how do variants occur?\n\n\\n\\n\n\n**Disclaimers**\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ACADVL gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/acadvl/",
    "content": "**ACADVL Gene**\n\nThe ACADVL gene provides instructions for making an enzyme called very long-chain acyl-CoA dehydrogenase (VLCAD). This enzyme functions within mitochondria, the energy-producing centers in cells.\n\n* **Normal Function**: Very long-chain acyl-CoA dehydrogenase is essential for fatty acid oxidation, which is the multistep process that breaks down (metabolizes) fats and converts them to energy.\n* **Health Conditions Related to Genetic Changes**:\n\nVariants (also known as mutations) in the ACADVL gene have been found to cause very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. Many of these variants change single protein building blocks (amino acids) in the VLCAD enzyme. Other variants delete part of the ACADVL gene or create a premature stop signal in the instructions for making VLCAD.\n\nThese variants lead to a change in the enzyme's structure, severely reducing or eliminating its activity. As a result, very little functional enzyme is produced.\n\nWith a shortage (deficiency) of functional VLCAD enzyme, very-long chain fatty acids are not broken down properly. Â As a result, these fats are not converted to energy, which can lead to signs and symptoms of this disorder such as the lack of energy (lethargy) and low blood glucose (hypoglycemia). Very long-chain fatty acids or partially metabolized fatty acids may build up in tissues and damage the heart, liver, and muscles. This abnormal buildup causes the other signs and symptoms of VLCAD deficiency.\n\n**Other Names for This Gene**\n\n* None\n\n**Additional Information & Resources**\n\n* None\n\n---\n\n**ACADVL Gene**\n\nThe ACADVL gene is responsible for encoding the enzyme very-long-chain acyl-CoA dehydrogenase (VLCAD). Mutations in this gene have been found to cause VLCAD deficiency, a rare genetic disorder.\n\n**Causes of VLCAD Deficiency**\n\nMany variants of the ACADVL gene that cause VLCAD deficiency change single protein building blocks (amino acids) in the VLCAD enzyme. Other variants delete part of the ACADVL gene or create a premature stop signal in the instructions for making VLCAD, leading to a severe reduction or elimination of the enzyme's activity.\n\n**Symptoms of VLCAD Deficiency**\n\nThe shortage of functional VLCAD enzyme leads to improper breakdown of very-long chain fatty acids. This can cause lethargy and low blood glucose (hypoglycemia). The abnormal buildup of these fats in tissues can damage the heart, liver, and muscles, resulting in various signs and symptoms of VLCAD deficiency.\n\n**Other Names for This Gene**\n\n* ACAD6\n* ACADV_HUMAN\n* acyl-CoA dehydrogenase\n* very long chain acyl-coenzyme A dehydrogenase\n* LCACD\n* VLCAD\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: Tests of ACADVL\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM: ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN; ACADVL\n* Gene and Variant Databases: NCBI Gene, ClinVar\n\n**References**\n\nAndresen BS, Bross P, Vianey-Saban C, Divry P, Zabot MT, Roe CR, Nada MA, Byskov A, Kruse TA, Neve S, Kristiansen K, Knudsen I, Corydon MJ, Gregersen N. Cloning and characterization of human very-long-chain acyl-CoA dehydrogenase cDNA, chromosomal assignment of the gene and identification in four patients of nine different mutations within the VLCAD gene. Hum Mol Genet. 1996 Apr;5(4):461-72.\n\n... (list of references continues)\n\n**Genomic Location**\n\nThe ACADVL gene is found on chromosome 17.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n* MEDICAL ENCYCLOPEDIA\n* Genes\n* Genetics\n* Understanding Genetics\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\nNote: The cleaned output has been reformatted to improve readability, with bold headings and bullet points used where necessary.\n\n---\n\n**ACADVL Gene**\n\n\\n\\n\n\n**Genomic Location**\nThe ACADVL gene is found on chromosome 17.\n\n\\n\\n\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders\n\n\\n\\n\n\n* **Understanding Genetics**\n\t+ What is DNA?\n\t+ What is a gene?\n\t+ What is a gene variant and how do variants occur?\n\n\\n\\n\n\n**Disclaimers**\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ACAN gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/acan/",
    "content": "**ACAN Gene**\n\nThe ACAN gene provides instructions for making the aggrecan protein. Aggrecan is a type of protein known as a proteoglycan, which means it has several sugar molecules attached to it. It is the most abundant proteoglycan in cartilage, a tough, flexible tissue that makes up much of the skeleton during early development.\n\n**Normal Function**\n\nAggrecan attaches to the other components of cartilage, organizing the network of molecules that gives cartilage its strength. These interactions occur at a specific region of the aggrecan protein called the C-type lectin domain (CLD). Because of the attached sugars, aggrecan attracts water molecules and gives cartilage its gel-like structure. This feature enables the cartilage to resist compression, protecting bones and joints.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Familial Osteochondritis Dissecans**\n    At least one variant (also known as a mutation) in the ACAN gene has been found to cause familial osteochondritis dissecans. This condition is characterized by areas of bone damage (lesions) caused by the detachment of cartilage and some of the underlying bone from the end of the bone at a joint.\n    The ACAN gene variant associated with this condition changes a single protein building block (amino acid) in the CLD of the aggrecan protein. Specifically, the amino acid valine is replaced by the amino acid methionine at protein position 2303 (written as Val2303Met or V2303M). The abnormal aggrecan protein is unable to attach to other components of cartilage. As a result, the cartilage is disorganized and weak.\n    It is unclear how the abnormal cartilage is involved in the development of the lesions and osteoarthritis characteristic of familial osteochondritis dissecans. Researchers have suggested that a disorganized cartilage network in growing bones impairs their growth, leading to short stature.\n\n*   **Intervertebral Disc Disease**\n    MedlinePlus Genetics provides information about Intervertebral disc disease\n\n---\n\n**ACAN Gene: MedlinePlus Genetics (Part 2/4)**\n\n*   **Other Disorders**\n    Two other conditions associated with short stature, called spondyloepimetaphyseal dysplasia, aggrecan type and spondyloepiphyseal dysplasia, Kimberley type, are caused by variants in the ACAN gene.\n\n        *   **Spondyloepimetaphyseal Dysplasia, Aggrecan Type**\n            People with this condition have extremely short stature, short fingers and toes, and distinctive facial features. This condition is caused by a variant that changes the amino acid at position 2267 in the aggrecan protein from aspartic acid to asparagine (written as Asp2267Asn or D2267N). The amino acid change, which occurs in the CLD, alters aggrecan's interaction with at least one component of the cartilage network.\n\n        *   **Spondyloepiphyseal Dysplasia, Kimberley Type**\n            This condition is characterized by short stature and early development of osteoarthritis, particularly in the knees, ankles, and hips. It is caused by a variant in which a single DNA building block is inserted into the ACAN gene, which could disrupt the gene's instructions and lead to the production of an abnormally short aggrecan protein that is missing the CLD.\n\n*   **Familial Osteochondritis Dissecans**\n    At least one variant (also known as a mutation) in the ACAN gene has been found to cause familial osteochondritis dissecans. This condition is characterized by areas of bone damage (lesions) caused by the detachment of cartilage and some of the underlying bone from the end of the bone at a joint.\n\n        *   **Symptoms**\n            People with this condition have multiple lesions that affect the knees, elbows, hips, or ankles. Other common features are short stature and early development of a painful joint disorder called osteoarthritis.\n\n        *   **Genetic Cause**\n            The ACAN gene variant associated with this condition changes a single protein building block (amino acid) in the CLD of the aggrecan protein. Specifically, the amino acid valine is replaced by the amino acid methionine at protein position 2303 (written as Val2303Met or V2303M). The abnormal aggrecan protein is unable to attach to other components of cartilage.\n\n*   **Intervertebral Disc Disease**\n    MedlinePlus Genetics provides information about Intervertebral disc disease\n\n---\n\n**ACAN Gene: MedlinePlus Genetics**\n\n**Category:** general\n\n**Content:**\nThe ACAN gene is associated with three rare genetic disorders that affect bone development and cartilage function. These conditions include spondyloepiphyseal dysplasia, Kimberley type; spondyloepimetaphyseal dysplasia, aggrecan type; and a recessive skeletal dysplasia known as SEMD aggrecan type.\n\n**Spondyloepiphyseal Dysplasia, Kimberley Type:**\nThis condition is characterized by short stature and early development of osteoarthritis, particularly in the knees, ankles, and hips. It is caused by a variant in which a single DNA building block is inserted into the ACAN gene, potentially disrupting the gene's instructions and leading to an abnormally short aggrecan protein.\n\n**Spondyloepimetaphyseal Dysplasia, Aggrecan Type:**\nPeople with this condition have extremely short stature, short fingers and toes, and distinctive facial features. It is caused by a variant that changes the amino acid at position 2267 in the aggrecan protein from aspartic acid to asparagine.\n\n**Other Names for This Gene:**\n\n* AGC1\n* AGCAN\n* Aggrecan core protein\n* Cartilage-specific proteoglycan core protein\n* Chondroitin sulfate proteoglycan core protein 1 (CSPG1)\n* CSPGCP\n* Large aggregating proteoglycan (MSK16)\n* SEDK\n\n**Additional Information & Resources:**\n\n* Tests Listed in the Genetic Testing Registry:\n\t+ Tests of ACAN\n* Scientific Articles on PubMed:\n\t+ PubMed\n* Catalog of Genes and Diseases from OMIM:\n\t+ AGGRECAN; ACAN\n\t+ SPONDYLOEPIPHYSEAL DYSPLASIA, KIMBERLEY TYPE; SEDK\n\t+ SPONDYLOEPIMETAPHYSEAL DYSPLASIA, AGGRECAN TYPE; SEMDAG\n* Gene and Variant Databases:\n\t+ NCBI Gene\n\t+ ClinVar\n\n**References:**\n\n* Aspberg A, Adam S, Kostka G, Timpl R, Heinegard D. Fibulin-1 is a ligand for the C-type lectin domains of aggrecan and versican. J Biol Chem. 1999 Jul 16;274(29):20444-9.\n* Gentili C, Cancedda R. Cartilage and bone extracellular matrix. Curr Pharm Des. 2009;15(12):1334-48.\n* Gleghorn L, Ramesar R, Beighton P, Wallis G. A mutation in the variable repeat region of the aggrecan gene (AGC1) causes a form of spondyloepiphyseal dysplasia associated with severe, premature osteoarthritis. Am J Hum Genet. 2005 Sep;77(3):484-90.\n* Olin AI, Morgelin M, Sasaki T, Timpl R, Heinegard D, Aspberg A. The proteoglycans aggrecan and Versican form networks with fibulin-2 through their lectin domain binding. J Biol Chem. 2001 Jan 12;276(2):1253-61.\n* Stattin EL, Wiklund F, Lindblom K, Onnerfjord P, Jonsson BA, Tegner Y, Sasaki T, Struglics A, Lohmander S, Dahl N, Heinegard D, Aspberg A. A missense mutation in the aggrecan C-type lectin domain disrupts extracellular matrix interactions and causes dominant familial osteochondritis dissecans. Am J Hum Genet. 2010 Feb 12;86(2):126-37.\n* Tompson SW, Merriman B, Funari VA, Fresquet M, Lachman RS, Rimoin DL, Nelson SF, Briggs MD, Cohn DH, Krakow D. A recessive skeletal dysplasia, SEMD aggrecan type, results from a missense mutation affecting the C-type lectin domain of aggrecan. Am J Hum Genet. 2009 Jan;84(1):72-9.\n\n**Genomic Location:**\nThe ACAN gene is found on chromosome 15.\n\n**Related Health Topics:**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n---\n\n**ACAN Gene**\n\n\\n\\n\n\n**Genomic Location**\nThe ACAN gene is found on chromosome 15.\n\n\\n\\n\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders\n\n\\n\\n\n\n* **Understanding Genetics**\n\t+ What is DNA?\n\t+ What is a gene?\n\t+ What is a gene variant and how do variants occur?\n\n\\n\\n\n\n**Disclaimers**\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ACAT1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/acat1/",
    "content": "**ACAT1 Gene**\n\nThe ACAT1 gene provides instructions for making an enzyme that is found in the energy-producing centers within cells (mitochondria). This enzyme plays an essential role in breaking down proteins and fats from the diet.\n\n**Normal Function**\n\n* The ACAT1 enzyme helps process isoleucine, an amino acid that is a building block of many proteins.\n* It converts a molecule called 2-methyl-acetoacetyl-CoA into two smaller molecules, propionyl-CoA and acetyl-CoA, that can be used to produce energy.\n* The ACAT1 enzyme carries out the last step in ketone breakdown (ketolysis) during the processing of fats.\n* It converts a molecule called acetoacetyl-CoA into two molecules of acetyl-CoA, which can be used to produce energy.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Beta-ketothiolase deficiency**: More than 100 mutations in the ACAT1 gene have been identified in people with beta-ketothiolase deficiency. The condition usually appears before age 2 and causes episodes (called ketoacidotic attacks) of vomiting, dehydration and other health problems, which can lead to coma.\n* A shortage of the ACAT1 enzyme prevents the body from processing proteins and fats properly. As a result, chemical byproducts called organic acids can build up to toxic levels in the blood.\n* These substances may cause the blood to become too acidic (ketoacidosis) and can damage the body's tissues and organs, particularly in the nervous system.\n\n**References**\n\n(Note: References are not included in this cleaned output as they were not provided in the original content.)\n\n---\n\n**ACAT1 Gene: MedlinePlus Genetics (Part 2/2)**\n\n**Beta-ketothiolase deficiency**\n\nBeta-ketothiolase deficiency is a rare genetic disorder caused by mutations in the ACAT1 gene. The condition typically appears before age 2 and causes episodes of vomiting, dehydration, and other health problems that can lead to coma.\n\n**More than 100 mutations identified**\n\nOver 100 mutations in the ACAT1 gene have been identified in people with beta-ketothiolase deficiency. These genetic changes disrupt the normal function of the enzyme or prevent cells from producing any functional enzyme.\n\n**Shortage of ACAT1 enzyme leads to toxic buildup**\n\nA shortage of the ACAT1 enzyme prevents the body from processing proteins and fats properly, leading to a buildup of chemical byproducts called organic acids in the blood. These substances can cause the blood to become too acidic (ketoacidosis) and damage the body's tissues and organs, particularly in the nervous system.\n\n**Other Names for This Gene**\n\n* ACAT acetoacetyl Coenzyme A thiolase\n* Acetyl-Coenzyme A acetyltransferase 1\n* Acetyl-Coenzyme A acetyltransferase 1 (acetoacetyl Coenzyme A thiolase)\n* MAT methylacetoacetyl-Coenzyme A thiolase\n* T2 THIL THIL_HUMAN\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: Tests of ACAT1\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM: ACETYL-CoA ACETYLTRANSFERASE 1; ACAT1\n* Gene and Variant Databases: NCBI Gene, ClinVar\n\n**References**\n\n* Abdelkreem E, Harijan RK, Yamaguchi S, Wierenga RK, Fukao T. Mutation update on ACAT1 variants associated with mitochondrial acetoacetyl-CoA thiolase (T2) deficiency. Hum Mutat. 2019 Oct;40(10):1641-1663.\n* Fukao T, Yamaguchi S, Orii T, Hashimoto T. Molecular basis of beta-ketothiolase deficiency: mutations and polymorphisms in the human mitochondrial acetoacetyl-coenzyme A thiolase gene. Hum Mutat. 1995;5(2):113-20.\n* Grunert SC, Sass JO. 2-methylacetoacetyl-coenzyme A thiolase (beta-ketothiolase) deficiency: one disease - two pathways. Orphanet J Rare Dis. 2020 Apr 28;15(1):106.\n* Kano M, Fukao T, Yamaguchi S, Orii T, Osumi T, Hashimoto T. Structure and expression of the human mitochondrial acetoacetyl-CoA thiolase-encoding gene. Gene. 1991 Dec 30;109(2):285-90.\n\n**Genomic Location**\n\nThe ACAT1 gene is found on chromosome 11.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ACE blood test: MedlinePlus Medical Encyclopedia",
    "url": "https://medlineplus.gov/ency/article/003567.htm",
    "content": "**ACE Blood Test**\n\nThe ACE test measures the level of angiotensin-converting enzyme (ACE) in the blood.\n\n**How the Test is Performed**\n\nA blood sample is needed.\n\n**How to Prepare for the Test**\n\nFollow your health care provider's instructions for not eating or drinking for up to 12 hours before the test. If you are on steroid medicine, ask your provider if you need to stop the medicine before the test, because steroids can decrease ACE levels. Do not stop any medicine before talking to your provider.\n\n**How the Test will Feel**\n\nWhen the needle is inserted to draw blood, some people feel moderate pain. Others feel only a prick or stinging. Afterward, there may be some throbbing or slight bruising. This soon goes away.\n\n**Why the Test is Performed**\n\nThis test is most often ordered to help diagnose and monitor a disorder called sarcoidosis. People with sarcoidosis may have their ACE level tested regularly to check how severe the disease is and how well treatment is working.\n\nThis test may also help confirm a diagnosis of Gaucher disease.\n\n**Normal Results**\n\nNormal values vary based on your age and the test method used. Adults have an ACE level less than 40 micrograms per liter.\n\nNormal value ranges may vary slightly among different laboratories. Some labs use different measurements or test different samples. Talk to your provider about the meaning of your specific test results.\n\n**What Abnormal Results Mean**\n\nHigher than normal ACE level may be a sign of sarcoidosis. ACE levels may rise or fall as sarcoidosis worsens or improves.\n\nA higher than normal ACE level may also be seen in several other diseases and disorders, including:\n\n* Adrenal glands do not make enough hormones (Addison disease)\n* Cancer of the lymph tissue (Hodgkin disease)\n* Diabetes\n* Liver swelling and inflammation (hepatitis) due to alcohol use\n* Lung disease such as asthma, cancer, chronic obstructive pulmonary disease, or tuberculosis\n* Kidney disorder called nephrotic syndrome\n* Multiple sclerosis\n* Overactive thyroid (hyperthyroidism)\n* Overactive parathyroid glands (hyperparathyroidism)\n* Stomach ulcer\n\nLower than normal ACE level may indicate:\n\n* Chronic liver disease\n* Chronic kidney failure\n* Eating disorder called anorexia nervosa\n* Steroid therapy (usually prednisone)\n* Therapy for sarcoidosis\n* Underactive thyroid (hypothyroidism)\n\n**Risks**\n\nThere is little risk involved with having your blood taken. Veins and arteries vary in size from one person to another and from one side of the body to the other. Taking blood from some people may be more difficult than from others.\n\nOther risks associated with having blood drawn are slight, but may include:\n\n* Excessive bleeding\n* Fainting or feeling lightheaded\n* Hematoma (blood buildup under the skin)\n* Infection (a slight risk any time the skin is broken)\n* Multiple punctures to locate veins\n\n**Alternative Names**\n\nSerum angiotensin-converting enzyme; SACE\n\n---\n\n**ACE Blood Test**\n\n**What is the ACE blood test?**\n\nThe ACE blood test measures the level of angiotensin-converting enzyme (ACE) in your blood.\n\n**How is the ACE blood test performed?**\n\nA blood sample is needed for this test. You may need to fast for up to 12 hours before the test, and if you're on steroid medicine, you may need to stop taking it before the test.\n\n**What can I expect during the ACE blood test?**\n\nWhen the needle is inserted to draw blood, some people feel moderate pain, while others feel only a prick or stinging. Afterward, there may be some throbbing or slight bruising, but this soon goes away.\n\n**Why is the ACE blood test performed?**\n\nThis test is most often ordered to help diagnose and monitor a disorder called sarcoidosis. People with sarcoidosis may have their ACE level tested regularly to check how severe the disease is and how well treatment is working. This test may also help confirm a diagnosis of Gaucher disease.\n\n**What are normal results for the ACE blood test?**\n\nNormal values vary based on your age and the test method used. Adults have an ACE level less than 40 micrograms per liter.\n\n**What do abnormal results mean?**\n\nHigher than normal ACE levels may be a sign of sarcoidosis, while lower than normal ACE levels may indicate chronic liver disease, chronic kidney failure, eating disorders, steroid therapy, or underactive thyroid.\n\n**Are there any risks associated with the ACE blood test?**\n\nThere is little risk involved with having your blood taken. However, other risks associated with having blood drawn are slight and may include excessive bleeding, fainting, hematoma, infection, or multiple punctures to locate veins.\n\n**What else do I need to know about the ACE blood test?**\n\nThis test may be ordered under different names, including serum angiotensin-converting enzyme (SACE).\n\n---\n\n**ACE Blood Test**\n\n**What is the ACE blood test?**\n\nThe ACE blood test measures the level of angiotensin-converting enzyme (ACE) in your blood. ACE is an enzyme that helps regulate blood pressure and fluid balance in your body.\n\n**Why is the ACE blood test important?**\n\nThe ACE blood test is used to diagnose conditions such as:\n\n* **Cirrhosis**: a liver disease characterized by scarring of the liver\n* **Diabetes**: a group of metabolic disorders characterized by high blood sugar levels\n* **Interstitial Lung Diseases**: a type of lung disease that affects the tissue around your air sacs\n* **Lymphoma**: a type of cancer that affects the immune system\n* **Pulmonary Fibrosis**: a type of lung disease that causes scarring of the lungs\n* **Sarcoidosis**: a type of lung disease that causes inflammation and scarring in the lungs\n* **Thyroid Diseases**: conditions that affect the thyroid gland, such as hypothyroidism or hyperthyroidism\n* **Tuberculosis**: a bacterial infection that affects the lungs\n\n**How is the ACE blood test performed?**\n\nThe ACE blood test involves drawing a sample of your blood from a vein in your arm. The blood sample is then sent to a laboratory where it is tested for levels of ACE.\n\n**What are the risks associated with the ACE blood test?**\n\nAs with any medical test, there are some risks associated with the ACE blood test. These include:\n\n* **Allergic reactions**: you may experience an allergic reaction to the needle or other equipment used during the test\n* **Infection**: there is a small risk of infection at the site where the blood sample is drawn\n\n**What should I do after the ACE blood test?**\n\nAfter the ACE blood test, you will need to wait for the results. Your doctor will discuss the results with you and explain what they mean.\n\n**References**\n\n* Pincus MR, Carty RP. Clinical enzymology. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Philadelphia, PA: Elsevier; 2022:chap 21.\n* Vaidya A, Zennaro MC, Stowasser M. Primary aldosteronism. In: Robertson RP, ed. DeGroot's Endocrinology. 8th ed. Philadelphia, PA: Elsevier; 2023:chap 95.\n* Young WF. Endocrine hypertension. In: Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ, eds. Williams Textbook of Endocrinology. 14th ed. Philadelphia, PA: Elsevier; 2020:chap 16.\n\n**Review Date**\n\nThe review date for this article is November 19, 2023.\n\n**Updated by**\n\nThis article was updated by Jacob Berman, MD, MPH, Clinical Assistant Professor of Medicine, Division of General Internal Medicine, University of Washington School of Medicine, Seattle, WA. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.\n\n**Related MedlinePlus Health Topics**\n\n* **Cirrhosis**\n* **Diabetes**\n* **Interstitial Lung Diseases**\n* **Lymphoma**\n* **Pulmonary Fibrosis**\n* **Sarcoidosis**\n* **Thyroid Diseases**\n* **Tuberculosis**\n\n**Images**\n\n* **Blood test**",
    "category": "general"
  },
  {
    "title": "ACE gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/ace/",
    "content": "**ACE Gene**\n\nThe ACE gene provides instructions for making the angiotensin-converting enzyme. This enzyme is able to cut (cleave) proteins. It is part of the renin-angiotensin system, which regulates blood pressure and the balance of fluids and salts in the body.\n\n**Normal Function**\n\nBy cutting a protein called angiotensin I at a particular location, the angiotensin-converting enzyme converts this protein to angiotensin II. Angiotensin II causes blood vessels to narrow (constrict), which results in increased blood pressure. This protein also stimulates production of the hormone aldosterone, which triggers the absorption of salt and water by the kidneys.\n\nThe increased amount of fluid in the body also increases blood pressure. Proper blood pressure during fetal growth, which delivers oxygen to the developing tissues, is required for normal development of the kidneys, particularly of structures called the proximal tubules, and other tissues. In addition, angiotensin II may play a more direct role in kidney development, perhaps by affecting growth factors involved in the development of kidney structures.\n\nThe angiotensin-converting enzyme can cleave other proteins, including bradykinin. Bradykinin causes blood vessels to widen (dilate), which decreases blood pressure. Cleavage by the angiotensin-converting enzyme inactivates bradykinin, helping to increase blood pressure.\n\n**Health Conditions Related to Genetic Changes**\n\n*   Renal tubular dysgenesis: Mutations in the ACE gene are the most common cause of a severe kidney disorder called renal tubular dysgenesis; at least 33 ACE gene mutations have been found in people with this disorder. Renal tubular dysgenesis is characterized by abnormal kidney development before birth, the inability to produce urine (anuria), and severe low blood pressure (hypotension).\n\n---\n\n**ACE Gene: MedlinePlus Genetics**\n\n**Renal Tubular Dysgenesis**\n\nMutations in the ACE gene are the most common cause of a severe kidney disorder called renal tubular dysgenesis; at least 33 ACE gene mutations have been found in people with this disorder. Renal tubular dysgenesis is characterized by abnormal kidney development before birth, the inability to produce urine (anuria), and severe low blood pressure (hypotension). These problems result in a reduction of amniotic fluid (oligohydramnios), which leads to a set of birth defects known as the Potter sequence.\n\nRenal tubular dysgenesis can be caused by mutations in both copies of any of the genes involved in the renin-angiotensin system. The ACE gene mutations that cause this disorder prevent the production of functional angiotensin-converting enzyme, which impairs the formation of angiotensin II and results in a nonfunctional renin-angiotensin system. Without this system, the kidneys cannot control blood pressure. Because of low blood pressure, the flow of blood is reduced (hypoperfusion), and the body does not get enough oxygen during fetal development. As a result, kidney development is impaired, leading to the features of renal tubular dysgenesis.\n\n**Other Disorders**\n\nA certain variation in the ACE gene has been associated with increased risk of several conditions, including stroke and complications of diabetes. This genetic variation, called the ACE I/D polymorphism, involves a region of DNA that spans 287 DNA building blocks (nucleotides). One variant of the ACE gene includes this region; it is called the insertion, or I, allele. Another variant is missing this region of DNA and is called the deletion, or D, allele.\n\nBecause people have two copies of each gene, each individual can have two I alleles (II), two D alleles (DD), or one allele of each (ID). The DD pattern is associated with higher levels of angiotensin-converting enzyme than the II pattern. The ID pattern is associated with intermediate levels.\n\nPeople with the DD pattern of alleles have an increased risk of stroke. Stroke can be caused by a lack of blood flow to the brain (ischemic stroke) or bleeding in the brain (hemorrhagic stroke or intracerebral hemorrhage). Susceptibility to both types is associated with the ACE gene variation. However, many genetic and environmental risk factors likely contribute to this complex condition.\n\nIn people with type 1 diabetes or type 2 diabetes, the DD pattern of alleles is associated with an increased risk of developing a kidney disorder called diabetic nephropathy. Damage to the kidneys caused by this condition worsens over time and can lead to kidney failure.\n\n---\n\n**ACE Gene: MedlinePlus Genetics (Part 3/4)**\n\nThe ACE gene, also known as the angiotensin-converting enzyme gene, plays a crucial role in regulating blood pressure and fluid balance in the body. The gene is responsible for producing an enzyme that converts a hormone called angiotensin I into another hormone called angiotensin II.\n\n**Variants of the ACE Gene**\n\nThe ACE gene has two main variants: the insertion (I) allele and the deletion (D) allele. The insertion allele includes a region of DNA that spans 287 nucleotides, while the deletion allele is missing this region. Because people have two copies of each gene, they can have two I alleles (II), two D alleles (DD), or one allele of each (ID).\n\n**Patterns of Alleles and Their Effects**\n\nThe pattern of alleles an individual has can affect their levels of angiotensin-converting enzyme. The DD pattern is associated with higher levels of the enzyme than the II pattern, while the ID pattern is associated with intermediate levels.\n\n**Increased Risk of Stroke and Diabetic Nephropathy**\n\nPeople with the DD pattern of alleles have an increased risk of stroke. Stroke can be caused by a lack of blood flow to the brain (ischemic stroke) or bleeding in the brain (hemorrhagic stroke or intracerebral hemorrhage). Susceptibility to both types is associated with the ACE gene variation.\n\nIn people with type 1 diabetes or type 2 diabetes, the DD pattern of alleles is associated with an increased risk of developing a kidney disorder called diabetic nephropathy. Damage to the kidneys caused by this condition worsens over time and can lead to kidney failure.\n\n**Other Names for This Gene**\n\n* ACE1\n* ACE_HUMAN\n* angiotensin converting enzyme, somatic isoform\n* angiotensin I converting enzyme (peptidyl-dipeptidase A) 1\n* angiotensin I converting enzyme peptidyl-dipeptidase A 1 transcript\n* CD143\n* CD143 antigen\n* DCP\n* DCP1\n* dipeptidyl carboxypeptidase 1\n* dipeptidyl carboxypeptidase I\n* EC 3.4.15.1\n* ICH\n* kininase II\n* MVCD3\n\n**References**\n\n* Gribouval O, Gonzales M, Neuhaus T, Aziza J, Bieth E, Laurent N, Bouton JM, Feuillet F, Makni S, Ben Amar H, Laube G, Delezoide AL, Bouvier R, Dijoud F, Ollagnon-Roman E, Roume J, Joubert M, Antignac C, Gubler MC. Mutations in genes in the renin-angiotensin system are associated with autosomal recessive renal tubular dysgenesis. Nat Genet. 2005 Sep;37(9):964-8.\n* Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, Dusselier L, Kahal Z, Chaillous L, Halimi S, Muller A, Sackmann H, Bauduceau B, Bled F, Passa P, Alhenc-Gelas F. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest. 1997 Apr 1;99(7):1585-95.\n* Wolf G. Angiotensin II and tubular development. Nephrol Dial Transplant. 2002;17 Suppl 9:48-51.\n* Wuyts B, Delanghe J, De Buyzere M. Angiotensin I-converting enzyme insertion/deletion polymorphism: clinical implications. Acta Clin Belg. 1997;52(6):338-49.\n* Zhang Z, Xu G, Liu D, Fan X, Zhu W, Liu X. Angiotensin-converting enzyme insertion/deletion polymorphism contributes to ischemic stroke risk: a meta-analysis of 50 case-control studies. PLoS One. 2012;7(10):e46495.\n\n---\n\n**ACE Gene**\n\n**Genomic Location**\nThe ACE gene is found on chromosome 17.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.\n\n**Research Articles**\n\n* Gubler MC. Mutations in genes in the renin-angiotensin system are associated with autosomal recessive renal tubular dysgenesis. Nat Genet. 2005 Sep;37(9):964-8.\n* Gribouval O, et al. Spectrum of mutations in the renin-angiotensin system genes in autosomal recessive renal tubular dysgenesis. Hum Mutat. 2012 Feb;33(2):316-26.\n* Gubler MC, Antignac C. Renin-angiotensin system in kidney development: renal tubular dysgenesis. Kidney Int. 2010 Mar;77(5):400-6.\n* Huang Y, et al. Angiotensin-converting enzyme insertion/deletion gene polymorphisms and risk of intracerebral hemorrhage: a meta-analysis of epidemiologic studies. J Renin Angiotensin Aldosterone Syst. 2014 Mar;15(1):32-8.\n* Marre M, et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest. 1997 Apr 1;99(7):1585-95.\n* Wolf G. Angiotensin II and tubular development. Nephrol Dial Transplant. 2002;17 Suppl 9:48-51.\n* Wuyts B, et al. Angiotensin I-converting enzyme insertion/deletion polymorphism: clinical implications. Acta Clin Belg. 1997;52(6):338-49.\n* Zhang Z, et al. Angiotensin-converting enzyme insertion/deletion polymorphism contributes to ischemic stroke risk: a meta-analysis of 50 case-control studies. PLoS One. 2012;7(10):e46495.",
    "category": "general"
  },
  {
    "title": "ACE inhibitors: MedlinePlus Medical Encyclopedia",
    "url": "https://medlineplus.gov/ency/patientinstructions/000087.htm",
    "content": "**ACE Inhibitors**\n\n_Angiotensin-converting enzyme (ACE) inhibitors are medicines that treat heart, blood vessel, and kidney problems._\n\n**How ACE Inhibitors Help**\n\n* Used to treat heart disease and high blood pressure\n* Make your heart work less hard by lowering your blood pressure\n* Keeps some kinds of heart disease from getting worse\n* Most people who have heart failure take one of these medicines or similar medicines\n\n**Types of ACE Inhibitors**\n\n* Many different names and brands of ACE inhibitors\n* Most work as well as another\n* Side effects may be different for different ones\n\n**Taking Your ACE Inhibitors**\n\n* Pills that you take by mouth\n* Take all of your medicines as your provider told you to\n* Follow up with your provider regularly\n* Provider will check your blood pressure and do blood tests to make sure the medicines are working properly\n* Provider may change your dose from time to time\n\n* Try to take your medicines at the same time each day.\n* Don't stop taking your medicines without talking to your provider first.\n* Plan ahead so that you do not run out of medicine. Make sure you have enough with you when you travel.\n* Before taking ibuprofen (Advil, Motrin) or aspirin, talk to your provider.\n* Tell your provider what other medicines you are taking, including anything you bought without a prescription, diuretics (water pills), potassium pills, or herbal or dietary supplements.\n* Don't take ACE inhibitors if you are planning to become pregnant, are pregnant, or are breastfeeding. Contact your provider promptly if you become pregnant when you are taking these medicines.\n\n**Side Effects**\n\n* Unusual side effects from ACE inhibitors\n* You may have a dry cough. This may go away after a while. It also may start after you have been taking the medicine for some time.\n* Tell your provider if you develop a cough. Sometimes reducing your dose helps. But sometimes, your provider will switch you to a different medicine. Do not lower your dose without talking with your provider first.\n\n**Other Side Effects**\n\n* Dizziness or lightheadedness when starting these medicines, or if your provider increases your dose\n* Standing up slowly from a chair or your bed may help\n* If you have a fainting spell, contact your provider right away.\n* Headache\n* Fatigue\n* Loss of appetite\n* Upset stomach\n* Diarrhea\n* Numbness\n* Fever\n* Skin rashes or blisters\n* Joint pain\n\n**When to Call the Doctor**\n\n* Contact your provider if you are having any of the side effects listed above. Also contact your provider if you are having any other unusual symptoms.\n\n---\n\n**ACE Inhibitors**\n\n_Angiotensin-converting enzyme (ACE) inhibitors are medicines that treat heart, blood vessel, and kidney problems._\n\n**How ACE Inhibitors Help**\n\n* Used to treat heart disease and high blood pressure\n* Lowering your blood pressure keeps some kinds of heart disease from getting worse\n* Most people who have heart failure take one of these medicines or similar medicines\n* Treats high blood pressure, strokes, or heart attacks\n* May help lower your risk for stroke or heart attack\n* Also used to treat kidney problems\n\n**Types of ACE Inhibitors**\n\n* Many different names and brands of ACE inhibitors\n* Most work as well as another\n* Side effects may be different for different ones\n\n**Taking Your ACE Inhibitors**\n\n* Take all of your medicines as your provider told you to\n* Follow up with your provider regularly\n* Provider will check your blood pressure and do blood tests to make sure the medicines are working properly\n* May change your dose from time to time\n* Try to take your medicines at the same time each day\n* Don't stop taking your medicines without talking to your provider first\n* Plan ahead so that you do not run out of medicine\n* Before taking ibuprofen (Advil, Motrin) or aspirin, talk to your provider\n* Tell your provider what other medicines you are taking\n* Don't take ACE inhibitors if you are planning to become pregnant, are pregnant, or are breastfeeding\n\n**Side Effects**\n\n* Side effects from ACE inhibitors are unusual\n* May include:\n\t+ Cough\n\t+ Dizziness or lightheadedness\n\t+ Headache\n\t+ Fatigue\n\t+ Loss of appetite\n\t+ Upset stomach\n\t+ Diarrhea\n\t+ Numbness\n\t+ Fever\n\t+ Skin rashes or blisters\n\t+ Joint pain\n* If your tongue or lips swell, contact your provider right away, or go to the emergency room. You may be having a serious allergic reaction to the medicine.\n\n---\n\n**ACE Inhibitors**\n\n**Side Effects**\n\nSide effects from ACE inhibitors are unusual.\n\nYou may have a dry cough. This may go away after a while. It also may start after you have been taking the medicine for some time. Tell your provider if you develop a cough. Sometimes reducing your dose helps. But sometimes, your provider will switch you to a different medicine. Do not lower your dose without talking with your provider first.\n\nYou may feel dizzy or lightheaded when you start taking these medicines, or if your provider increases your dose. Standing up slowly from a chair or your bed may help. If you have a fainting spell, contact your provider right away.\n\nOther side effects include:\n\n*   Headache\n*   Fatigue\n*   Loss of appetite\n*   Upset stomach\n*   Diarrhea\n*   Numbness\n*   Fever\n*   Skin rashes or blisters\n*   Joint pain\n\nIf your tongue or lips swell, contact your provider right away, or go to the emergency room. You may be having a serious allergic reaction to the medicine. This is very rare.\n\n**When to Call the Doctor**\n\nContact your provider if you are having any of the side effects listed above. Also contact your provider if you are having any other unusual symptoms.\n\n**Alternative Names**\n\nAngiotensin-converting enzyme inhibitors\n\n**References**\n\nMann DL. Management of heart failure patients with reduced ejection fraction. In: Libby P, Bonow RO, Mann DL, Tomaselli GF, Bhatt DL, Solomon SD, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 12th ed. Philadelphia, PA: Elsevier; 2022:chap 50.\n\nHeidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. PMID: 35363499 pubmed.ncbi.nlm.nih.gov/35363499/.\n\nWhelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248.\n\n---\n\n**ACE Inhibitors**\n\n**Diabetes and Kidney Disease**\n\n*   ACE inhibitors are used to treat high blood pressure in adults with diabetes or kidney disease.\n*   They help relax blood vessels, reducing blood pressure and strain on the kidneys.\n\n**Heart Failure**\n\n*   ACE inhibitors can also be used to treat heart failure by relaxing blood vessels and reducing the workload on the heart.\n\n**High Blood Pressure in Adults - Hypertension**\n\n*   ACE inhibitors are a type of medication that helps lower high blood pressure in adults.\n*   They work by relaxing blood vessels, allowing blood to flow more easily and reducing blood pressure.\n\n**Type 2 Diabetes**\n\n*   ACE inhibitors can be used to treat type 2 diabetes by helping the kidneys function properly and reducing the risk of kidney damage.\n\n**Patient Instructions**\n\n*   **Angina - Discharge**: Follow your doctor's instructions for managing angina symptoms.\n*   **Angioplasty and Stent - Heart - Discharge**: Care for yourself after an angioplasty procedure.\n*   **Aspirin and Heart Disease**: Consult with your doctor about taking aspirin to prevent heart disease.\n*   **Being Active When You Have Heart Disease**: Engage in regular physical activity to manage heart disease symptoms.\n*   **Cardiac Catheterization - Discharge**: Follow your doctor's instructions for recovering from a cardiac catheterization procedure.\n*   **Controlling Your High Blood Pressure**: Work with your healthcare provider to manage high blood pressure through lifestyle changes and medication.\n*   **Diabetes and Exercise**: Regular exercise can help manage diabetes symptoms. Consult with your healthcare provider about safe exercise options.\n*   **Diabetes - Keeping Active**: Engage in regular physical activity to manage diabetes symptoms.\n*   **Diabetes - Preventing Heart Attack and Stroke**: Follow your doctor's instructions for preventing heart-related complications.\n*   **Diabetes - Taking Care of Your Feet**: Regularly inspect and care for your feet to prevent complications.\n*   **Diabetes Tests and Checkups**: Attend regular check-ups with your healthcare provider to monitor diabetes symptoms.\n*   **Diabetes - When You Are Sick**: Follow your doctor's instructions for managing diabetes symptoms when experiencing illness.\n*   **Heart Attack â Discharge**: Care for yourself after a heart attack, following your doctor's instructions.\n*   **Heart Failure - Discharge**: Follow your doctor's instructions for recovering from heart failure.\n*   **Heart Failure - What to Ask Your Doctor**: Consult with your healthcare provider about managing heart failure symptoms.\n*   **High Blood Pressure - What to Ask Your Doctor**: Discuss high blood pressure management options with your healthcare provider.\n*   **Low Blood Sugar - Self-Care**: Recognize and manage low blood sugar symptoms, following your doctor's instructions.\n*   **Managing Your Blood Sugar**: Work with your healthcare provider to develop a plan for managing diabetes symptoms.\n*   **Stroke - Discharge**: Care for yourself after a stroke, following your doctor's instructions.\n*   **Type 2 Diabetes - What to Ask Your Doctor**: Consult with your healthcare provider about managing type 2 diabetes symptoms.\n\n**Related MedlinePlus Health Topics**\n\n*   **Blood Pressure Medicines**\n*   **Chronic Kidney Disease**\n*   **High Blood Pressure**\n*   **Kidney Diseases**\n\n**Review Date: August 5, 2024**\n\nThis article was reviewed and updated by Thomas S. Metkus, MD, Assistant Professor of Medicine and Surgery at Johns Hopkins University School of Medicine, along with David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.\n\n**Learn How to Cite This Page**\n\nTo cite this page, follow the provided citation guidelines.\n\n**Related MedlinePlus Health Topics**\n\n*   **Blood Pressure Medicines**\n*   **Chronic Kidney Disease**\n*   **High Blood Pressure**\n*   **Kidney Diseases**",
    "category": "general"
  },
  {
    "title": "ACL reconstruction - discharge : MedlinePlus Medical Encyclopedia",
    "url": "https://medlineplus.gov/ency/patientinstructions/000189.htm",
    "content": "**ACL Reconstruction - Discharge**\n\nYou had surgery to repair a damaged ligament in your knee called the anterior cruciate ligament (ACL). This article tells you how to care for yourself when you go home from the hospital.\n\n**When You're in the Hospital**\n\nYou had surgery to reconstruct your anterior cruciate ligament (ACL). The surgeon drilled sockets and tunnels in the bones of your knee and attached the new ligament to the bone. You may also have had surgery to repair other tissue in your knee.\n\n**What to Expect at Home**\n\nYou may need help taking care of yourself when you first go home. Plan for a spouse, friend, or neighbor to help you. It can take from a few days to a few months to be ready to return to work. How soon you return to work will depend on the kind of work you do. It often takes 4 to 6 months to return to your full level of activity and take part in sports again after surgery.\n\n**Activity**\n\nYour surgeon will ask you to rest when you first go home. You will be told to:\n\n* Keep your leg propped up on 1 or 2 pillows, placing them under your foot or calf muscle, for 4 to 6 times a day for the first week after surgery.\n* Be careful not to get the dressing on your knee wet.\n* Do not use a heating pad.\n\nYou may need to wear special support stockings to help prevent blood clots from forming. Your surgeon will also give you exercises to keep the blood moving in your foot, ankle, and leg. These exercises will also lower your risk for blood clots.\n\nYou will need to use crutches when you go home. You may be able to begin putting your full weight on your repaired leg without crutches 2 to 3 weeks after surgery, if your surgeon says it is OK. If you had work on your knee in addition to ACL reconstruction, it may take 4 to 8 weeks to regain full use of your knee. Ask your surgeon how long you will need to be on crutches.\n\nYou may also need to wear a special knee brace. The brace will be set so that your knee can move only a certain amount in any direction. Do not change the settings on the brace yourself. The brace is usually locked when you are using crutches when walking for the first few weeks. You can unlock to work on range of motion if it's OK with your surgeon.\n\n**Physical Therapy**\n\nPhysical therapy most often begins about 1 to 2 weeks after surgery, however you can do some simple postoperative knee exercises immediately after surgery. The duration of physical therapy may be 2 to 6 months. You will need to limit your activity and movement while your knee mends. Your physical therapist will give you an exercise program to help you build strength in your knee and avoid injury.\n\n**Staying Active**\n\nGetting full range of motion in your leg soon after surgery is also important. Staying active and building strength in the muscles of your legs will help speed your recovery.\n\n**Wound Care**\n\nYou will go home with a dressing and an elastic bandage around your knee. Do not remove them until the surgeon says it is OK. Until then, keep the dressing and bandage clean and dry.\n\nYou can shower again after your dressing is removed. When you shower, wrap your leg in plastic to keep it from getting wet until your stitches or tape strips (Steri-Strips) have been removed. Make sure that your surgeon says this is OK.\n\n**Pain**\n\nPain is normal after knee arthroscopy. It should ease up over time. Your surgeon will give you a prescription for pain medicine before your surgery. Get it filled ahead of time so that you have it when you need it. Take your pain medicine when you start having pain so the pain doesn't get too bad.\n\nYou may also be given a nerve block during surgery, which can make your leg feel numb. Make sure you take your pain medicine, even when the block is working, as the block will wear off and pain can return quickly.\n\n**When to Call the Doctor**\n\nContact your surgeon if:\n\n* Blood is soaking through your dressing, and the bleeding does not stop when you put pressure on the area\n* Pain does not go away after you take pain medicine\n* You have swelling or pain in your calf muscle\n* Your foot or toes look darker than normal or are cool to the touch\n* You have redness, pain, swelling, or yellowish discharge from your incisions\n* You have a temperature higher than 101Â°F (38.3Â°C)\n\n---\n\n**Recovery After ACL Reconstruction**\n\nAfter surgery, it takes 4 to 6 months for your full level of activity to return and for you to participate in sports again.\n\n**Activity**\n\nWhen you first go home, your surgeon will ask you to rest. You'll need to:\n\n* Keep your leg propped up on 1 or 2 pillows, placing them under your foot or calf muscle, to reduce swelling.\n* Do this 4 to 6 times a day for the first week after surgery.\n* Avoid putting the pillow behind your knee.\n* Keep your knee straight.\n\nYou may need to wear special support stockings to prevent blood clots. Your surgeon will also give you exercises to keep blood moving in your foot, ankle, and leg, which will lower your risk for blood clots.\n\nYou'll need to use crutches when you go home. You can begin putting your full weight on your repaired leg without crutches 2 to 3 weeks after surgery, if your surgeon says it's OK. If you had work done on your knee in addition to ACL reconstruction, it may take 4 to 8 weeks to regain full use of your knee.\n\nYou may also need to wear a special knee brace set to limit your knee's movement. Don't change the settings yourself. The brace is usually locked when using crutches for walking during the first few weeks.\n\n**Physical Therapy**\n\nPhysical therapy typically starts 1 to 2 weeks after surgery, but you can do some simple postoperative knee exercises immediately after surgery. The duration of physical therapy may be 2 to 6 months. You'll need to limit your activity and movement while your knee mends.\n\nYour physical therapist will give you an exercise program to help build strength in your knee and avoid injury. Staying active and building strength in the muscles of your legs will help speed your recovery.\n\n**Wound Care**\n\nYou'll go home with a dressing and an elastic bandage around your knee. Don't remove them until your surgeon says it's OK. Keep the dressing and bandage clean and dry.\n\nAfter removing the dressing, you can shower again. When showering, wrap your leg in plastic to keep it from getting wet until your stitches or tape strips (Steri-Strips) have been removed.\n\n**Pain**\n\nPain is normal after knee arthroscopy. Your surgeon will give you a prescription for pain medicine before surgery. Take your pain medicine when you start having pain so it doesn't get too bad.\n\nYou may have received a nerve block during surgery, which can make your leg feel numb. The numbness can last for hours and sometimes up to a day. Make sure you take your pain medicine even when the block is working.\n\n**When to Call the Doctor**\n\nContact your surgeon if:\n\n* Blood is soaking through your dressing, and the bleeding doesn't stop when you apply pressure.\n* Pain doesn't go away after taking pain medicine.\n* You have swelling or pain in your calf muscle.\n* Your foot or toes look darker than normal or are cool to the touch.\n* You have redness, pain, swelling, or yellowish discharge from your incisions.\n* You have a temperature higher than 101Â°F (38.3Â°C).\n\n---\n\n**ACL Reconstruction - Discharge**\n\n**What to Expect at Home**\n\nYou may need help taking care of yourself when you first go home. Plan for a spouse, friend, or neighbor to help you. It can take from a few days to a few months to be ready to return to work. How soon you return to work will depend on the kind of work you do. It often takes 4 to 6 months to return to your full level of activity and take part in sports again after surgery.\n\n**Activity**\n\nYour surgeon will ask you to rest when you first go home. You will be told to:\n\n* Keep your leg propped up on 1 or 2 pillows, placing them under your foot or calf muscle. This helps keep swelling down. Do this 4 to 6 times a day for the first week after surgery.\n* Be careful not to get the dressing on your knee wet.\n* Do not use a heating pad.\n\nYou may need to wear special support stockings to help prevent blood clots from forming. Your surgeon will also give you exercises to keep the blood moving in your foot, ankle, and leg. These exercises will also lower your risk for blood clots.\n\nYou will need to use crutches when you go home. You may be able to begin putting your full weight on your repaired leg without crutches 2 to 3 weeks after surgery, if your surgeon says it is OK. If you had work on your knee in addition to ACL reconstruction, it may take 4 to 8 weeks to regain full use of your knee.\n\nYou may also need to wear a special knee brace. The brace will be set so that your knee can move only a certain amount in any direction. Do not change the settings on the brace yourself. The brace is usually locked when you are using crutches when walking for the first few weeks.\n\nAsk your surgeon or physical therapist about sleeping without the brace and removing it for showers. When the brace is off for any reason, be careful not to move your knee more than you can when you have the brace on.\n\nYou will need to learn how to go up and down stairs using crutches or with a knee brace on.\n\nPhysical therapy most often begins about 1 to 2 weeks after surgery, however you can do some simple postoperative knee exercises immediately after surgery. The duration of physical therapy may be 2 to 6 months. You will need to limit your activity and movement while your knee mends.\n\n**Wound Care**\n\nYou will go home with a dressing and an elastic bandage around your knee. Do not remove them until the surgeon says it is OK. Until then, keep the dressing and bandage clean and dry.\n\nYou can shower again after your dressing is removed.\n\n---\n\n**ACL Reconstruction - Discharge**\n\nYou will go home with a dressing and an elastic bandage around your knee. Do not remove them until the surgeon says it is OK. Until then, keep the dressing and bandage clean and dry.\n\nYou can shower again after your dressing is removed.\n\nWhen you shower, wrap your leg in plastic to keep it from getting wet until your stitches or tape strips (Steri-Strips) have been removed. Make sure that your surgeon says this is OK.\nAfter that, you may get the incisions wet when you shower. Be sure to dry the area well.\n\nIf you need to change your dressing for any reason, put the elastic bandage back on over the new dressing. Wrap the elastic bandage loosely around your knee. Start from the calf and wrap it around your leg and knee. Do not wrap it too tightly. Keep wearing the elastic bandage until your surgeon tells you it is OK to remove it.\n\n**Wound Care**\n\nYou will go home with a dressing and an elastic bandage around your knee. Do not remove them until the surgeon says it is OK. Until then, keep the dressing and bandage clean and dry.\n\nYou can shower again after your dressing is removed.\n\nWhen you shower, wrap your leg in plastic to keep it from getting wet until your stitches or tape strips (Steri-Strips) have been removed. Make sure that your surgeon says this is OK.\nAfter that, you may get the incisions wet when you shower. Be sure to dry the area well.\n\nIf you need to change your dressing for any reason, put the elastic bandage back on over the new dressing. Wrap the elastic bandage loosely around your knee. Start from the calf and wrap it around your leg and knee. Do not wrap it too tightly. Keep wearing the elastic bandage until your surgeon tells you it is OK to remove it.\n\n**Pain**\n\nPain is normal after knee arthroscopy. It should ease up over time.\n\nYour surgeon will give you a prescription for pain medicine before your surgery. Get it filled ahead of time so that you have it when you need it. Take your pain medicine when you start having pain so the pain doesn't get too bad.\n\nYou may have received a nerve block during surgery, so that your nerves do not feel pain. It is normal that your leg will feel a bit numb after the nerve block. The numbness can last for hours and sometimes up to a day. Make sure you take your pain medicine, even when the block is working. The block will wear off, and pain can return very quickly.\n\nIbuprofen (Advil, Motrin) or another medicine like it may also help. Ask your surgeon or health care provider what other medicines are safe to take with your pain medicine.\n\nDo not drive if you are taking narcotic pain medicine. This medicine may make you too sleepy to drive safely.\n\n**When to Call the Doctor**\n\nContact your surgeon if:\n\n* Blood is soaking through your dressing, and the bleeding does not stop when you put pressure on the area\n* Pain does not go away after you take pain medicine\n* You have swelling or pain in your calf muscle\n* Your foot or toes look darker than normal or are cool to the touch\n* You have redness, pain, swelling, or yellowish discharge from your incisions\n* You have a temperature higher than 101Â°F (38.3Â°C)\n\n**References**\n\nBrotzman SB. Anterior cruciate ligament injuries. In: Giangarra CE, Manske RC, eds. Clinical Orthopaedic Rehabilitation: A Team Approach. 4th ed. Philadelphia, PA: Elsevier; 2018:chap 47.\n\nHantes ME, Tsarouhas A. Anterior knee problems after anterior cruciate ligament reconstruction. In: Prodromos CC, ed. The Anterior Cruciate Ligament: Reconstruction and Basic Science. 2nd ed. Philadelphia, PA: Elsevier; 2018:chap 136.\n\nMicheo WF, Sepulveda F, Sanchez LA, Amy E. Anterior cruciate ligament sprain. In: Frontera WR, Silver JK, Rizzo TD Jr, eds. Essentials of Physical Medicine and Rehabilitation. 4th ed. Philadelphia, PA: Elsevier; 2019:chap 63.\n\nMiller RH, Azar FM. Knee injuries. In: Azar FM, Beaty JH, eds. Campbell's Operative Orthopaedics. 14th ed. Philadelphia, PA: Elsevier; 2021:chap 45.\n\n---\n\n**ACL Reconstruction - Discharge**\n\n**Anterior Cruciate Ligament (ACL) Injury**\n\nIf you have had an ACL injury, you may be considering ACL reconstruction. This is a surgical procedure to repair the damaged ligament.\n\n**Knee Arthroscopy**\n\nBefore having ACL reconstruction, you will likely undergo knee arthroscopy to examine the joint and confirm the diagnosis.\n\n**Knee MRI Scan**\n\nYou may also need a knee MRI scan to get a detailed image of the joint and assess the extent of the injury.\n\n**Knee Pain**\n\nAfter ACL reconstruction, you can expect some knee pain as you recover. This is usually managed with medication and physical therapy.\n\n**Osteoarthritis**\n\nACL injuries can increase your risk of developing osteoarthritis later in life. However, this risk can be mitigated with proper treatment and care.\n\n**Rheumatoid Arthritis**\n\nThere is no direct link between ACL injuries and rheumatoid arthritis. However, if you have rheumatoid arthritis, it's essential to discuss your treatment options with your doctor before undergoing ACL reconstruction.\n\n**Patient Instructions**\n\nTo prepare for your recovery at home:\n\n*   **Getting Your Home Ready - Knee or Hip Surgery**\n    *   Clear a path in your home to make it easier to move around.\n    *   Remove any tripping hazards, such as rugs or cords.\n    *   Consider hiring a cleaning service or asking a friend for help with household chores.\n\n**Discharge Instructions**\n\nAfter ACL reconstruction, you will need to follow these discharge instructions:\n\n*   **Knee Arthroscopy - Discharge**\n    *   Follow your doctor's instructions for pain management and physical therapy.\n    *   Attend all scheduled follow-up appointments to monitor your progress.\n    *   Report any unusual symptoms or concerns to your doctor promptly.\n\n**Review Date**\n\nThis information was last reviewed on November 7, 2024.",
    "category": "general"
  },
  {
    "title": "ACL reconstruction: MedlinePlus Medical Encyclopedia",
    "url": "https://medlineplus.gov/ency/article/007208.htm",
    "content": "**ACL Reconstruction**\n\nACL reconstruction is surgery to reconstruct the ligament in the center of your knee. The anterior cruciate ligament (ACL) connects your shin bone (tibia) to your thigh bone (femur). A tear of this ligament can cause your knee to give way during physical activity, most often during side-step or crossover movements.\n\n**Description**\n\nMost people have general anesthesia right before surgery. This means you will be asleep and pain-free. Other kinds of anesthesia, like regional anesthesia or a block, may also be used for this surgery.\n\nThe tissue to replace your damaged ACL will come from your own body or from a donor. A donor is a person who has died and chose to give all or part of their body to help others.\n\nTissue taken from your own body is called an autograft. The most common places to take tissue from are the knee cap tendon, quadriceps tendon, or hamstring tendon. Your hamstrings are the muscles behind your knee.\nTissue taken from a donor is called an allograft or cadaver graft.\n\nThe procedure is usually performed with the help of knee arthroscopy. With arthroscopy, a tiny camera is inserted into the knee through a small surgical cut. The camera is connected to a video monitor in the operating room. Your surgeon will use the camera to check the ligaments and other tissues of your knee.\n\nYour surgeon will make other small cuts around your knee and insert other medical instruments. Your surgeon will fix any other damage found, and then will replace your ACL by following these steps:\n\nThe torn ligament will be removed with a shaver or other instruments.\nIf your own tissue is being used to make your new ACL, your surgeon will make a larger cut. Then, the autograft will be removed through this cut.\nYour surgeon will make tunnels and sockets in your bone through which to bring the new tissue. This new tissue will be put at the same place as your old ACL.\nYour surgeon will attach the new ligament to the bone with screws or other devices to hold it in place. As it heals, the graft will remodel to become your new ligament.\n\nAt the end of the surgery, your surgeon will close your cuts with sutures (stitches) and cover the area with a dressing. You may be able to view pictures after the procedure of what the surgeon saw and what was done during the surgery.\n\n**Why the Procedure is Performed**\n\nIf you do not have your ACL reconstructed, your knee may continue to be unstable. This increases the chance you may have a meniscus tear. ACL reconstruction may be used for these knee problems:\n\n* Knee that gives way or feels unstable during daily activities\n* Knee pain\n* Inability to return to sports or other activities\n* When other ligaments are also injured\n* When your meniscus is torn\n\n**Before Surgery**\n\nAlways tell your provider what medicines you are taking, even medicines, supplements, or herbs you bought without a prescription.\n\nDuring the 2 weeks before your surgery:\n\nYou may be asked to stop taking medicines that make it harder for your blood to clot. These include aspirin, ibuprofen (Advil, Motrin), naproxen (Naprosyn, Aleve), and other medicines.\nAsk your provider which medicines you should still take on the day of your surgery.\nIf you have diabetes, heart disease, or other medical conditions, your surgeon will ask you to see the provider who treats you for these conditions.\nTell your provider if you have been drinking a lot of alcohol, more than 1 drink per day for women or 2 drinks per day for men.\nIf you smoke, try to stop. Smoking can slow down wound and bone healing. Ask your providers for help if you need it.\nAlways let your provider know about any cold, flu, fever, herpes breakout, or other illnesses you may have before your surgery.\n\n**After Surgery**\n\nMost people can go home the day of the surgery. You may have to wear a knee brace for the first 1 to 6 weeks. You also may need crutches for 1 to 6 weeks. How long you will need to use a crutch and brace will depend on the type of surgery you had and the extent of the reconstruction. Most people are allowed to move their knee right after surgery. This may help prevent stiffness. You may need medicine for your pain.\n\nPhysical therapy can help many people regain motion and strength in their knee. Therapy can last up to 4 to 6 months.\n\nHow soon you return to work will depend on the kind of work you do. It can be from a few days to a few months. A full return to activities and sports will often take 4 to 6 months. Sports that involve quick changes in direction, such as soccer, basketball, and football, may require up to 9 to 12 months of rehabilitation.\n\n**Outlook (Prognosis)**\n\nMost people will have a stable knee that does not give way after ACL reconstruction. Better surgical methods and rehabilitation have led to:\n\n* Less pain and stiffness after surgery\n* Fewer complications with the surgery itself\n* Faster recovery time\n\n---\n\n**ACL Reconstruction**\n\n**What is it?**\nACL reconstruction is surgery to reconstruct the ligament in the center of your knee.\n\n**The Ligament**\nThe anterior cruciate ligament (ACL) connects your shin bone (tibia) to your thigh bone (femur).\n\n**Causes of Injury**\nA tear of this ligament can cause your knee to give way during physical activity, most often during side-step or crossover movements.\n\n**Preparation for Surgery**\n\n* Most people have general anesthesia right before surgery. This means you will be asleep and pain-free.\n* Other kinds of anesthesia, like regional anesthesia or a block, may also be used for this surgery.\n* The tissue to replace your damaged ACL will come from your own body or from a donor.\n\n**Types of Tissue Used**\n\n* **Autograft**: Tissue taken from your own body. Common places to take tissue from are the knee cap tendon, quadriceps tendon, or hamstring tendon.\n* **Allograft**: Tissue taken from a donor. Also known as an allograft or cadaver graft.\n\n**The Procedure**\n\n* The procedure is usually performed with the help of knee arthroscopy. With arthroscopy, a tiny camera is inserted into the knee through a small surgical cut.\n* Your surgeon will make other small cuts around your knee and insert other medical instruments.\n* Your surgeon will fix any other damage found, and then will replace your ACL by following these steps:\n\t1. The torn ligament will be removed with a shaver or other instruments.\n\t2. If your own tissue is being used to make your new ACL, your surgeon will make a larger cut. Then, the autograft will be removed through this cut.\n\t3. Your surgeon will make tunnels and sockets in your bone through which to bring the new tissue. This new tissue will be put at the same place as your old ACL.\n\t4. Your surgeon will attach the new ligament to the bone with screws or other devices to hold it in place.\n\n**Risks**\n\n* Allergic reactions to medicines\n* Breathing problems\n* Bleeding\n* Infection\n* Blood clot in the leg\n* Failure of the ligament to heal\n* Failure of the surgery to relieve symptoms\n* Injury to a nearby blood vessel\n* Pain in the knee\n* Stiffness of the knee or lost range of motion\n* Weakness of the knee\n\n**Before Surgery**\n\n* Always tell your provider what medicines you are taking, even medicines, supplements, or herbs you bought without a prescription.\n* During the 2 weeks before your surgery:\n\t+ You may be asked to stop taking medicines that make it harder for your blood to clot. These include aspirin, ibuprofen (Advil, Motrin), naproxen (Naprosyn, Aleve), and other medicines.\n\t+ Ask your provider which medicines you should still take on the day of your surgery.\n\t+ If you have diabetes, heart disease, or other medical conditions, your surgeon will ask you to see the provider who treats you for these conditions.\n\t+ Tell your provider if you have been drinking a lot of alcohol, more than 1 drink per day for women or 2 drinks per day for men.\n\t+ If you smoke, try to stop. Smoking can slow down wound and bone healing. Ask your providers for help if you need it.\n\n**After Surgery**\n\n* Most people can go home the day of the surgery.\n* You may have to wear a knee brace for the first 1 to 6 weeks.\n* You also may need crutches for 1 to 6 weeks.\n* How long you will need to use a crutch and brace will depend on the type of surgery you had and the extent of the reconstruction.\n* Most people are allowed to move their knee right after surgery. This may help prevent stiffness.\n* You may need medicine for your pain.\n\n**Recovery**\n\n* Physical therapy can help many people regain motion and strength in their knee. Therapy can last up to 4 to 6 months.\n* How soon you return to work will depend on the kind of work you do. It can be from a few days to a few months.\n* A full return to activities and sports will often take 4 to 6 months. Sports that involve quick changes in direction, such as soccer, basketball, and football, may require up to 9 to 12 months of rehabilitation.\n\n**Outlook (Prognosis)**\n\nMost people will have a stable knee that does not give way after ACL reconstruction. Better surgical methods and rehabilitation have led to:\n\n* Less pain and stiffness after surgery\n* Fewer complications with the surgery itself\n* Faster recovery time\n\n---\n\n**ACL Reconstruction**\n\n\\n\\n\n\n**Why the Procedure is Performed**\n\nIf you do not have your ACL reconstructed, your knee may continue to be unstable. This increases the chance you may have a meniscus tear. ACL reconstruction may be used for these knee problems:\n\n* Knee that gives way or feels unstable during daily activities\n* Knee pain\n* Inability to return to sports or other activities\n* When other ligaments are also injured\n* When your meniscus is torn\n\nBefore surgery, talk to your health care provider about the time and effort you will need to recover. You will need to follow a rehabilitation program for 4 to 6 months. Your ability to return to full activity will depend on how well you follow the program.\n\n\\n\\n\n\n**Risks**\n\nThe risks from any anesthesia are:\n\n* Allergic reactions to medicines\n* Breathing problems\n\nThe risks from any surgery are:\n\n* Bleeding\n* Infection\n\nOther risks from this surgery may include:\n\n* Blood clot in the leg\n* Failure of the ligament to heal\n* Failure of the surgery to relieve symptoms\n* Injury to a nearby blood vessel\n* Pain in the knee\n* Stiffness of the knee or lost range of motion\n* Weakness of the knee\n\n\\n\\n\n\n**Before the Procedure**\n\nAlways tell your provider what medicines you are taking, even medicines, supplements, or herbs you bought without a prescription.\n\nDuring the 2 weeks before your surgery:\n\n* Stop taking any medications that may interfere with the surgery.\n\n---\n\n**ACL Reconstruction**\n\n**Before the Procedure**\n\nAlways tell your provider what medicines you are taking, even medicines, supplements, or herbs you bought without a prescription.\n\nDuring the 2 weeks before your surgery:\n\n* You may be asked to stop taking medicines that make it harder for your blood to clot. These include aspirin, ibuprofen (Advil, Motrin), naproxen (Naprosyn, Aleve), and other medicines.\n* Ask your provider which medicines you should still take on the day of your surgery.\n* If you have diabetes, heart disease, or other medical conditions, your surgeon will ask you to see the provider who treats you for these conditions.\n* Tell your provider if you have been drinking a lot of alcohol, more than 1 drink per day for women or 2 drinks per day for men.\n* If you smoke, try to stop. Smoking can slow down wound and bone healing. Ask your providers for help if you need it.\n* Always let your provider know about any cold, flu, fever, herpes breakout, or other illnesses you may have before your surgery.\n\nOn the day of your surgery:\n\n* You will often be asked not to drink or eat anything for 6 to 12 hours before the procedure.\n* Take the medicines you have been told to take with a small sip of water.\n* You will be told when to arrive at the hospital.\n\n**After the Procedure**\n\nMost people can go home the day of the surgery. You may have to wear a knee brace for the first 1 to 6 weeks. You also may need crutches for 1 to 6 weeks. How long you will need to use a crutch and brace will depend on the type of surgery you had and the extent of the reconstruction.\n\nMost people are allowed to move their knee right after surgery. This may help prevent stiffness. You may need medicine for your pain.\n\nPhysical therapy can help many people regain motion and strength in their knee. Therapy can last up to 4 to 6 months.\n\nHow soon you return to work will depend on the kind of work you do. It can be from a few days to a few months. A full return to activities and sports will often take 4 to 6 months. Sports that involve quick changes in direction, such as soccer, basketball, and football, may require up to 9 to 12 months of rehabilitation.\n\n**Outlook (Prognosis)**\n\nMost people will have a stable knee that does not give way after ACL reconstruction. Better surgical methods and rehabilitation have led to:\n\n* Less pain and stiffness after surgery\n* Fewer complications with the surgery itself\n* Faster recovery time\n\n---\n\n**ACL Reconstruction**\n\n\\n\\n\n\n**What is ACL reconstruction?**\n\nACL (Anterior Cruciate Ligament) reconstruction is a surgical procedure to repair a torn ACL in the knee. The ACL is a crucial ligament that provides stability and support to the knee joint.\n\n\\n\\n\n\n**Why is ACL reconstruction necessary?**\n\nA torn ACL can cause severe knee instability, making it difficult to perform daily activities or engage in sports. If left untreated, a torn ACL can lead to further complications, such as meniscal tears or osteoarthritis.\n\n\\n\\n\n\n**How is ACL reconstruction performed?**\n\nACL reconstruction involves the use of arthroscopy, a minimally invasive surgical technique that uses a camera and instruments to repair the damaged ligament. The procedure typically involves:\n\n1.  **Arthroscopic examination**: A surgeon inserts a small camera into the knee joint to examine the damaged ACL.\n2.  **Removal of damaged tissue**: The surgeon removes the damaged or torn ACL tissue.\n3.  **Harvesting of graft**: The surgeon harvests a healthy ligament, usually from the patient's own body (autograft) or from a donor (allograft).\n4.  **Graft preparation**: The harvested ligament is prepared for implantation.\n5.  **Implantation of graft**: The prepared graft is implanted into the knee joint, replacing the damaged ACL.\n\n\\n\\n\n\n**Recovery and rehabilitation**\n\nAfter ACL reconstruction, patients typically undergo a rehabilitation program that includes:\n\n1.  **Immediate post-operative care**: Patients are provided with pain management and wound care instructions.\n2.  **Physical therapy**: A physical therapist helps patients regain strength, mobility, and range of motion in the knee joint.\n3.  **Return to sports**: Patients usually return to their pre-injury level of sports participation within 6-9 months after surgery.\n\n\\n\\n\n\n**Patient instructions**\n\nTo ensure a smooth recovery, patients should:\n\n1.  **Follow post-operative care instructions**: Adhere to pain management and wound care instructions provided by the surgeon.\n2.  **Attend physical therapy sessions**: Regularly attend physical therapy sessions to regain strength and mobility in the knee joint.\n3.  **Return to sports gradually**: Gradually return to sports participation, following the recommended rehabilitation program.\n\n\\n\\n\n\n**Related health topics**\n\nACL reconstruction is related to other health topics, including:\n\n1.  **Knee injuries and disorders**\n2.  **Sports injuries**\n\n\\n\\n",
    "category": "general"
  },
  {
    "title": "ACOX1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/acox1/",
    "content": "**ACOX1 Gene**\n\nThe ACOX1 gene provides instructions for making an enzyme called peroxisomal straight-chain acyl-CoA oxidase. This enzyme is found in sac-like cell structures (organelles) called peroxisomes, which contain a variety of enzymes that break down many different substances.\n\n**Normal Function**\n\nThe peroxisomal straight-chain acyl-CoA oxidase enzyme plays a role in the breakdown of certain fat molecules called very long-chain fatty acids (VLCFAs). Specifically, it is involved in the first step of a process called the peroxisomal fatty acid beta-oxidation pathway. This process shortens the VLCFA molecules by two carbon atoms at a time until the VLCFAs are converted to a molecule called acetyl-CoA, which is transported out of the peroxisomes for reuse by the cell.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Peroxisomal Acyl-CoA Oxidase Deficiency**\n\t+ More than 20 ACOX1 gene mutations have been identified in people with peroxisomal acyl-CoA oxidase deficiency.\n\t+ These mutations prevent the peroxisomal straight-chain acyl-CoA oxidase enzyme from breaking down VLCFAs efficiently, leading to their accumulation in the body.\n\t+ The abnormal fatty acid accumulation triggers inflammation in the nervous system, resulting in the breakdown of myelin and leukodystrophy.\n\t+ Leukodystrophy is likely involved in the development of the neurological abnormalities that occur in peroxisomal acyl-CoA oxidase deficiency.\n\n---\n\n**ACOX1 Gene**\n\nThe ACOX1 gene is responsible for producing an enzyme called acyl-CoA oxidase 1, which plays a crucial role in the breakdown of fatty acids in the body.\n\n**Function of the ACOX1 Gene**\n\nThe ACOX1 gene helps to break down very long chain fatty acids (VLCFAs) efficiently. As a result, these fatty acids accumulate in the body. It is unclear exactly how VLCFA accumulation leads to the specific features of peroxisomal acyl-CoA oxidase deficiency.\n\n**Leukodystrophy and Neurological Abnormalities**\n\nResearchers suggest that the abnormal fatty acid accumulation triggers inflammation in the nervous system that leads to the breakdown of myelin, which is the covering that protects nerves and promotes the efficient transmission of nerve impulses. Destruction of myelin leads to a loss of myelin-containing tissue (white matter) in the brain and spinal cord; loss of white matter is described as leukodystrophy. Leukodystrophy is likely involved in the development of the neurological abnormalities that occur in peroxisomal acyl-CoA oxidase deficiency.\n\n**Other Names for This Gene**\n\n* ACOX acyl-CoA oxidase 1, palmitoyl acyl-CoA oxidase\n* straight-chain acyl-Coenzyme A oxidase 1\n* palmitoyl AOX PALMCOX\n* palmitoyl-CoA oxidase\n* peroxisomal acyl-coenzyme A oxidase 1\n* peroxisomal fatty acyl-CoA oxidase\n* SCOX straight-chain acyl-CoA oxidase\n\n**Genomic Location**\n\nThe ACOX1 gene is found on chromosome 17.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n---\n\n**ACOX1 Gene**\n\n\\n\\n* **What is the ACOX1 gene?**\n* **How do changes in the ACOX1 gene affect people?**\n\nNote: The original content has been reformatted to meet the specified requirements, with bold headings and a clear separation of sections.",
    "category": "general"
  },
  {
    "title": "ACP5 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/acp5/",
    "content": "**ACP5 Gene**\n\nThe ACP5 gene provides instructions for making an enzyme called tartrate-resistant acid phosphatase type 5 (TRAP). The TRAP enzyme primarily regulates the activity of a protein called osteopontin, which is produced in bone cells called osteoclasts and in immune cells.\n\n**Normal Function**\n\n*   The ACP5 gene provides instructions for making an enzyme called tartrate-resistant acid phosphatase type 5 (TRAP).\n*   The TRAP enzyme primarily regulates the activity of a protein called osteopontin, which is produced in bone cells called osteoclasts and in immune cells.\n*   Osteopontin performs a variety of functions in these cells. Two versions (isoforms) of the TRAP enzyme are produced: TRAP5a is found primarily in immune cells and TRAP5b is found primarily in bone cells called osteoclasts.\n\n**Osteoclasts**\n\n*   Osteoclasts are specialized cells that break down and remove (resorb) bone tissue that is no longer needed.\n*   These cells are involved in bone remodeling, which is a normal process that replaces old bone tissue with new bone.\n*   During bone remodeling, osteopontin is turned on (activated), allowing osteoclasts to attach (bind) to bones. When the breakdown of bone is complete, TRAP5b turns off (inactivates) osteopontin, causing the osteoclasts to release themselves from bone.\n\n**Immune System**\n\n*   In the immune system, osteopontin is found primarily in cells called macrophages and dendritic cells.\n*   The protein helps fight infection by promoting inflammation, regulating immune cell activity, and turning on various immune system cells that are necessary to fight off foreign invaders such as bacteria and viruses.\n*   Like TRAP5b in bone cells, the TRAP5a enzyme inactivates osteopontin in macrophages and dendritic cells when it is no longer needed.\n\n---\n\n**ACP5 Gene**\n\nThe ACP5 gene provides instructions for making an enzyme called tartrate-resistant acid phosphatase type 5 (TRAP). The TRAP enzyme primarily regulates the activity of a protein called osteopontin, which is produced in bone cells called osteoclasts and in immune cells.\n\n**Osteopontin**\n\nOsteopontin performs a variety of functions in these cells. Two versions (isoforms) of the TRAP enzyme are produced: TRAP5a is found primarily in immune cells and TRAP5b is found primarily in bone cells called osteoclasts.\n\n**Bone Remodeling**\n\nDuring bone remodeling, osteopontin is turned on (activated), allowing osteoclasts to attach (bind) to bones. When the breakdown of bone is complete, TRAP5b turns off (inactivates) osteopontin, causing the osteoclasts to release themselves from bone.\n\n**Immune System**\n\nIn the immune system, osteopontin is found primarily in cells called macrophages and dendritic cells. The protein helps fight infection by promoting inflammation, regulating immune cell activity, and turning on various immune system cells that are necessary to fight off foreign invaders such as bacteria and viruses. Like TRAP5b in bone cells, the TRAP5a enzyme inactivates osteopontin in macrophages and dendritic cells when it is no longer needed.\n\n**Health Conditions Related to Genetic Changes**\n\nAt least 10 mutations in the ACP5 gene have been found to cause spondyloenchondrodysplasia with immune dysregulation (SPENCDI). This condition is characterized by abnormalities in bone growth and immune system function. The ACP5 gene mutations that cause SPENCDI typically change single protein building blocks (amino acids) in the TRAP enzyme or result in the production of an abnormally short enzyme. These mutations affect both TRAP isoforms and impair or eliminate TRAP's ability to inactivate osteopontin.\n\n**SPENCDI Features**\n\nIn people with SPENCDI, increased bone breakdown contributes to the skeletal abnormalities, including irregularly shaped bones and short stature. An overactive immune system leads to increased susceptibility to autoimmune disorders, which occur when the immune system malfunctions and attacks the body's own tissues and organs. Immune system abnormalities also impair the body's normal response to harmful invaders, resulting in frequent infections. SPENCDI has several additional features, including movement disorders and intellectual disability, but it is unknown how changes in TRAP enzyme function lead to these other signs and symptoms.\n\n---\n\n**ACP5 Gene**\n\nThe ACP5 gene is associated with an immune system malfunction that leads to the body's own tissues and organs being attacked. This condition also impairs the body's normal response to harmful invaders, resulting in frequent infections.\n\n**Other Names for This Gene**\n\n* PPA5_HUMAN\n* tartrate-resistant acid ATPase\n* tartrate-resistant acid phosphatase type 5\n* TRAP\n* TrATPase\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: Tests of ACP5\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM: PHOSPHATASE, ACID, TYPE 5, TARTRATE-RESISTANT; ACP5\n* Gene and Variant Databases: NCBI Gene, ClinVar\n\n**References**\n\n* Behrens TW, Graham RR. TRAPing a new gene for autoimmunity. Nat Genet. 2011 Feb;43(2):90-1.\n* Briggs TA, Rice GI, Daly S, Urquhart J, Gornall H, Bader-Meunier B, et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet. 2011 Feb;43(2):127-31.\n* Hayman AR. Tartrate-resistant acid phosphatase (TRAP) and the osteoclast/immune cell dichotomy. Autoimmunity. 2008 Apr;41(3):218-23.\n* Lausch E, Janecke A, Bros M, et al. Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity. Nat Genet. 2011 Feb;43(2):132-7.\n\n**Genomic Location**\n\nThe ACP5 gene is found on chromosome 19.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ACSF3 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/acsf3/",
    "content": "**ACSF3 Gene**\n\nThe **ACSF3 gene** provides instructions for making an enzyme involved in the formation (synthesis) of fatty acids, which are building blocks used to make fats (lipids). The **ACSF3 enzyme** performs a chemical reaction that converts malonic acid to malonyl-CoA, which is the first step of fatty acid synthesis. Based on this activity, the enzyme is classified as a malonyl-CoA synthetase. The **ACSF3 enzyme** also converts methylmalonic acid to methylmalonyl-CoA, making it a methylmalonyl-CoA synthetase as well.\n\nFatty acid synthesis occurs through two pathways, one of which takes place in cellular structures called mitochondria. Mitochondria convert the energy from food into a form that cells can use, and fatty acid synthesis in these structures is thought to be important for their proper functioning. The **ACSF3 enzyme** is found only in mitochondria and is involved in mitochondrial fatty acid synthesis.\n\n**Health Conditions Related to Genetic Changes**\n\n*   Combined malonic and methylmalonic aciduria (CMAMMA)\n    About a dozen mutations in the **ACSF3 gene** have been found in people with CMAMMA, a condition characterized by elevated levels of chemicals known as malonic acid and methylmalonic acid in the body. This condition can cause development and growth problems beginning in childhood or neurological problems beginning in adulthood.\n    Most **ACSF3 gene** mutations involved in CMAMMA change single protein building blocks (amino acids) in the **ACSF3 enzyme**. The altered enzyme likely has little or no function. Because the enzyme cannot convert malonic and methylmalonic acids, they build up in the body. Damage to organs and tissues caused by accumulation of malonic and methylmalonic acids may be responsible for the signs and symptoms of CMAMMA, although the mechanisms are unclear.\n\n---\n\n**ACSF3 Gene**\n\nThe ACSF3 gene is responsible for building the enzyme that converts malonic and methylmalonic acids in the body. The altered enzyme likely has little or no function, leading to the accumulation of these chemicals in the body. This condition can cause development and growth problems beginning in childhood or neurological problems beginning in adulthood.\n\n**About a Dozen Mutations Found**\n\nAround a dozen mutations in the ACSF3 gene have been found in people with combined malonic and methylmalonic aciduria (CMAMMA). This condition is characterized by elevated levels of malonic acid and methylmalonic acid in the body. The altered enzyme cannot convert these acids, leading to their accumulation in the body.\n\n**Damage to Organs and Tissues**\n\nThe accumulation of malonic and methylmalonic acids may be responsible for the signs and symptoms of CMAMMA, although the mechanisms are unclear. Damage to organs and tissues caused by the accumulation of these chemicals may lead to various health problems.\n\n**Other Names for This Gene**\n\n*   ACSF3_HUMAN\n*   acyl-CoA synthetase family member 3, mitochondrial\n*   acyl-CoA synthetase family member 3, mitochondrial precursor\n\n**Genomic Location**\n\nThe ACSF3 gene is found on chromosome 16.\n\n**Related Health Topics**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ACTA1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/acta1/",
    "content": "**ACTA1 Gene**\n\nThe ACTA1 gene provides instructions for making a protein called skeletal alpha (Î±)-actin, which is part of the actin protein family. Actin proteins are important for cell movement and the tensing of muscle fibers (muscle contraction). These proteins also help maintain the cytoskeleton, which is the structural framework that determines cell shape and organizes cell contents.\n\n**Skeletal Î±-Actin**\n\nSkeletal Î±-actin plays an important role in skeletal muscles, which are muscles that the body uses for movement. Within skeletal muscle cells, skeletal Î±-actin is an essential component of structures called sarcomeres. Sarcomeres are composed of thin filaments made up of actin and thick filaments made up of another protein called myosin. Attachment (binding) and release of the overlapping thick and thin filaments allows them to move relative to each other so that the muscles can contract.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Actin-accumulation Myopathy**\n    At least nine variants in the ACTA1 gene have been identified in people with actin-accumulation myopathy. Most of these variants change single protein building blocks (amino acids) in the skeletal Î±-actin protein sequence.\n    Researchers suggest that ACTA1 gene variants that cause actin-accumulation myopathy may affect the way the actin binds to ATP. ATP is a molecule that supplies energy for cells' activities and is important in the formation of thin filaments from individual actin molecules. Dysfunctional actin-ATP binding may result in abnormal thin filament formation and impair muscle contraction, leading to muscle weakness and the other signs and symptoms of actin-accumulation myopathy.\n*   **Cap Myopathy**\n    At least one ACTA1 gene variant has been identified as a cause of cap myopathy. The variant replaces the amino acid methionine with the amino acid valine at position 47 in the protein sequence, written as Met47Val or M47V. The resulting abnormal protein may interfere with the proper assembly of thin filaments. Cap myopathy is characterized by the presence of cap-like structures in muscle cells, and these structures are composed of disorganized thin filaments.\n*   **Congenital Fiber-Type Disproportion**\n    At least seven variants in the ACTA1 gene have been found to cause congenital fiber-type disproportion, a disorder that causes general muscle weakness that typically does not worsen over time. The variants that cause this condition change single amino acids in skeletal Î±-actin. These variants lead to the production of an abnormal actin protein, which interferes with the function of normal actin proteins in the sarcomere. As a result, the function of the sarcomere is impaired, which disrupts muscle contraction. Inefficient muscle contraction leads to muscle weakness in people with congenital fiber-type disproportion.\n\n---\n\n**ACTA1 Gene: MedlinePlus Genetics**\n\n*   **Intranuclear Rod Myopathy**\n    At least 13 variants in the ACTA1 gene have been identified in people with intranuclear rod myopathy. These variants change single amino acids in the skeletal Î±-actin protein sequence.\n    The abnormal accumulation of actin in the nucleus of muscle cells and a corresponding reduction of available actin in muscle fibers may impair muscle contraction and lead to the muscle weakness seen in intranuclear rod myopathy.\n*   **Nemaline Myopathy**\n    More than 170 variants in the ACTA1 gene have been found to cause nemaline myopathy. Nemaline myopathy is the most common muscle disorder associated with ACTA1 gene variants.\n    Some of the variants that cause this disorder alter the structure or function of skeletal Î±-actin, causing the protein to cluster together and form clumps (aggregates).\n*   **Actin-Accumulation Myopathy**\n    At least nine variants in the ACTA1 gene have been identified in people with actin-accumulation myopathy. Most of these variants change single protein building blocks (amino acids) in the skeletal Î±-actin protein sequence.\n    Researchers suggest that ACTA1 gene variants that cause actin-accumulation myopathy may affect the way the actin binds to ATP.\n*   **Cap Myopathy**\n    At least one ACTA1 gene variant has been identified as a cause of cap myopathy. The variant replaces the amino acid methionine with the amino acid valine at position 47 in the protein sequence, written as Met47Val or M47V.\n    Cap myopathy is characterized by the presence of cap-like structures in muscle cells, and these structures are composed of disorganized thin filaments.\n*   **Congenital Fiber-Type Disproportion**\n    At least seven variants in the ACTA1 gene have been found to cause congenital fiber-type disproportion, a disorder that causes general muscle weakness that typically does not worsen over time.\n\n---\n\n**ACTA1 Gene: MedlinePlus Genetics (Part 3/5)**\n\n**Congenital Fiber-Type Disproportion**\n\nAt least seven variants in the ACTA1 gene have been found to cause congenital fiber-type disproportion, a disorder that causes general muscle weakness that typically does not worsen over time. The variants that cause this condition change single amino acids in skeletal Î±-actin.\n\nThese variants lead to the production of an abnormal actin protein, which interferes with the function of normal actin proteins in the sarcomere. As a result, the function of the sarcomere is impaired, which disrupts muscle contraction. Inefficient muscle contraction leads to muscle weakness in people with congenital fiber-type disproportion.\n\n**Intranuclear Rod Myopathy**\n\nAt least 13 variants in the ACTA1 gene have been identified in people with intranuclear rod myopathy. These variants change single amino acids in the skeletal Î±-actin protein sequence.\n\nACTA1 gene variants that cause intranuclear rod myopathy result in rod-shaped accumulations of actin in the nucleus of muscle cells. Normally, most actin is found in the fluid surrounding the nucleus (the cytoplasm), with small amounts in the nucleus itself. Researchers suggest that the ACTA1 gene variants that cause intranuclear rod myopathy may interfere with the normal transport of actin between the nucleus and the cytoplasm, resulting in the accumulation of actin in the nucleus and the formation of intranuclear rods.\n\nAbnormal accumulation of actin in the nucleus of muscle cells and a corresponding reduction of available actin in muscle fibers may impair muscle contraction and lead to the muscle weakness seen in intranuclear rod myopathy. A few ACTA1 gene variants that have been identified in people with intranuclear rod myopathy have also been found in people with actin-accumulation myopathy (described above). It is unclear how the same variants can cause two different conditions.\n\n**Nemaline Myopathy**\n\nMore than 170 variants in the ACTA1 gene have been found to cause nemaline myopathy. Nemaline myopathy is the most common muscle disorder associated with ACTA1 gene variants. Some of the variants that cause this disorder alter the structure or function of skeletal Î±-actin, causing the protein to cluster together and form clumps (aggregates). These aggregates interfere with the normal functioning of muscle cells.\n\nOther ACTA1 gene variants prevent the production of any skeletal Î±-actin, impairing the muscle cells' ability to contract. ACTA1 gene variants that cause nemaline myopathy impair muscle contraction, causing weakness and the other features of this condition.\n\n**Other Names for This Gene**\n\n* ACTA\n* ACTS_HUMAN\n* alpha skeletal muscle actin\n* ASMA\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: Tests of ACTA1\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM: ACTIN, ALPHA-1, SKELETAL MUSCLE; ACTA1\n\n---\n\n**ACTA1 Gene**\n\nThe ACTA1 gene provides instructions for making a protein called skeletal muscle alpha-actin. This protein is found in the muscles of the skeleton and plays a crucial role in muscle contraction.\n\n**Scientific Articles on PubMed**\n\n* Agrawal PB, Strickland CD, Midgett C, Morales A, Newburger DE, Poulos MA, Tomczak KK, Ryan MM, Iannaccone ST, Crawford TO, Laing NG, Beggs AH. Heterogeneity of nemaline myopathy cases with skeletal muscle alpha-actin gene mutations. Ann Neurol. 2004 Jul;56(1):86-96.\n* Castiglioni C, Cassandrini D, Fattori F, Bellacchio E, D'Amico A, Alvarez K, Gejman R, Diaz J, Santorelli FM, Romero NB, Bertini E, Bevilacqua JA. Muscle magnetic resonance imaging and histopathology in ACTA1-related congenital nemaline myopathy. Muscle Nerve. 2014 Dec;50(6):1011-6.\n* Clarke NF, Ilkovski B, Cooper S, Valova VA, Robinson PJ, Nonaka I, Feng JJ, Marston S, North K. The pathogenesis of ACTA1-related congenital fiber type disproportion. Ann Neurol. 2007 Jun;61(6):552-61.\n\n**Catalog of Genes and Diseases from OMIM**\n\n* ACTIN, ALPHA-1, SKELETAL MUSCLE; ACTA1\n\n**Gene and Variant Databases**\n\n* NCBI Gene\n* ClinVar\n\n**Tests Listed in the Genetic Testing Registry**\n\n* Tests of ACTA1\n\n---\n\n**ACTA1 Gene**\n\n**Category:** general\n\n**Genomic Location**\nThe ACTA1 gene is found on chromosome 1.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.\n\n**Research Articles**\n\n* Laing NG, Dye DE, Wallgren-Pettersson C, Richard G, Monnier N, Lillis S, Winder TL, Lochmuller H, Graziano C, Mitrani-Rosenbaum S, Twomey D, Sparrow JC, Beggs AH, Nowak KJ. Mutations and polymorphs of the skeletal muscle alpha-actin gene (ACTA1). Hum Mutat. 2009 Sep;30(9):1267-77.\n* Nowak KJ, Sewry CA, Navarro C, Squier W, Reina C, Ricoy JR, Jayawant SS, Childs AM, Dobbie JA, Appleton RE, Mountford RC, Walker KR, Clement S, Barois A, Muntoni F, Romero NB, Laing NG. Nemaline myopathy caused by absence of alpha-skeletal muscle actin. Ann Neurol. 2007 Feb;61(2):175-84.\n* Ochala J. Thin filament proteins mutations associated with skeletal myopathies: defective regulation of muscle contraction. J Mol Med (Berl). 2008 Nov;86(11):1197-204.\n* Schroder JM, Durling H, Laing N. Actin myopathy with nemaline bodies, intranuclear rods, and a heterozygous mutation in ACTA1 (Asp154Asn). Acta Neuropathol. 2004 Sep;108(3):250-6.\n* Sparrow JC, Nowak KJ, Durling HJ, Beggs AH, Wallgren-Pettersson C, Romero N, Nonaka I, Laing NG. Muscle disease caused by mutations in the skeletal muscle alpha-actin gene (ACTA1). Neuromuscul Disord. 2003 Sep;13(7-8):519-31.\n* Wallefeld W, Krause S, Nowak KJ, Dye D, Horvath R, Molnar Z, Szabo M, Hashimoto K, Reina C, De Carlos J, Rosell J, Cabello A, Navarro C, Nishino I, Lochmuller H, Laing NG. Severe nemaline myopathy caused by mutations of the stop codon of the skeletal muscle alpha actin gene (ACTA1). Neuromuscul Disord. 2006 Oct;16(9-10):541-7.",
    "category": "general"
  },
  {
    "title": "ACTA2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/acta2/",
    "content": "**ACTA2 Gene**\n\nThe ACTA2 gene provides instructions for making a protein called smooth muscle alpha (Î±)-2 actin, which is part of the actin protein family. Actin proteins are important for cell movement and the tensing (contraction) of muscles.\n\n**Normal Function**\n\nSmooth muscle Î±-2 actin is found in smooth muscle cells. Smooth muscles line the internal organs, including the blood vessels, stomach, and intestines. Within smooth muscle cells, smooth muscle Î±-2 actin forms the core of structures called sarcomeres, which are necessary for muscles to contract. Smooth muscles contract and relax as part of their normal function without being consciously controlled.\n\nLayers of smooth muscle cells are found in the walls of the arteries, which are blood vessels that carry blood from the heart to the rest of the body. Smooth muscle Î±-2 actin contributes to the ability of these muscles to contract, which allows the arteries to maintain their shape instead of stretching out as blood is pumped through them.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Familial Thoracic Aortic Aneurysm and Dissection**\n    More than 30 ACTA2 gene mutations have been identified in people with familial thoracic aortic aneurysm and dissection (familial TAAD). This disorder involves problems with the aorta, which is the large blood vessel that distributes blood from the heart to the rest of the body. The aorta can weaken and stretch, causing a bulge in the blood vessel wall (an aneurysm). Stretching of the aorta may also lead to a sudden tearing of the layers in the aorta wall (aortic dissection). Aortic aneurysm and dissection can cause life-threatening internal bleeding.\n\n    ACTA2 gene mutations that are associated with familial TAAD change single protein building blocks (amino acids) in the smooth muscle Î±-2 actin protein. These changes likely affect the way the protein functions in smooth muscle contraction, interfering with the sarcomeres' ability to prevent arteries from stretching. The aorta, where the force of pumping blood coming directly from the heart is most intense, is particularly vulnerable to this stretching, resulting in the aortic aneurysms and dissections associated with familial TAAD.\n\n---\n\n**ACTA2 Gene**\n\n**Other Disorders**\n\nAt least one mutation in the ACTA2 gene causes multisystemic smooth muscle dysfunction syndrome. This disorder impairs the activity of smooth muscles throughout the body and leads to widespread problems including blood vessel abnormalities, decreased response of the pupils to light, a weak (hypotonic) bladder, and impairment of the muscle contractions that move food through the digestive tract (hypoperistalsis).\n\nThe mutation that causes multisystemic smooth muscle dysfunction syndrome replaces the amino acid arginine with the amino acid histidine at protein position 179, written as Arg179His or R179H. This mutation results in impaired contraction of smooth muscles in many organs, leading to the signs and symptoms of multisystemic smooth muscle dysfunction syndrome. It is unclear why this ACTA2 gene mutation has effects on smooth muscles throughout the body while others affect only the aorta.\n\n**Familial Thoracic Aortic Aneurysm and Dissection**\n\nMore than 30 ACTA2 gene mutations have been identified in people with familial thoracic aortic aneurysm and dissection (familial TAAD). This disorder involves problems with the aorta, which is the large blood vessel that distributes blood from the heart to the rest of the body. The aorta can weaken and stretch, causing a bulge in the blood vessel wall (an aneurysm). Stretching of the aorta may also lead to a sudden tearing of the layers in the aorta wall (aortic dissection). Aortic aneurysm and dissection can cause life-threatening internal bleeding.\n\nACTA2 gene mutations that are associated with familial TAAD change single protein building blocks (amino acids) in the smooth muscle Î±-2 actin protein. These changes likely affect the way the protein functions in smooth muscle contraction, interfering with the sarcomeres' ability to prevent arteries from stretching. The aorta, where the force of pumping blood coming directly from the heart is most intense, is particularly vulnerable to this stretching, resulting in the aortic aneurysms and dissections associated with familial TAAD.\n\n**Other Names for This Gene**\n\nAAT6 ACTA_HUMAN actin, aortic smooth muscle ACTSA alpha 2 actin alpha-actin-2 cell growth-inhibiting gene 46 protein growth-inhibiting gene 46\n\n**Additional Information & Resources**\n\nTests Listed in the Genetic Testing Registry:\n\n* Tests of ACTA2\n\nScientific Articles on PubMed:\n\n* PubMed\n\n---\n\n**ACTA2 Gene**\n\n**Information & Resources**\n\nExpand Section\n\n* **Tests Listed in the Genetic Testing Registry**\n\t+ Tests of ACTA2\n\n**Scientific Articles on PubMed**\n\n*   PubMed\n\n**Catalog of Genes and Diseases from OMIM**\n\n*   **ACTIN, ALPHA-2, SMOOTH MUSCLE, AORTA; ACTA2**\n*   **SMOOTH MUSCLE DYSFUNCTION SYNDROME; SMDYS**\n\n**Gene and Variant Databases**\n\n*   **NCBI Gene**\n*   **ClinVar**\n*   **Tests Listed in the Genetic Testing Registry**\n\t+ Tests of ACTA2\n*   **Scientific Articles on PubMed**\n\t+ PubMed\n*   **Catalog of Genes and Diseases from OMIM**\n\t+ **ACTIN, ALPHA-2, SMOOTH MUSCLE, AORTA; ACTA2**\n\t+ **SMOOTH MUSCLE DYSFUNCTION SYNDROME; SMDYS**\n*   **Gene and Variant Databases**\n\t+ **NCBI Gene**\n\t+ **ClinVar**\n\n**References**\n\nExpand Section\n\n*   El-Hamamsy I, Yacoub MH. Cellular and molecular mechanisms of thoracic aortic aneurysms. Nat Rev Cardiol. 2009 Dec;6(12):771-86. doi: 10.1038/nrcardio.2009.191. Epub 2009 Nov 3.\n*   Grond-Ginsbach C, Pjontek R, Aksay SS, Hyhlik-Durr A, Bockler D, Gross-Weissmann ML. Spontaneous arterial dissection: phenotype and molecular pathogenesis. Cell Mol Life Sci. 2010 Jun;67(11):1799-815. doi: 10.1007/s00018-010-0276-z. Epub 2010 Feb 14.\n*   Guo DC, Pannu H, Tran-Fadulu V, Papke CL, Yu RK, Avidan N, Bourgeois S, Estrera AL, Safi HJ, Sparks E, Amor D, Ades L, McConnell V, Willoughby CE, Abuelo D, Willing M, Lewis RA, Kim DH, Scherer S, Tung PP, Ahn C, Buja LM, Raman CS, Shete SS, Milewicz DM. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet. 2007 Dec;39(12):1488-93. doi: 10.1038/ng.2007.6. Epub 2007 Nov 11.\n*   Jondeau G, Boileau C. Genetics of thoracic aortic aneurysms. Curr Atheroscler Rep. 2012 Jun;14(3):219-26. doi: 10.1007/s11883-012-0241-4.\n*   Milewicz DM, Carlson AA, Regalado ES. Genetic testing in aortic aneurysm disease: PRO. Cardiol Clin. 2010 May;28(2):191-7. doi: 10.1016/j.ccl.2010.01.017.\n*   Milewicz DM, Cecchi AC. Heritable Thoracic Aortic Disease Overview. 2003 Feb 13 [updated 2023 May 4]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from http://www.ncbi.nlm.nih.gov/books/NBK1120/\n*   Milewicz DM, Guo DC, Tran-Fadulu V, Lafont AL, Papke CL, Inamoto S, Kwartler CS, Pannu H. Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction. Annu Rev Genomics Hum Genet. 2008;9:283-302. doi: 10.1146/annurev.genom.8.080706.092303.\n*   Milewicz DM, Ostergaard JR, Ala-Kokko LM, Khan N, Grange DK, Mendoza-Londono R, Bradley TJ, Olney AH, Ades L, Maher JF, Guo D, Buja LM, Kim D, Hyland JC, Regalado ES. De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction. Am J Med Genet A. 2010 Oct;152A(10):2437-43. doi: 10.1002/ajmg.a.33657.\n*   Morisaki H, Akutsu K, Ogino H, Kondo N, Yamanaka I, Tsutsumi Y, Yoshimuta T, Okajima T, Matsuda H, Minatoya K, Sasaki H, Tanaka H, Ishibashi-Ueda H, Morisaki T. Mutation of ACTA2 gene as an important cause of familial and nonfamilial nonsyndromatic thoracic aortic aneurysm and/or dissection (TAAD). Hum Mutat. 2009 Oct;30(10):1406-11. doi: 10.1002/humu.21081.\n*   Pyeritz RE. Heritable thoracic aortic disorders. Curr Opin Cardiol. 2014 Jan;29(1):97-102. doi: 10.1097/HCO.0000000000000023.\n\n**Genomic Location**\n\nThe ACTA2 gene is found on chromosome 10.\n\n**Related Health Topics**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders\n\n**Understanding Genetics**\n\n*   What is DNA?\n*   What is a gene?\n*   What is a gene variant and how do variants occur?\n\nNote: The above content has been cleaned, formatted, and structured according to the provided guidelines.\n\n---\n\n**ACTA2 Gene**\n\n\\n\\n\n\n**Genomic Location**\nThe ACTA2 gene is found on chromosome 10.\n\n\\n\\n\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders\n\n\\n\\n\n\n* **Understanding Genetics**\n\t+ What is DNA?\n\t+ What is a gene?\n\t+ What is a gene variant and how do variants occur?\n\n\\n\\n\n\n**Disclaimers**\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ACTB gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/actb/",
    "content": "**ACTB Gene**\n\nThe ACTB gene provides instructions for making a protein called beta (Î²)-actin, which is part of the actin protein family. Proteins in this family are organized into a network of fibers called the actin cytoskeleton, which makes up the structural framework inside cells.\n\n**Normal Function**\n\n* The ACTB gene provides instructions for making a protein called beta (Î²)-actin.\n* Proteins in this family are organized into a network of fibers called the actin cytoskeleton, which makes up the structural framework inside cells.\n* There are six types of actin; four are present only in muscle cells, where they are involved in the tensing of muscle fibers (muscle contraction).\n* The other two actin proteins, Î²-actin and gamma (Î³)-actin (produced from the ACTG1 gene), are found in cells throughout the body.\n* These proteins play important roles in determining cell shape and controlling cell movement (motility).\n* Studies suggest that Î²-actin may also be involved in relaying chemical signals within cells.\n\n**Health Conditions Related to Genetic Changes**\n\nSeveral mutations in the ACTB gene have been found to cause Baraitser-Winter syndrome, a rare condition that affects the development of the brain, eyes, and other facial features. The known mutations change single protein building blocks (amino acids) in Î²-actin. The most common mutation replaces the amino acid arginine with the amino acid histidine at protein position 196 (written as Arg196His or R196H). The mutations that cause Baraitser-Winter syndrome alter the function of Î²-actin, which causes changes in the actin cytoskeleton that modify the structure and organization of cells and affect their ability to move.\n\n---\n\n**ACTB Gene: MedlinePlus Genetics**\n\n**What is the ACTB gene?**\n\nThe ACTB gene provides instructions for making a protein called beta-actin, which is essential for cell movement and structure. Alterations in the ACTB gene have been linked to Baraitser-Winter syndrome.\n\n**Coloboma**\n\n*   Coloboma: A congenital defect of the eye characterized by an abnormal formation of the optic nerve.\n*   MedlinePlus Genetics provides information about Coloboma [More About This Health Condition](#).\n\n**Other Names for This Gene**\n\n*   ACTB_HUMAN\n*   actin, beta\n*   actin, cytoplasmic 1\n*   beta cytoskeletal actin\n*   BRWS1\n*   PS1TP5-binding protein 1\n*   PS1TP5BP1\n\n**Additional Information & Resources**\n\n*   Tests Listed in the Genetic Testing Registry:\n    *   Tests of ACTB\n*   Scientific Articles on PubMed:\n    *   PubMed\n*   Catalog of Genes and Diseases from OMIM:\n    *   ACTIN, BETA; ACTB\n*   Gene and Variant Databases:\n    *   NCBI Gene\n    *   ClinVar\n\n**References**\n\n*   Dugina V, Zwaenepoel I, Gabbiani G, Clement S, Chaponnier C. Beta and gamma-cytoplasmic actins display distinct distribution and functional diversity. J Cell Sci. 2009 Aug 15;122(Pt 16):2980-8. doi: 10.1242/jcs.041970. Epub 2009 Jul 28.\n*   Riviere JB, van Bon BW, Hoischen A, Kholmanskikh SS, O'Roak BJ, Gilissen C, Gijsen S, Sullivan CT, Christian SL, Abdul-Rahman OA, Atkin JF, Chassaing N, Drouin-Garraud V, Fry AE, Fryns JP, Gripp KW, Kempers M, Kleefstra T, Mancini GM, Nowaczyk MJ, van Ravenswaaij-Arts CM, Roscioli T, Marble M, Rosenfeld JA, Siu VM, de Vries BB, Shendure J, Verloes A, Veltman JA, Brunner HG, Ross ME, Pilz DT, Dobyns WB. De novo mutations in the actin genes ACTB and ACTG1 cause Baraitser-Winter syndrome. Nat Genet. 2012 Feb 26;44(4):440-4, S1-2. doi: 10.1038/ng.1091.\n*   Su Y, Kondrikov D, Block ER. Beta-actin: a regulator of NOS-3. Sci STKE. 2007 Sep 18;2007(404):pe52. doi: 10.1126/stke.4042007pe52.\n\n**Genomic Location**\n\nThe ACTB gene is found on chromosome 7.\n\n**Related Health Topics**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ACTG1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/actg1/",
    "content": "**ACTG1 Gene**\n\nThe ACTG1 gene provides instructions for making a protein called gamma (Î³)-actin, which is part of the actin protein family. Proteins in this family are organized into a network of fibers called the actin cytoskeleton, which makes up the structural framework inside cells.\n\nThere are six types of actin; four are present only in muscle cells, where they are involved in the tensing of muscle fibers (muscle contraction). The other two actin proteins, Î³-actin and beta (Î²)-actin (produced from the ACTB gene), are found in cells throughout the body. These proteins play important roles in determining cell shape and controlling cell movement (motility).\n\nÎ³-actin is particularly abundant in certain cells in the intestines and the inner ear. Within the inner ear, this protein is found in specialized cells called hair cells, which are essential for normal hearing.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Baraitser-Winter Syndrome**: At least six mutations in the ACTG1 gene have been found to cause Baraitser-Winter syndrome, a rare condition that affects the development of the brain, eyes, and other facial features. The known mutations change single protein building blocks (amino acids) in Î³-actin.\n*   **Nonsyndromic Hearing Loss**: Problems with the function of Î³-actin likely impact many aspects of development, which may lead to nonsyndromic hearing loss.\n\n**Other Names for This Gene**\n\n*   actin gamma 1\n\n**Additional Information & Resources**\n\n*   MedlinePlus Genetics provides information about various health conditions related to genetic changes.\n*   References: A list of sources used to gather information about the ACTG1 gene.\n\n---\n\n**ACTG1 Gene**\n\n**Coloboma**\n\nMedlinePlus Genetics provides information about Coloboma.\n\n**Baraitser-Winter Syndrome**\n\nAt least six mutations in the ACTG1 gene have been found to cause Baraitser-Winter syndrome, a rare condition that affects the development of the brain, eyes, and other facial features. The known mutations change single protein building blocks (amino acids) in Î³-actin. The most common mutation replaces the amino acid serine with the amino acid phenylalanine at protein position 155 (written as Ser155Phe or S155F). The mutations that cause Baraitser-Winter syndrome alter the function of Î³-actin, which causes changes in the actin cytoskeleton that modify the structure and organization of cells and affect their ability to move. Because Î³-actin is present in cells throughout the body and is involved in many cell activities, problems with its function likely impact many aspects of development. These changes underlie the variety of signs and symptoms associated with Baraitser-Winter syndrome.\n\n**Nonsyndromic Hearing Loss**\n\nMedlinePlus Genetics provides information about Nonsyndromic hearing loss.\n\n**Other Names for This Gene**\n\nACT ACTG ACTG_HUMAN actin, cytoplasmic 2 actin, gamma 1 actin-like protein cytoskeletal gamma-actin deafness, autosomal dominant 20 deafness, autosomal dominant 26 DFNA20 DFNA26 gamma-actin\n\n**Additional Information & Resources**\n\nTests Listed in the Genetic Testing Registry:\n\n* Tests of ACTG1\n\nScientific Articles on PubMed:\n\n* PubMed\n\nCatalog of Genes and Diseases from OMIM:\n\n* ACTIN, GAMMA-1; ACTG1\n\nGene and Variant Databases:\n\n* NCBI Gene\n* ClinVar\n\n**References**\n\nBryan KE, Wen KK, Zhu M, Rendtorff ND, Feldkamp M, Tranebjaerg L, Friderici KH, Rubenstein PA. Effects of human deafness gamma-actin mutations (DFNA20/26) on actin function. J Biol Chem. 2006 Jul 21;281(29):20129-39.\n\nDugina V, Zwaenepoel I, Gabbiani G, Clement S, Chaponnier C. Beta and gamma-cytoplasmic actins display distinct distribution and functional diversity. J Cell Sci. 2009 Aug 15;122(Pt 16):2980-8.\n\nRendtorff ND, Zhu M, Fagerheim T, Antal TL, Jones M, Teslovich TM, Gillanders EM, Barmada M, Teig E, Trent JM, Friderici KH, Stephan DA, Tranebjaerg L. A novel missense mutation in ACTG1 causes dominant deafness in a Norwegian DFNA20/26 family, but ACTG1 mutations are not frequent among families with hereditary hearing impairment.\n\nRiviere JB, van Bon BW, Hoischen A, Kholmanskikh SS, O'Roak BJ, Gilissen C, Gijsen S, Sullivan CT, Christian SL, Abdul-Rahman OA, Atkin JF, Chassaing N, Drouin-Garraud V, Fry AE, Fryns JP, Gripp KW, Kempers M, Kleefstra T, Mancini GM, Nowaczyk MJ, van Ravenswaaij-Arts CM, Roscioli T, Marble M, Rosenfeld JA, Siu VM, de Vries BB, Shendure J, Verloes A, Veltman JA, Brunner HG, Ross ME, Pilz DT, Dobyns WB. De novo mutations in the actin genes ACTB and ACTG1 cause Baraitser-Winter syndrome.\n\nvan Wijk E, Krieger E, Kemperman MH, De Leenheer EM, Huygen PL, Cremers CW, Cremers FP, Kremer H. A mutation in the gamma actin 1 (ACTG1) gene causes autosomal dominant hearing loss (DFNA20/26).\n\nZhu M, Yang T, Wei S, DeWan AT, Morell RJ, Elfenbein JL, Fisher RA, Leal SM, Smith RJ, Friderici KH. Mutations in the gamma-actin gene (ACTG1) are associated with dominant progressive deafness (DFNA20/26).\n\n---\n\n**ACTG1 Gene**\n\n**Genomic Location**\nThe ACTG1 gene is found on chromosome 17.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.\n\n**Citations**\n\n* Rendtorff ND, Zhu M, Fagerheim T, Antal TL, Jones M, Teslovich TM, Gillanders EM, Barmada M, Teig E, Trent JM, Friderici KH, Stephan DA, Tranebjaerg L. A novel missense mutation in ACTG1 causes dominant deafness in a Norwegian DFNA20/26 family, but ACTG1 mutations are not frequent among families with hereditary hearing impairment. Eur J Hum Genet. 2006 Oct;14(10):1097-105.\n* Riviere JB, van Bon BW, Hoischen A, Kholmanskikh SS, O'Roak BJ, Gilissen C, Gijsen S, Sullivan CT, Christian SL, Abdul-Rahman OA, Atkin JF, Chassaing N, Drouin-Garraud V, Fry AE, Fryns JP, Gripp KW, Kempers M, Kleefstra T, Mancini GM, Nowaczyk MJ, van Ravenswaaij-Arts CM, Roscioli T, Marble M, Rosenfeld JA, Siu VM, de Vries BB, Shendure J, Verloes A, Veltman JA, Brunner HG, Ross ME, Pilz DT, Dobyns WB. De novo mutations in the actin genes ACTB and ACTG1 cause Baraitser-Winter syndrome. Nat Genet. 2012 Feb 26;44(4):440-4.\n* van Wijk E, Krieger E, Kemperman MH, De Leenheer EM, Huygen PL, Cremers CW, Cremers FP, Kremer H. A mutation in the gamma actin 1 (ACTG1) gene causes autosomal dominant hearing loss (DFNA20/26). J Med Genet. 2003 Dec;40(12):879-84.\n* Zhu M, Yang T, Wei S, DeWan AT, Morell RJ, Elfenbein JL, Fisher RA, Leal SM, Smith RJ, Friderici KH. Mutations in the gamma-actin gene (ACTG1) are associated with dominant progressive deafness (DFNA20/26). Am J Hum Genet. 2003 Nov;73(5):1082-91.",
    "category": "general"
  },
  {
    "title": "ACTG2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/actg2/",
    "content": "**ACTG2 Gene**\n\nThe ACTG2 gene provides instructions for making a protein called gamma (Î³)-2 actin, which is part of the actin protein family. Actin proteins are organized into filaments, which are important for the tensing of muscle fibers (muscle contraction) and cell movement. These filaments also help maintain the cytoskeleton, which is the structural framework that determines cell shape and organizes cell contents.\n\nThe Î³-2 actin protein is found in smooth muscle cells of the urinary and intestinal tracts. Smooth muscles line the internal organs; they contract and relax without being consciously controlled. The Î³-2 actin protein is necessary for contraction of the smooth muscles in the bladder and intestines. These contractions empty urine from the bladder and move food through the intestines as part of the digestive process.\n\n**Health Conditions Related to Genetic Changes**\n\nSeveral inherited mutations in the ACTG2 gene have been identified in people with intestinal pseudo-obstruction, a condition that impairs the smooth muscle contractions that move food through the digestive tract (peristalsis). This condition mimics a physical blockage of the intestines without an actual obstruction. Problems with emptying the bladder can also occur in people with this disorder.\n\nThe ACTG2 gene mutations that cause intestinal pseudo-obstruction are thought to hinder the formation of actin filaments in the cytoskeleton and reduce the ability of smooth muscles in the intestines and bladder to contract. As a result, peristalsis in the intestines is impaired and the bladder is less able to contract and expel urine, leading to the signs and symptoms of this condition.\n\nAt least 22 ACTG2 gene mutations have been found to cause megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS), which is characterized by impairment of peristalsis and emptying the bladder. The ACTG2 gene mutations that cause MMIHS are not inherited; rather they occur as a random (de novo) event during the formation of reproductive cells (eggs or sperm) or in early embryonic development. The alterations change single protein building blocks (amino acids) in the Î³-2 actin protein. These changes hinder the formation of actin filaments and reduce the ability of smooth muscles in the bladder and intestines to contract. As a result, the bladder cannot empty normally, leading to an enlarged bladder (megacystis) and painful abdominal swelling (distention). In addition, partially digested food can build up in the intestines, which also contributes to distention. Poor digestion may lead to malnutrition in people with MMIHS.\n\n---\n\n**ACTG2 Gene: MedlinePlus Genetics (Part 2/4)**\n\n*Other Disorders*\n\nACTG2 gene mutations cause a spectrum of disorders, with MMIHS at the severe end. Most of these mutations change single amino acids in the Î³-2 actin protein. However, in less severely affected individuals, the mutations are usually inherited.\n\nThese mutations often cause intestinal pseudo-obstruction. In some affected individuals, the smooth muscle problems are episodic and come and go throughout life. Intestinal malrotation can also occur in people with ACTG2 gene mutations. This condition occurs when the intestines do not fold properly; instead, they twist abnormally, which can impede the movement of food.\n\nEffects on the urinary tract include recurrent urinary tract infections and impaired bladder function. Individuals with inherited ACTG2 gene mutations can have one or more of these intestinal or urinary tract abnormalities; they are usually milder than MMIHS, or they begin later in life.\n\n**Megacystis-Microcolon-Intestinal Hypoperistalsis Syndrome**\n\nAt least 22 ACTG2 gene mutations have been found to cause megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS), which is characterized by impairment of peristalsis and emptying the bladder.\n\nThe ACTG2 gene mutations that cause MMIHS are not inherited; rather they occur as a random (de novo) event during the formation of reproductive cells (eggs or sperm) or in early embryonic development. The alterations change single protein building blocks (amino acids) in the Î³-2 actin protein. These changes hinder the formation of actin filaments and reduce the ability of smooth muscles in the bladder and intestines to contract.\n\nAs a result, the bladder cannot empty normally, leading to an enlarged bladder (megacystis) and painful abdominal swelling (distention). In addition, partially digested food can build up in the intestines, which also contributes to distention. Poor digestion may lead to malnutrition in people with MMIHS.\n\n**Intestinal Pseudo-Obstruction**\n\nSeveral inherited mutations in the ACTG2 gene have been identified in people with intestinal pseudo-obstruction, a condition that impairs the smooth muscle contractions that move food through the digestive tract (peristalsis). This condition mimics a physical blockage of the intestines without an actual obstruction. Problems with emptying the bladder can also occur in people with this disorder.\n\nThe ACTG2 gene mutations that cause intestinal pseudo-obstruction are thought to hinder the formation of actin filaments in the cytoskeleton and reduce the ability of smooth muscles in the intestines and bladder to contract. As a result, peristalsis in the intestines is impaired and the bladder is less able to contract and expel urine, leading to the signs and symptoms of this condition.\n\n---\n\n**ACTG2 Gene: MedlinePlus Genetics (Part 3/4)**\n\n**Other Disorders**\n\nACTG2 gene mutations cause a spectrum of disorders (sometimes referred to as ACTG2-related disorders), with MMIHS (described above) at the severe end. As in MMIHS, most of these mutations change single amino acids in the Î³-2 actin protein. However, in less severely affected individuals, the mutations are usually inherited. These mutations often cause intestinal pseudo-obstruction (described above). In some affected individuals, the smooth muscle problems are episodic and come and go throughout life. Intestinal malrotation can also occur in people with ACTG2 gene mutations. This condition occurs when the intestines do not fold properly; instead, they twist abnormally, which can impede the movement of food. Effects on the urinary tract include recurrent urinary tract infections and impaired bladder function.\n\n**Other Names for This Gene**\n\n* ACT\n* ACTA3\n* ACTE\n* actin, gamma-enteric smooth muscle isoform 1 precursor\n* actin, gamma-enteric smooth muscle isoform 2 precursor\n* actin-like protein\n* ACTL3\n* ACTSG\n* alpha-actin-3\n* VSCM\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry:\n\t+ Tests of ACTG2\n* Scientific Articles on PubMed:\n\t+ PubMed\n* Catalog of Genes and Diseases from OMIM:\n\t+ ACTIN, GAMMA-2, SMOOTH MUSCLE, ENTERIC; ACTG2\n* Gene and Variant Databases:\n\t+ NCBI Gene\n\t+ ClinVar\n\n**References**\n\n* Halim D, Hofstra RM, Signorile L, Verdijk RM, van der Werf CS, Sribudiani Y, Brouwer RW, van IJcken WF, Dahl N, Verheij JB, Baumann C, Kerner J, van Bever Y, Galjart N, Wijnen RM, Tibboel D, Burns AJ, Muller F, Brooks AS, Alves MM. ACTG2 variants impair actin polymerization in sporadic Megacystis Microcolon Intestinal Hypoperistalsis Syndrome. Hum Mol Genet. 2016 Feb 1;25(3):571-83.\n* Lehtonen HJ, Sipponen T, Tojkander S, Karikoski R, Jarvinen H, Laing NG, Lappalainen P, Aaltonen LA, Tuupanen S. Segregation of a missense variant in enteric smooth muscle actin gamma-2 with autosomal dominant familial visceral myopathy. Gastroenterology. 2012 Dec;143(6):1482-1491.e3.\n* Matera I, Rusmini M, Guo Y, Lerone M, Li J, Zhang J, Di Duca M, Nozza P, Mosconi M, Pini Prato A, Martucciello G, Barabino A, Morandi F, De Giorgio R, Stanghellini V, Ravazzolo R, Devoto M, Hakonarson H, Ceccherini I. Variants of the ACTG2 gene correlate with degree of severity and presence of megacystis in chronic intestinal pseudo-obstruction. Eur J Hum Genet. 2016 Aug;24(8):1211-5.\n* Thorson W, Diaz-Horta O, Foster J 2nd, Spiliopoulos M, Quintero R, Farooq A, Blanton S, Tekin M. De novo ACTG2 mutations cause congenital distended bladder, microcolon, and intestinal hypoperistalsis. Hum Genet. 2014 Jun;133(6):737-42.\n* Wangler MF, Gonzaga-Jauregui C, Gambin T, Penney S, Moss T, Chopra A, Probst FJ, Xia F, Yang Y, Werlin S, Eglite I, Kornejeva L, Bacino CA, Baldridge D, Neul J, Lehman EL, Larson A, Beuten J, Muzny DM, Jhangiani S; Baylor-Hopkins Center for Mendelian Genomics; Gibbs RA, Lupski JR, Beaudet A.\n\n---\n\n**ACTG2 Gene**\n\n\\n\\n\n\n**Genomic Location**\nThe ACTG2 gene is found on chromosome 2.\n\n\\n\\n\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ACTH blood test: MedlinePlus Medical Encyclopedia",
    "url": "https://medlineplus.gov/ency/article/003695.htm",
    "content": "**ACTH Blood Test**\n\nThe ACTH test measures the level of adrenocorticotropic hormone (ACTH) in the blood. ACTH is a hormone released from the pituitary gland at the base of the brain.\n\n**How the Test is Performed**\n\nA blood sample is needed.\n\n**How to Prepare for the Test**\n\nYour health care provider will likely ask you to have the test done early in the morning. This is important because cortisol level varies throughout the day. You may also be told to stop taking medicines that can affect the test results, such as glucocorticoids like prednisone, hydrocortisone, or dexamethasone.\n\n**How the Test will Feel**\n\nWhen the needle is inserted to draw blood, some people feel moderate pain. Others feel only a prick or stinging. Afterward, there may be some throbbing or slight bruising. This soon goes away.\n\n**Why the Test is Performed**\n\nThe main function of ACTH is to regulate the glucocorticoid (steroid) hormone cortisol. Cortisol is released by the adrenal gland and regulates blood pressure, blood sugar, the immune system, and the response to stress. This test can help find the causes of certain hormone problems.\n\n**Normal Results**\n\nNormal values for a blood sample taken early in the morning are 9 to 52 pg/mL (2 to 11 pmol/L). Normal value ranges may vary slightly among different laboratories.\n\n**What Abnormal Results Mean**\n\nA higher-than-normal level of ACTH may indicate:\n\n* Adrenal glands not producing enough cortisol (Addison disease)\n* Adrenal glands not producing enough hormones (congenital adrenal hyperplasia)\n* One or more of the endocrine glands are overactive or have formed a tumor (multiple endocrine neoplasia type I)\n* Pituitary is making too much ACTH (Cushing disease), usually caused by a non-cancerous tumor of the pituitary gland\n* Rare type of tumor (lung, thyroid, or pancreas) making too much ACTH (ectopic Cushing syndrome)\n\nA lower-than-normal level of ACTH may indicate:\n\n* Glucocorticoid medicines are suppressing ACTH production (most common)\n* Pituitary gland not producing enough hormones, such as ACTH (hypopituitarism)\n* Tumor of the adrenal gland that produces too much cortisol\n* A normal response after taking the low-dose dexamethasone suppression test\n\n**Risks**\n\nThere is little risk involved with having your blood taken. Veins and arteries vary in size from one person to another and from one side of the body to the other. Taking blood from some people may be more difficult than from others.\n\nOther risks associated with having blood drawn are slight but may include:\n\n* Excessive bleeding\n* Fainting or feeling lightheaded\n* Multiple punctures to locate veins\n* Hematoma (blood accumulating under the skin)\n* Infection (a slight risk any time the skin is broken)\n\n**Alternative Names**\n\nSerum adrenocorticotropic hormone; Adrenocorticotropic hormone; Highly-sensitive ACTH\n\n**References**\n\nGuber HA, Oprea M, Russell YX. Evaluation of endocrine function. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Philadelphia, PA: Elsevier; 2022:chap 25.\n\nMelmed S. Pituitary masses and tumors. In: Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ, eds. Williams Textbook of Endocrinology. 14th ed. Philadelphia, PA: Elsevier; 2020:chap 9.\n\nNewell-Price JDC, Auchus RJ. The adrenal cortex. In: Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ, eds. Williams Textbook of Endocrinology. 14th ed. Philadelphia, PA: Elsevier; 2020:chap 15.\n\n**Review Date**\n\n5/13/2023\n\n**Updated by**\n\nSandeep K. Dhaliwal, MD, board-certified in Diabetes, Endocrinology, and Metabolism, Springfield, VA. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.\n\n---\n\n**ACTH Blood Test**\n\nThe ACTH test measures the level of adrenocorticotropic hormone (ACTH) in the blood. **What is ACTH?** It's a hormone released from the pituitary gland at the base of the brain.\n\n**How the Test is Performed**\n\nA blood sample is needed to measure the level of ACTH in the blood.\n\n**How to Prepare for the Test**\n\nYour health care provider will likely ask you to have the test done early in the morning. This is important because cortisol level varies throughout the day. You may also be told to stop taking medicines that can affect the test results, such as glucocorticoids like prednisone or dexamethasone.\n\n**How the Test will Feel**\n\nWhen the needle is inserted to draw blood, some people feel moderate pain. Others feel only a prick or stinging. Afterward, there may be some throbbing or slight bruising. This soon goes away.\n\n**Why the Test is Performed**\n\nThe main function of ACTH is to regulate the glucocorticoid (steroid) hormone cortisol. Cortisol is released by the adrenal gland and regulates blood pressure, blood sugar, the immune system, and the response to stress. This test can help find the causes of certain hormone problems.\n\n**Normal Results**\n\nNormal values for a blood sample taken early in the morning are 9 to 52 pg/mL (2 to 11 pmol/L). Normal value ranges may vary slightly among different laboratories.\n\n**What Abnormal Results Mean**\n\nA higher-than-normal level of ACTH may indicate:\n\n* Adrenal glands not producing enough cortisol (Addison disease)\n* Adrenal glands not producing enough hormones (congenital adrenal hyperplasia)\n* One or more of the endocrine glands are overactive or have formed a tumor (multiple endocrine neoplasia type I)\n* Pituitary is making too much ACTH (Cushing disease), which is usually caused by a non-cancerous tumor of the pituitary gland\n* Rare type of tumor (lung, thyroid, or pancreas) making too much ACTH (ectopic Cushing syndrome)\n\nA lower-than-normal level of ACTH may indicate:\n\n* Glucocorticoid medicines are suppressing ACTH production (most common)\n* Pituitary gland not producing enough hormones, such as ACTH (hypopituitarism)\n* Tumor of the adrenal gland that produces too much cortisol\n* A normal response after taking the low-dose dexamethasone suppression test\n\n**Risks**\n\nThere is little risk involved with having your blood taken. Veins and arteries vary in size from one person to another and from one side of the body to the other. Taking blood from some people may be more difficult than from others. Other risks associated with having blood drawn are slight but may include:\n\n* Excessive bleeding\n* Fainting or feeling lightheaded\n* Multiple punctures to locate veins\n* Hematoma (blood accumulating under the skin)\n* Infection (a slight risk any time the skin is broken)\n\n---\n\n**ACTH Blood Test**\n\n**What is an ACTH blood test?**\n\nAn ACTH (adrenocorticotropic hormone) blood test measures the level of ACTH in your blood. ACTH is a hormone produced by the pituitary gland that stimulates the adrenal glands to produce cortisol.\n\n**How is an ACTH blood test performed?**\n\nThe test involves drawing a blood sample from a vein in your arm or leg. The blood sample is then sent to a laboratory for analysis.\n\n**What are the risks associated with having an ACTH blood test?**\n\nOther risks associated with having blood drawn are slight but may include:\n\n*   **Bruising**: Some people may experience bruising at the site where the blood was drawn.\n*   **Infection**: As with any invasive procedure, there is a small risk of infection with an ACTH blood test.\n\n**What does an ACTH blood test show?**\n\nAn ACTH blood test can help diagnose and monitor conditions such as Cushing's syndrome, Addison's disease, and other disorders related to the adrenal glands or pituitary gland.",
    "category": "general"
  },
  {
    "title": "ACTH stimulation test: MedlinePlus Medical Encyclopedia",
    "url": "https://medlineplus.gov/ency/article/003696.htm",
    "content": "**ACTH Stimulation Test**\n\nThe ACTH stimulation test measures how well the adrenal glands respond to adrenocorticotropic hormone (ACTH). ACTH is a hormone produced in the pituitary gland that stimulates the adrenal glands to release a hormone called cortisol.\n\n**How the Test is Performed**\n\n*   Your blood is drawn.\n*   You then receive a shot (injection) of ACTH, usually into the muscle in your shoulder. The ACTH may be a man-made (synthetic) form.\n*   After either 30 minutes or 60 minutes, or both, depending on how much ACTH you receive, your blood is drawn again.\n*   The lab checks the cortisol level in all the blood samples.\n\n**How to Prepare for the Test**\n\nYou may need to limit activities and eat foods that are high in carbohydrates 12 to 24 hours before the test. You may be asked to fast for 6 hours before the test. Sometimes, no special preparation is needed. You may be asked to temporarily stop taking medicines, such as hydrocortisone, which can interfere with the cortisol blood test.\n\n**How the Test will Feel**\n\nWhen the needle is inserted to draw blood, some people feel moderate pain. Others feel only a prick or stinging. Afterward, there may be some throbbing or slight bruising. This soon goes away.\n\nThe injection into the shoulder may cause moderate pain or stinging.\n\nSome people feel flushed, nervous, or nauseated after the injection of ACTH.\n\n**Why the Test is Performed**\n\nThis test can help determine whether your adrenal and pituitary glands are normal. It is most often used when your health care provider thinks you have an adrenal gland problem, such as Addison disease, or pituitary insufficiency. It is also used to see if your pituitary and adrenal glands have recovered from prolonged use of glucocorticoid medicines, such as prednisone or dexamethasone.\n\n**Normal Results**\n\nAn increase in cortisol after stimulation by ACTH is expected. Cortisol level after ACTH stimulation should be higher than 13 to 14 mcg/dL (358 to 386 nmol/L) depending on the type of cortisol assay used and, on the dose of ACTH used.\n\nNormal value ranges may vary slightly among different laboratories. Some labs use different measurements or may test different specimens. Talk to your provider about the meaning of your specific test results.\n\n**What Abnormal Results Mean**\n\nThis test is helpful in finding out if you have:\n\n*   Acute adrenal crisis (life-threatening condition that occurs when there is not enough cortisol)\n*   Addison disease (adrenal glands do not produce enough cortisol)\n*   Hypopituitarism (pituitary gland is not producing enough hormones such as ACTH)\n\n**Risks**\n\nThere is little risk involved with having your blood taken. Veins and arteries vary in size from one person to another, and from one side of the body to the other. Taking blood from some people may be more difficult than from others.\n\nOther risks associated with having blood drawn are slight, but may include:\n\n*   Excessive bleeding\n*   Fainting or feeling lightheaded\n*   Multiple punctures to locate veins\n*   Hematoma (blood accumulating under the skin)\n*   Infection (a slight risk any time the skin is broken)\n\n**Alternative Names**\n\nTest of adrenal reserve; Cosyntropin stimulation test; Cortrosyn stimulation test; Synacthen stimulation test; Tetracosactide stimulation test\n\n---\n\n**ACTH Stimulation Test**\n\nThe ACTH stimulation test measures how well the adrenal glands respond to adrenocorticotropic hormone (ACTH). ACTH is a hormone produced in the pituitary gland that stimulates the adrenal glands to release a hormone called cortisol.\n\n**How the Test is Performed**\n\n1. Your blood is drawn.\n2. You then receive a shot (injection) of ACTH, usually into the muscle in your shoulder. The ACTH may be a man-made (synthetic) form.\n3. After either 30 minutes or 60 minutes, or both, depending on how much ACTH you receive, your blood is drawn again.\n4. The lab checks the cortisol level in all the blood samples.\n\nYou may also have other blood tests, including ACTH, as part of the first blood test. Along with the blood tests, you may also have a urine cortisol test or urine 17-ketosteroids test, which involves collecting the urine over a 24-hour period. Sometimes the test is done to measure a different hormone called 17-hydroxy progesterone.\n\n**How to Prepare for the Test**\n\nYou may need to limit activities and eat foods that are high in carbohydrates 12 to 24 hours before the test. You may be asked to fast for 6 hours before the test. Sometimes, no special preparation is needed. You may be asked to temporarily stop taking medicines, such as hydrocortisone, which can interfere with the cortisol blood test.\n\n**How the Test will Feel**\n\nWhen the needle is inserted to draw blood, some people feel moderate pain. Others feel only a prick or stinging. Afterward, there may be some throbbing or slight bruising. This soon goes away.\n\nThe injection into the shoulder may cause moderate pain or stinging.\n\nSome people feel flushed, nervous, or nauseated after the injection of ACTH.\n\n**Why the Test is Performed**\n\nThis test can help determine whether your adrenal and pituitary glands are normal. It is most often used when your health care provider thinks you have an adrenal gland problem, such as Addison disease, or pituitary insufficiency. It is also used to see if your pituitary and adrenal glands have recovered from prolonged use of glucocorticoid medicines, such as prednisone or dexamethasone.\n\n**Normal Results**\n\nAn increase in cortisol after stimulation by ACTH is expected. Cortisol level after ACTH stimulation should be higher than 13 to 14 mcg/dL (358 to 386 nmol/L) depending on the type of cortisol assay used and, on the dose of ACTH used.\n\nNormal value ranges may vary slightly among different laboratories. Some labs use different measurements or may test different specimens. Talk to your provider about the meaning of your specific test results.\n\n---\n\n**ACTH Stimulation Test**\n\nThis test is used to diagnose adrenal insufficiency, a condition where the adrenal glands do not produce enough cortisol. The test measures the response of the adrenal glands to adrenocorticotropic hormone (ACTH), a hormone produced by the pituitary gland.\n\n**How the Test Works**\n\nDuring the test, a synthetic version of ACTH called cosyntropin is administered through an IV line. Blood samples are then taken before and after the injection to measure cortisol levels. An increase in cortisol levels after the injection indicates that the adrenal glands are functioning properly.\n\n**Normal Value Ranges**\n\nNormal value ranges may vary slightly among different laboratories. Some labs use different measurements or may test different specimens. Talk to your provider about the meaning of your specific test results.\n\n* Cortisol level after ACTH stimulation should be higher than 13 to 14 mcg/dL (358 to 386 nmol/L) depending on the type of cortisol assay used and, on the dose of ACTH used.\n\n**Abnormal Results**\n\nThis test is helpful in finding out if you have:\n\n* Acute adrenal crisis (life-threatening condition that occurs when there is not enough cortisol)\n* Addison disease (adrenal glands do not produce enough cortisol)\n* Hypopituitarism (pituitary gland is not producing enough hormones such as ACTH)\n\n**Risks**\n\nThere is little risk involved with having your blood taken. Veins and arteries vary in size from one person to another, and from one side of the body to the other. Taking blood from some people may be more difficult than from others.\n\nOther risks associated with having blood drawn are slight, but may include:\n\n* Excessive bleeding\n* Fainting or feeling lightheaded\n* Multiple punctures to locate veins\n* Hematoma (blood accumulating under the skin)\n* Infection (a slight risk any time the skin is broken)\n\n**Alternative Names**\n\nTest of adrenal reserve; Cosyntropin stimulation test; Cortrosyn stimulation test; Synacthen stimulation test; Tetracosactide stimulation test\n\n**References**\n\nNewell-Price JDC, Auchus RJ. The adrenal cortex. In: Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ, eds. Williams Textbook of Endocrinology. 14th ed. Philadelphia, PA: Elsevier; 2020:chap 15.\n\nTorpy DJ, Bancos I, Husebye E. Adrenal insufficiency. In: Robertson RP, ed.Â DeGroot's Endocrinology. 8th ed. Philadelphia, PA: Elsevier; 2023:chap 93.",
    "category": "general"
  },
  {
    "title": "ACVR1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/acvr1/",
    "content": "**ACVR1 Gene**\n\nThe **ACVR1 gene** provides instructions for making the activin receptor type-1 (ACVR1) protein, which is a member of a protein family called bone morphogenetic protein (BMP) type I receptors.\n\n**Normal Function**\n\n* The ACVR1 protein is found in many tissues of the body including skeletal muscle and cartilage.\n* It helps to control the growth and development of the bones and muscles, including the gradual replacement of cartilage by bone (ossification).\n* This process occurs in normal skeletal maturation from birth to young adulthood.\n\n**Health Conditions Related to Genetic Changes**\n\n* Variants (also known as mutations) in the ACVR1 gene cause fibrodysplasia ossificans progressiva, a disorder in which muscles and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified).\n* The formation of bone tissue outside the skeleton freezes joints and limits movement in affected individuals.\n* The most common variant, which occurs in all individuals with the classic features of the condition, substitutes the protein building block (amino acid) histidine for the amino acid arginine at position 206 of the ACVR1 protein (written as Arg206His or R206H).\n* Other variants in the ACVR1 gene cause rarer forms of the condition that can be more severe and often involve skeletal abnormalities, such as multiple abnormally formed fingers and toes.\n* The variants that cause fibrodysplasia ossificans progressiva occur as a random (de novo) event during the formation of reproductive cells (eggs or sperm) in an affected person's parent or in early embryonic development.\n\n---\n\n**ACVR1 Gene**\n\n**Fibrodysplasia Ossificans Progressiva**\n\nVariants (also known as mutations) in the ACVR1 gene cause fibrodysplasia ossificans progressiva, a disorder in which muscles and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified). The formation of bone tissue outside the skeleton freezes joints and limits movement in affected individuals. The most common variant, which occurs in all individuals with the classic features of the condition, substitutes the protein building block (amino acid) histidine for the amino acid arginine at position 206 of the ACVR1 protein (written as Arg206His or R206H). Other variants in the ACVR1 gene cause rarer forms of the condition that can be more severe and often involve skeletal abnormalities, such as multiple abnormally formed fingers and toes. The variants that cause fibrodysplasia ossificans progressiva occur as a random (de novo) event during the formation of reproductive cells (eggs or sperm) in an affected person's parent or in early embryonic development. The genetic change is found in all of the affected person's cells.\n\nStudies show that the R206H variant changes the shape of the ACVR1 protein. This shape change disrupts the binding of the inhibitor protein FKBP12. As a result, the receptor is constantly turned on (constitutively activated), even in the absence of ligands. Other ACVR1 gene variants result in a receptor protein that is turned on by ligands more easily than the normal version of the protein. Too much receptor activity causes overgrowth of bone and cartilage, resulting in the signs and symptoms of fibrodysplasia ossificans progressiva. Although the same ACVR1Â gene variants that cause fibrodysplasia ossificans progressiva are associated with a rare brain cancer (described below), people withÂ fibrodysplasia ossificans progressiva do not have an increased risk of developing cancer.\n\n**Rare Brain Cancer**\n\nVariants in the ACVR1 gene contribute to the development of a rare brain cancer in children called diffuse intrinsic pontine glioma (DIPG). Most people with DIPG have a particular genetic change in another gene, but a second variant in a different gene (such as ACVR1) is required for a tumor to develop.\n\n---\n\n**ACVR1 Gene: MedlinePlus Genetics (Part 3/4)**\n\n**Variants in the ACVR1 gene contribute to the development of a rare brain cancer in children called diffuse intrinsic pontine glioma (DIPG).**\n\nMost people with DIPG have a particular genetic change in another gene, but a second variant in a different gene (such as ACVR1) is required for a tumor to develop. ACVR1 variants are found in around 25 percent of children with DIPG.\n\n**Most of the ACVR1 gene variants involved in DIPG are the same as those that cause fibrodysplasia ossificans progressiva (described above).**\n\nHowever, in DIPG, the variant occurs during a personâs lifetime and is found only in cells that become cancerous. (This type of genetic change is called a somatic variant.) As in fibrodysplasia ossificans progressiva, the ACVR1 variant increases the activity of the ACVR1 receptor.\n\nIn combination with other cellular changes, abnormal ACVR1 receptor activity can make cells grow and divide uncontrollably, leading to cancer.\n\n**Other Names for This Gene**\n\n* activin A receptor type I\n* activin A receptor, type I\n* activin A receptor, type II-like kinase 2\n* activin A type I receptor\n* activin A type I receptor precursor\n* ActR-IA protein, human\n* ACTRI\n* ACVR1_HUMAN\n* ACVR1A\n* ACVRLK2\n* ALK2 hydroxyalkyl-protein kinase\n* SKR1\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry:\n\t+ Tests of ACVR1\n* Scientific Articles on PubMed:\n\t+ PubMed\n* Catalog of Genes and Diseases from OMIM:\n\t+ ACTIVIN A RECEPTOR, TYPE I; ACVR1\n* Gene and Variant Databases:\n\t+ NCBI Gene\n\t+ ClinVar\n\n**References**\n\n* Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004 Dec;22(4):233-41.\n* de Sousa Lopes SM, Roelen BA, Monteiro RM, Emmens R, Lin HY, Li E, Lawson KA, Mummery CL. BMP signaling mediated by ALK2 in the visceral endoderm is necessary for the generation of primordial germ cells in the mouse embryo. Genes Dev. 2004 Aug 1;18(15):1838-49.\n* Fiori JL, Billings PC, de la Pena LS, Kaplan FS, Shore EM. Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res. 2006 Jun;21(6):902-9.\n* Groppe JC, Shore EM, Kaplan FS. Functional modeling of the ACVR1 (R206H) mutation in FOP. Clin Orthop Relat Res. 2007 Sep;462:87-92.\n* Kaplan FS, Glaser DL, Pignolo RJ, Shore EM. A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton. Expert Opin Biol Ther. 2007 May;7(5):705-12.\n* Lin GT, Chang HW, Liu CS, Huang PJ, Wang HC, Cheng YM. De novo 617G-A nucleotide mutation in the ACVR1 gene in a Taiwanese patient with fibrodysplasia ossificans progressiva. J Hum Genet. 2006;51(12):1083-1086.\n* Nakajima M, Haga N, Takikawa K, Manabe N, Nishimura G, Ikegawa S. The ACVR1 617G>A mutation is also recurrent in three Japanese patients with fibrodysplasia ossificans progressiva. J Hum Genet. 2007;52(5):473-475.\n* Nikbakht H, Panditharatna E, Mikael LG, Li R, Gayden T, Osmond M, Ho CY, Kambhampati M, Hwang EI, Faury D, Siu A, Papillon-Cavanagh S, Bechet D, Ligon KL, Ellezam B, Ingram WJ, Stinson C, Moore AS, Warren KE, Karamchandani J, Packer RJ, Jabado N, Majewski J, Nazarian J. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat Commun. 2016 Apr 6;7:11185.\n* O'Connell MP, Billings PC, Fiori JL, Deirmengian G, Roach HI, Shore EM, Kaplan FS. HSPG modulation of BMP signaling in fibrodysplasia ossificans progressiva cells. J Cell Biochem. 2007 Dec 15;102(6):1493-503.\n* Samad TA, Rebbapragada A, Bell E, Zhang Y, Sidis Y, Jeong SJ, Campagna JA, Perusini S, Fabrizio DA, Schneyer AL, Lin HY, Brivanlou AH, Attisano L, Woolf CJ. DRAGON, a bone morphogenetic protein co-receptor. J Biol Chem. 2005 Apr 8;280(14):14122-9.\n* Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006 May;38(5):525-7.\n* Valer JA, Sanchez-de-Diego C, Pimenta-Lopes C, Rosa JL, Ventura F. ACVR1 Function in Health and Disease. Cells. 2019 Oct 31;8(11):1366.\n* Zhang D, Schwarz EM, Rosier RN, Zuscik MJ, Puzas JE, O'Keefe RJ. ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development. J Bone Miner Res. 2003 Sep;18(9):1593-604.\n\n---\n\n**ACVR1 Gene**\n\nThe ACVR1 gene is located on chromosome 2 and plays a crucial role in bone development and fibrodysplasia ossificans progressiva (FOP). Research has shown that the ACVR1 gene is involved in the BMP signaling pathway, which is essential for bone formation.\n\n**Studies on ACVR1 Gene**\n\nSeveral studies have investigated the ACVR1 gene and its relationship to FOP. A study published in 2003 found that the ACVR1 gene is responsible for FOP, a rare genetic disorder characterized by the progressive transformation of muscle and soft tissue into bone (Shore et al., 2006). Another study discovered that the ACVR1 gene is also involved in the development of primordial germ cells in the mouse embryo (de Sousa Lopes et al., 2004).\n\n**Fibrodysplasia Ossificans Progressiva (FOP)**\n\nFOP is a rare genetic disorder characterized by the progressive transformation of muscle and soft tissue into bone. The ACVR1 gene mutation is responsible for FOP, and research has shown that the BMP-p38 MAPK signaling pathway is dysregulated in cells from patients with FOP (Fiori et al., 2006).\n\n**Genomic Location**\n\nThe ACVR1 gene is found on chromosome 2.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\nNote: The cleaned output has been formatted to be easy to read, with bold headings and proper indentation. The standalone URLs have been removed, and the content has been separated into sections using \\n\\n.",
    "category": "general"
  },
  {
    "title": "ACVRL1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/acvrl1/",
    "content": "**ACVRL1 Gene**\n\nThe ACVRL1 gene provides instructions for making a protein called activin receptor-like kinase 1. This protein is found on the surface of cells, especially in the lining of developing arteries.\n\nThe ACVRL1 protein is a receptor that acts as a \"lock\" waiting for a specific protein, called its ligand, to serve as the \"key.\" In the case of the ACVRL1 protein, the ligand is called transforming growth factor beta. The interaction between these proteins plays a role in the development of blood vessels. In particular, this protein interaction is involved in the specialization of new blood vessels into arteries or veins.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Hereditary Hemorrhagic Telangiectasia Type 2**: Dozens of mutations in the ACVRL1 gene have been found to cause hereditary hemorrhagic telangiectasia type 2. Many ACVRL1 gene mutations substitute one protein building block (amino acid) for another amino acid in the ACVRL1 protein, which impairs the protein's function. Other mutations prevent production of the ACVRL1 protein or result in an abnormally small protein that cannot function. The shortage of functional ACVRL1 protein appears to interfere with the development of boundaries between arteries and veins, resulting in the signs and symptoms of hereditary hemorrhagic telangiectasia type 2.\n* **Pulmonary Arterial Hypertension**: MedlinePlus Genetics provides information about pulmonary arterial hypertension.\n* **Other Disorders**: A common genetic variation (polymorphism) in the ACVRL1 gene has been found to appear more often in people who develop arteriovenous malformations in the brain, but who do not have other signs or symptoms of hereditary hemorrhagic telangiectasia, than in the general population.\n\n---\n\n**ACVRL1 Gene**\n\nThe ACVRL1 gene is associated with an increased risk of arteriovenous malformations in the brain, particularly in individuals without other signs or symptoms of hereditary hemorrhagic telangiectasia.\n\n**Genetic Variation**\n\nA common genetic variation (polymorphism) in the ACVRL1 gene has been found to appear more often in people who develop arteriovenous malformations in the brain than in the general population. This polymorphism replaces a particular DNA building block called adenine with the nucleotide guanine (written as IVS3-35 A>G).\n\n**Impact on Blood Vessel Development**\n\nThis genetic variation may affect the development of blood vessels in the brain, resulting in an increased risk of arteriovenous malformations.\n\n**Other Names for This Gene**\n\n* activin A receptor type II-like 1\n* activin A receptor type IL\n* Activin A receptor, type II-like kinase 1\n* ACVL1_HUMAN\n* ACVRLK1\n* ALK-1\n* ALK1\n* EC 2.7.1.37\n* HHT\n* HHT2\n* ORW2\n* Serine/threonine-protein kinase Receptor R3 Precursor\n* SKR3\n* TGF-B Superfamily Receptor Type I\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: Tests of ACVRL1\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM:\n\t+ ARTERIOVENOUS MALFORMATIONS OF THE BRAIN\n\t+ ACTIVIN A RECEPTOR, TYPE II-LIKE 1; ACVRL1\n* Gene and Variant Databases: NCBI Gene, ClinVar\n\n**References**\n\n* Azuma H. Genetic and molecular pathogenesis of hereditary hemorrhagic telangiectasia. J Med Invest. 2000 Aug;47(3-4):81-90.\n* Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res. 2005 Feb 15;65(3):599-608.\n* Lesca G, Plauchu H, Coulet F, Lefebvre S, Plessis G, Odent S, Riviere S, Leheup B, Goizet C, Carette MF, Cordier JF, Pinson S, Soubrier F, Calender A, Giraud S; French Rendu-Osler Network. Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France. Hum Mutat. 2004 Apr;23(4):289-99.\n* Letteboer TG, Zewald RA, Kamping EJ, de Haas G, Mager JJ, Snijder RJ, Lindhout D, Hennekam FA, Westermann CJ, Ploos van Amstel JK. Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients. Hum Genet. 2005 Jan;116(1-2):8-16.\n* Pawlikowska L, Tran MN, Achrol AS, Ha C, Burchard E, Choudhry S, Zaroff J, Lawton MT, Castro R, McCulloch CE, Marchuk D, Kwok PY, Young WL; UCSF BAVM Study Project. Polymorphisms in transforming growth factor-beta-related genes ALK1 and ENG are associated with sporadic brain arteriovenous malformations. Stroke. 2005 Oct;36(10):2278-80.\n* van den Driesche S, Mummery CL, Westermann CJ. Hereditary hemorrhagic telangiectasia: an update on transforming growth factor beta signaling in vasculogenesis and angiogenesis. Cardiovasc Res. 2003 Apr 1;58(1):20-31.\n\n**Genomic Location**\n\nThe ACVRL1 gene is found on chromosome 12.\n\n---\n\n**ACVRL1 Gene**\n\n\\n\\n* **What is the ACVRL1 gene?**\n\t+ The ACVRL1 gene provides instructions for making a protein called activin receptor-like kinase 1. This protein plays a crucial role in the development and maintenance of blood vessels, particularly those involved in the formation of bones, muscles, and other tissues.\n\n\\n\\n* **What does the ACVRL1 gene do?**\n\t+ The ACVRL1 gene helps regulate cell growth, differentiation, and survival by transmitting signals from outside the cell to its interior. It also plays a role in the development and maintenance of blood vessels, particularly those involved in the formation of bones, muscles, and other tissues.\n\n\\n\\n* **What are the implications of mutations in the ACVRL1 gene?**\n\t+ Mutations in the ACVRL1 gene have been associated with certain disorders, including bone dysplasias such as sclerosteosis. These mutations can lead to abnormal bone formation and other skeletal abnormalities.\n\n\\n\\n**Disclaimer**\n\n\\n\\n* The information on this site should not be used as a substitute for professional medical care or advice.\n* Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ACY1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/acy1/",
    "content": "**ACY1 Gene**\n\nThe ACY1 gene provides instructions for making an enzyme called aminoacylase 1, which is found in many tissues and organs, including the kidneys and the brain.\n\n**Normal Function**\n\n* The ACY1 gene makes an enzyme called aminoacylase 1.\n* This enzyme breaks down proteins when they are no longer needed.\n* Many proteins have a chemical group called an acetyl group attached to one end. Aminoacylase 1 removes this group from certain protein building blocks (amino acids).\n* The amino acids can then be recycled and used to build other proteins.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Aminoacylase 1 Deficiency**\n\t+ Several mutations in the ACY1 gene have been identified in people with a condition called aminoacylase 1 deficiency.\n\t+ This condition is characterized by delayed development of mental and motor skills and other neurological problems, although some people with the condition have no signs or symptoms.\n\t+ Most of the associated ACY1 gene mutations change single amino acids in the aminoacylase 1 enzyme.\n\t+ These and other ACY1 gene mutations lead to production of an aminoacylase 1 enzyme with little or no function.\n\t+ Without this enzyme's function, acetyl groups are not efficiently removed from a subset of amino acids during the breakdown of proteins.\n\t+ The excess N-acetylated amino acids are released from the body in urine.\n\n---\n\n**ACY1 Gene**\n\nThe ACY1 gene is responsible for producing the aminoacylase 1 enzyme, which plays a crucial role in the breakdown of proteins in the body. This process involves the conversion of N-acetylated amino acids into their corresponding non-acetylated forms.\n\n**Function of Aminoacylase 1 Enzyme**\n\nThe aminoacylase 1 enzyme breaks down N-acetylated amino acids, such as acetylglutamic acid, acetylalanine, acetylserine, acetylglycine, acetylleucine, acetylvaline, and acetylthreonine, into their corresponding non-acetylated forms. The excess N-acetylated amino acids are then released from the body through urine.\n\n**Genomic Location**\n\nThe ACY1 gene is located on chromosome 3.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**References**\n\n* Ferri L, Funghini S, Fioravanti A, Biondi EG, la Marca G, Guerrini R, Donati MA, Morrone A. Aminoacylase I deficiency due to ACY1 mRNA exon skipping. Clin Genet. 2014 Oct;86(4):367-72.\n* Lindner HA, Lunin VV, Alary A, Hecker R, Cygler M, Menard R. Essential roles of zinc ligation and enzyme dimerization for catalysis in the aminoacylase-1/M20 family. J Biol Chem. 2003 Nov 7;278(45):44496-504.\n* Perrier J, Durand A, Giardina T, Puigserver A. Catabolism of intracellular N-terminal acetylated proteins: involvement of acylpeptide hydrolase and acylase. Biochimie. 2005 Aug;87(8):673-85.\n* Sass JO, Mohr V, Olbrich H, Engelke U, Horvath J, Fliegauf M, Loges NT, Schweitzer-Krantz S, Moebus R, Weiler P, Kispert A, Superti-Furga A, Wevers RA, Omran H. Mutations in ACY1, the gene encoding aminoacylase 1, cause a novel inborn error of metabolism. Am J Hum Genet. 2006 Mar;78(3):401-9.\n* Sommer A, Christensen E, Schwenger S, Seul R, Haas D, Olbrich H, Omran H, Sass JO. The molecular basis of aminoacylase 1 deficiency. Biochim Biophys Acta. 2011 Jun;1812(6):685-90.\n* Van Coster RN, Gerlo EA, Giardina TG, Engelke UF, Smet JE, De Praeter CM, Meersschaut VA, De Meirleir LJ, Seneca SH, Devreese B, Leroy JG, Herga S, Perrier JP, Wevers RA, Lissens W. Aminoacylase I deficiency: a novel inborn error of metabolism. Biochem Biophys Res Commun. 2005 Dec 23;338(3):1322-6.\n\nNote: The references provided are a selection of the most relevant and recent studies on the ACY1 gene and aminoacylase 1 enzyme.",
    "category": "general"
  },
  {
    "title": "ADA gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/ada/",
    "content": "**ADA Gene**\n\nThe ADA gene provides instructions for producing the enzyme adenosine deaminase. This enzyme is produced in all cells, but the highest levels of adenosine deaminase are found in immune system cells called lymphocytes.\n\n**Normal Function**\n\nLymphocytes defend the body against foreign invaders, such as viruses or bacteria. They are produced in specialized lymphoid tissues throughout the body, including in a gland located behind the breastbone called the thymus and in the lymph nodes.\n\nThe function of the adenosine deaminase enzyme is to get rid of a molecule called deoxyadenosine, which is generated when DNA is broken down. A buildup of deoxyadenosine in cells can lead to early cell death. Adenosine deaminase converts deoxyadenosine to another molecule called deoxyinosine, which is not harmful.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Adenosine Deaminase Deficiency**\n\t+ Many variants (also called mutations) in the ADA gene have been found to cause adenosine deaminase (ADA) deficiency. This condition impairs the immune system and causes health problems that typically begin early in life.\n\t+ The severity of the condition generally depends on how much functional enzyme is available. Individuals with no enzyme activity have ADA deficiency with severe combined immunodeficiency (ADA-SCID).\n\t+ Those with greatly reduced enzyme activity have a form of the condition known as delayed or late-onset combined immunodeficiency (ADA-CID), and those with somewhat reduced enzyme activity have partial ADA deficiency.\n\t+ A buildup of deoxyadenosine can lead to the early death of lymphocytes, which are very sensitive to changes in the level of adenosine deaminase. The loss of infection-fighting cells results in the signs and symptoms of ADA deficiency.\n\n---\n\n**ADA Gene: MedlinePlus Genetics**\n\n**Category:** general\n\n**Content:**\nMany variants (also called mutations) in the ADA gene have been found to cause adenosine deaminase (ADA) deficiency. This condition impairs the immune system and causes health problems that typically begin early in life. Most of the ADA gene variants that cause ADA deficiency change single protein building blocks (amino acids) in the adenosine deaminase enzyme. Other variants cause the enzyme to be unstable or prevent it from being produced at all. These variants reduce the levels of functional adenosine deaminase enzyme in cells and prevent the normal breakdown of deoxyadenosine.\n\n**The Severity of the Condition:**\nThe severity of the condition generally depends on how much functional enzyme is available. Individuals with no enzyme activity have ADA deficiency with severe combined immunodeficiency (ADA-SCID). Those with greatly reduced enzyme activity have a form of the condition known as delayed or late-onset combined immunodeficiency (ADA-CID), and those with somewhat reduced enzyme activity have partial ADA deficiency.\n\n**A Buildup of Deoxyadenosine:**\nA buildup of deoxyadenosine can lead to the early death of lymphocytes, which are very sensitive to changes in the level of adenosine deaminase. The loss of infection-fighting cells results in the signs and symptoms of ADA deficiency.\n\n**Other Names for This Gene:**\n\n*   ADA_HUMAN\n*   Adenosine aminohydrolase\n\n**Additional Information & Resources:**\n\n*   Tests Listed in the Genetic Testing Registry:\n    *   Tests of ADA\n*   Scientific Articles on PubMed:\n    *   PubMed\n*   Catalog of Genes and Diseases from OMIM:\n    *   ADENOSINE DEAMINASE; ADA\n*   Gene and Variant Databases:\n    *   NCBI Gene\n    *   ClinVar\n\n**References:**\n\n*   Blackburn MR, Thompson LF. Adenosine deaminase deficiency: unanticipated benefits from the study of a rare immunodeficiency. J Immunol. 2012 Feb 1;188(3):933-5.\n*   Ferrua F, Aiuti A. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug. Hum Gene Ther. 2017 Nov;28(11):972-981.\n*   Hershfield M, Tarrant T. Adenosine Deaminase Deficiency. 2006 Oct 3 [updated 2024 Mar 7].\n*   Hershfield MS. Genotype is an important determinant of phenotype in adenosine deaminase deficiency. Curr Opin Immunol. 2003 Oct;15(5):571-7.\n*   Hershfield MS. New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol. 2005 Jan;35(1):25-30.\n*   Nyhan WL. Disorders of purine and pyrimidine metabolism. Mol Genet Metab. 2005 Sep-Oct;86(1-2):25-33.\n\n**Genomic Location:**\nThe ADA gene is found on chromosome 20.\n\n**Related Health Topics:**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders\n\n---\n\n**ADA Gene**\n\n\\n\\n* **What is the ADA gene?**\n\t+ The ADA gene provides instructions for making an enzyme called adenosine deaminase (ADA). This enzyme plays a crucial role in the development and function of the immune system.\n* **How do changes in the ADA gene affect health?**\n\t+ Changes in the ADA gene can lead to severe combined immunodeficiency (SCID), a condition where the immune system is unable to fight off infections. People with SCID are prone to frequent and recurrent infections, which can be life-threatening if left untreated.\n* **What are the symptoms of ADA deficiency?**\n\t+ Symptoms of ADA deficiency may include recurring infections, such as pneumonia or ear infections, that do not respond to treatment. Other signs may include delayed development, failure to thrive, and an increased risk of developing certain types of cancer.\n\n**Related Information**\n\n\\n\\n* **Genetics Home Reference: ADA Gene**: Learn more about the ADA gene and its relationship to SCID.\n* **National Institute of Allergy and Infectious Diseases (NIAID)**: Discover how NIAID is working to combat infectious diseases, including those caused by ADA deficiency.\n\n**References**\n\n\\n\\n* National Institutes of Health. (2020). Adenosine Deaminase Deficiency. MedlinePlus Genetics.\n* National Library of Medicine. (2022). ADA Gene. Genetics Home Reference.",
    "category": "general"
  },
  {
    "title": "ADA2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/ada2/",
    "content": "**ADA2 Gene**\n\nThe ADA2 gene provides instructions for making an enzyme called adenosine deaminase 2. This enzyme breaks down molecules called adenosine and 2'-deoxyadenosine. Because this enzyme functions in the spaces between cells, it is described as extracellular. Another form of the enzyme, adenosine deaminase 1, breaks down the same molecules inside cells. This other version of the enzyme is produced from the ADA gene.\n\n**Normal Function**\n\nResearchers are still working to determine the functions of adenosine deaminase 2. Studies suggest that it acts as a growth factor, which means that it stimulates cell growth and division. In particular, the enzyme appears to be involved in the growth and development of certain immune system cells, including macrophages, which are a type of white blood cell that plays a critical role in inflammation. Inflammation is a normal immune system response to injury and foreign invaders (such as bacteria). Some macrophages are pro-inflammatory, meaning they promote inflammation, while others are anti-inflammatory, meaning they reduce inflammation.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Adenosine Deaminase 2 Deficiency**\n    More than 60 mutations in the ADA2 gene have been found to cause adenosine deaminase 2 deficiency, a disorder characterized by abnormal inflammation of various organs and tissues, particularly the blood vessels (vasculitis). These mutations severely reduce or eliminate the function of adenosine deaminase 2. Researchers do not fully understand how a shortage (deficiency) of this enzyme's activity leads to vasculitis and immune system abnormalities. They speculate that the enzyme deficiency may disrupt the balance between pro-inflammatory and anti-inflammatory macrophages in various tissues, leading to a buildup of pro-inflammatory macrophages and abnormal inflammation.\n\n---\n\n**ADA2 Gene: MedlinePlus Genetics (Part 2/3)**\n\n**What is the ADA2 gene?**\n\nThe ADA2 gene provides instructions for making a protein called adenosine deaminase 2, which plays a crucial role in breaking down a compound called adenosine into another compound called inosine. This process helps maintain proper immune system function and prevent excessive inflammation.\n\n**How does a shortage of ADA2 enzyme activity lead to vasculitis and immune system abnormalities?**\n\nResearchers do not fully understand how a deficiency of ADA2 enzyme activity leads to vasculitis and immune system abnormalities. However, they speculate that the enzyme deficiency may disrupt the balance between pro-inflammatory and anti-inflammatory macrophages in various tissues, leading to a buildup of pro-inflammatory macrophages and abnormal inflammation.\n\n**What are the symptoms of ADA2 gene deficiency?**\n\nMore than 60 mutations in the ADA2 gene have been found to cause adenosine deaminase 2 deficiency, a disorder characterized by abnormal inflammation of various organs and tissues, particularly the blood vessels (vasculitis). Symptoms may include:\n\n* Abnormal inflammation of various organs and tissues\n* Vasculitis (inflammation of blood vessels)\n* Immune system abnormalities\n\n**Other Names for This Gene**\n\n* Adenosine deaminase CECR1\n* ADGF\n* Cat eye syndrome chromosome region, candidate 1\n* Cat eye syndrome critical region protein 1\n* CECR1\n* IDGFL\n* SNEDS\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry:\n\t+ Tests of ADA2\n* Scientific Articles on PubMed:\n\t+ PubMed\n* Catalog of Genes and Diseases from OMIM:\n\t+ ADENOSINE DEAMINASE 2; ADA2\n* Gene and Variant Databases:\n\t+ NCBI Gene\n\t+ ClinVar\n\n**References**\n\n* Meyts I, Aksentijevich I. Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment. J Clin Immunol. 2018 Jul;38(5):569-578.\n* Nanthapisal S, Murphy C, Omoyinmi E, Hong Y, Standing A, Berg S, Ekelund M, Jolles S, Harper L, Youngstein T, Gilmour K, Klein NJ, Eleftheriou D, Brogan PA. Deficiency of Adenosine Deaminase Type 2: A Description of Phenotype and Genotype in Fifteen Cases. Arthritis Rheumatol. 2016 Sep;68(9):2314-22.\n* Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, Zlotogorski A, Berkun Y, Press JJ, Mukamel M, Voth I, Hashkes PJ, Harel L, Hoffer V, Ling E, Yalcinkaya F, Kasapcopur O, Lee MK, Klevit RE, Renbaum P, Weinberg-Shukron A, Sener EF, Schormair B, Zeligson S, Marek-Yagel D, Strom TM, Shohat M, Singer A, Rubinow A, Pras E, Winkelmann J, Tekin M, Anikster Y, King MC, Levy-Lahad E. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014 Mar 6;370(10):921-31.\n* Van Montfrans JM, Hartman EA, Braun KP, Hennekam EA, Hak EA, Nederkoorn PJ, Westendorp WF, Bredius RG, Kollen WJ, Scholvinck EH, Legger GE, Meyts I, Liston A, Lichtenbelt KD, Giltay JC, Van Haaften G, De Vries Simons GM, Leavis H, Sanders CJ, Bierings MB, Nierkens S, Van Gijn ME. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford). 2016 May;55(5):902-10.\n* Zavialov AV, Engstrom A. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J. 2005 Oct 1;391(Pt 1):51-7.\n* Zavialov AV, Yu X, Spillmann D, Lauvau G, Zavialov AV. Structural basis for the growth factor activity of human adenosine deaminase ADA2. J Biol Chem. 2010 Apr 16;285(16):12367-77.\n* Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, Stone DL, Chae JJ, Rosenzweig SD, Bishop K, Barron KS, Kuehn HS, Hoffmann P, Negro A, Tsai WL, Cowen EW, Pei W, Milner JD, Silvin C, Heller T, Chin DT, Patronas NJ, Barber JS, Lee CC, Wood GM, Ling A, Kelly SJ, Kleiner DE, Mullikin JC, Ganson NJ, Kong HH, Hambleton S, Candotti F, Quezado MM, Calvo KR, Alao H, Barham BK, Jones A, Meschia JF, Worrall BB, Kasner SE, Rich SS, Goldbach-Mansky R, Abinun M, Chalom E, Gotte AC, Punaro M, Pascual V, Verbsky JW, Torgerson TR, Singer NG, Gershon TR, Ozen S, Karadag O, Fleisher TA, Remmers EF, Burgess SM, Moir SL, Gadina M, Sood R, Hershfield MS, Boehm M, Kastner DL, Aksentijevich I. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014 Mar 6;370(10):911-20.\n\n---\n\n**ADA2 Gene**\n\n**Genomic Location**\nThe ADA2 gene is found on chromosome 22.\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\nNote: The cleaned output only includes the relevant medical content, removing code blocks, ads, disclaimers, standalone URLs, and other unnecessary information. The **bold** headings and * for lists are used as specified in the formatting rules.",
    "category": "general"
  },
  {
    "title": "ADAMTS10 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/adamts10/",
    "content": "**ADAMTS10 Gene**\n\nThe **ADAMTS10 gene** provides instructions for making an enzyme that is found in many of the body's cells and tissues. This enzyme is part of a family of metalloproteases, which are zinc-containing enzymes that cut apart other proteins.\n\n**Normal Function**\n\n* The ADAMTS10 enzyme is critical for growth before and after birth.\n* Researchers believe that it may be involved in the development of structures including the skin, eyes, heart, and skeleton.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Weill-Marchesani Syndrome**: At least five mutations in the ADAMTS10 gene have been identified in people with Weill-Marchesani syndrome. Each of these mutations prevents the cell from producing any functional ADAMTS10 enzyme.\n* A loss of this enzyme disrupts skeletal development, leading to short stature and unusually short fingers and toes (brachydactyly).\n* A shortage of the ADAMTS10 enzyme also interferes with the development and function of the lens of the eye, causing eye abnormalities and impaired vision.\n* Additionally, a lack of this enzyme may disrupt the normal development of the heart, resulting in the heart defects occasionally seen in people with Weill-Marchesani syndrome.\n\n**Other Names for This Gene**\n\n* A disintegrin and metalloproteinase with thrombospondin motifs 10\n* A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 10\n* A disintegrin-like and metalloprotease domain with thrombospondin type I repeats 10\n* ADAM metallopeptidase with thrombospondin type 1 motif, 10\n* ADAM-TS10\n* ADAMTS-10\n* ATS10_HUMAN\n\n---\n\n**ADAMTS10 Gene**\n\n**Gene and Variant Databases**\n\n*   **NCBI Gene**: The ADAMTS10 gene is found on chromosome 19.\n*   **ClinVar**: No variants listed in ClinVar.\n\n**Tests Listed in the Genetic Testing Registry**\n\n*   **Tests of ADAMTS10**: No tests listed in the Genetic Testing Registry.\n\n**Scientific Articles on PubMed**\n\n*   **PubMed**: Search results for ADAMTS10 gene.\n\n**Catalog of Genes and Diseases from OMIM**\n\n*   **A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 10; ADAMTS10**: No information listed in the Catalog of Genes and Diseases from OMIM.\n\n**References**\n\n*   Dagoneau N, Benoist-Lasselin C, Huber C, Faivre L, Megarbane A, Alswaid A, Dollfus H, Alembik Y, Munnich A, Legeai-Mallet L, Cormier-Daire V. ADAMTS10 mutations in autosomal recessive Weill-Marchesani syndrome. Am J Hum Genet. 2004 Nov;75(5):801-6. doi: 10.1086/425231. Epub 2004 Sep 13.\n*   Kutz WE, Wang LW, Dagoneau N, Odrcic KJ, Cormier-Daire V, Traboulsi EI, Apte SS. Functional analysis of an ADAMTS10 signal peptide mutation in Weill-Marchesani syndrome demonstrates a long-range effect on secretion of the full-length enzyme. Hum Mutat. 2008 Dec;29(12):1425-34. doi: 10.1002/humu.20797.\n*   Nicholson AC, Malik SB, Logsdon JM Jr, Van Meir EG. Functional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organization. BMC Evol Biol. 2005 Feb 4;5:11. doi: 10.1186/1471-2148-5-11.\n*   Somerville RP, Jungers KA, Apte SS. Discovery and characterization of a novel, widely expressed metalloprotease, ADAMTS10, and its proteolytic activation. J Biol Chem. 2004 Dec 3;279(49):51208-17. doi: 10.1074/jbc.M409036200.\n\n**Genomic Location**\n\nThe ADAMTS10 gene is found on chromosome 19.\n\n**Related Health Topics**\n\n*   **Genes and Gene Therapy**\n*   **Genetic Disorders**",
    "category": "general"
  },
  {
    "title": "ADAMTS13 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/adamts13/",
    "content": "**ADAMTS13 Gene**\n\nThe ADAMTS13 gene provides instructions for making an enzyme that is involved in regulating blood clotting.\n\n**Normal Function**\n\nAfter an injury, clots normally protect the body by sealing off damaged blood vessels and preventing further blood loss. The ADAMTS13 enzyme processes a large protein called von Willebrand factor. This protein is involved in the first step of blood clotting at the site of injury, which is to help cells called platelets stick together and attach to the walls of blood vessels, forming temporary clots.\n\nThe ADAMTS13 enzyme cuts von Willebrand factor into smaller pieces to regulate its interaction with platelets. By processing von Willebrand factor in this way, the enzyme prevents it from triggering the formation of blood clots in normal circulation.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Thrombotic Thrombocytopenic Purpura (TTP)**: More than 150 mutations in the ADAMTS13 gene have been reported in people with the familial form of TTP. This condition causes blood clots (thrombi) to form in small blood vessels throughout the body, leading to serious medical problems if they block vessels and restrict blood flow to organs such as the brain, kidneys, and heart.\n\n    Most of these mutations change single protein building blocks (amino acids) in the ADAMTS13 enzyme. Other mutations lead to the production of an abnormally small version of the enzyme that cannot function properly. These mutations severely reduce the activity of the ADAMTS13 enzyme, resulting in abnormal clots throughout the body.\n\n    The uncut version of von Willebrand factor is hyperactive and may induce platelets to stick together, even in the absence of injury, leading to the signs and symptoms of TTP.\n\n---\n\n**ADAMTS13 Gene**\n\nThe ADAMTS13 gene is responsible for producing an enzyme that helps regulate blood clotting. Mutations in this gene can lead to thrombotic thrombocytopenic purpura (TTP), a rare disorder characterized by the formation of abnormal blood clots throughout the body.\n\n**What is Thrombotic Thrombocytopenic Purpura?**\n\nTTP is a serious medical condition that occurs when the ADAMTS13 enzyme is not functioning properly. This can lead to the formation of abnormal blood clots in small blood vessels, which can cause a range of symptoms including:\n\n* Neurological problems such as personality changes, headaches, confusion, and slurred speech\n* Fever\n* Abnormal kidney function\n* Abdominal pain\n* Heart problems\n\n**How Do Mutations in the ADAMTS13 Gene Cause TTP?**\n\nMost mutations that lead to TTP change single protein building blocks (amino acids) in the ADAMTS13 enzyme. Other mutations result in the production of an abnormally small version of the enzyme that cannot function properly. These mutations severely reduce the activity of the ADAMTS13 enzyme, leading to abnormal blood clot formation.\n\n**Other Names for the ADAMTS13 Gene**\n\nThe ADAMTS13 gene has several other names, including:\n\n* ADAM metallopeptidase with thrombospondin type 1 motif, 13\n* ADAMTS-13\n* ATS13_HUMAN\n* C9orf8\n* von Willebrand factor-cleaving protease\n* vWF-cleaving protease\n* vWF-CP\n* VWFCP\n\n**Genomic Location**\n\nThe ADAMTS13 gene is located on chromosome 9.\n\n**Related Health Topics**\n\nThe ADAMTS13 gene is related to several health topics, including:\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ADAMTS2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/adamts2/",
    "content": "**ADAMTS2 Gene**\n\nThe ADAMTS2 gene provides instructions for making an enzyme that processes several types of procollagen molecules. Procollagens are the precursors of collagens, which are complex molecules found in the spaces between cells that add strength, support, and stretchiness (elasticity) to many body tissues.\n\n**Normal Function**\n\nThe ADAMTS2 enzyme cuts a short chain of protein building blocks (amino acids) off one end of procollagens. This clipping step is necessary for the resulting collagen molecules to assemble into strong, slender fibrils.\n\n**Health Conditions Related to Genetic Changes**\n\nSeveral mutations in the ADAMTS2 gene have been identified in people with a form of Ehlers-Danlos syndrome called the dermatosparaxis type. Ehlers-Danlos syndrome is a group of disorders that affect the connective tissues supporting the skin, bones, blood vessels, and many other organs and tissues.\n\nThe dermatosparaxis type is characterized by soft, fragile skin that sags and wrinkles; easy bruising; and distinctive facial features. Mutations in the ADAMTS2 gene greatly reduce the production or activity of the ADAMTS2 enzyme. Without enough of this enzyme, procollagens cannot be processed correctly. As a result, collagen fibrils are not assembled properly. The resulting fibrils are disorganized, which weakens connective tissues and leads to the signs and symptoms of the disorder.\n\n**Other Names for This Gene**\n\n* A disintegrin and metalloproteinase with thrombospondin motifs 2\n* A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 2\n* ADAM metallopeptidase with thrombospondin type 1 motif, 2\n* ADAM-TS2\n* ATS2_HUMAN\n* hPCPNI\n* NPI\n* PCINP\n* PCPNI\n* pNPI\n* Procollagen I N-proteinase\n* Procollagen I/II amino-propeptide processing enzyme\n* Procollagen N-endopeptidase\n\n---\n\n**ADAMTS2 Gene**\n\n**Gene and Variant Databases**\n\n*   NCBI Gene\n*   ClinVar\n\n**Tests Listed in the Genetic Testing Registry**\n\n*   Tests of ADAMTS2\n\n**Scientific Articles on PubMed**\n\n*   Wang WM, Lee S, Steiglitz BM, Scott IC, Lebares CC, Allen ML, Brenner MC, Takahara K, Greenspan DS. Transforming growth factor-beta induces secretion of activated ADAMTS-2. A procollagen III N-proteinase. J Biol Chem. 2003 May 23;278(21):19549-57.\n*   Colige A, Sieron AL, Li SW, Schwarze U, Petty E, Wertelecki W, Wilcox W, Krakow D, Cohn DH, Reardon W, Byers PH, Lapiere CM, Prockop DJ, Nusgens BV. Human Ehlers-Danlos syndrome type VII C and bovine dermatosparaxis are caused by mutations in the procollagen I N-proteinase gene. Am J Hum Genet. 1999 Aug;65(2):308-17.\n*   Colige A, Nuytinck L, Hausser I, van Essen AJ, Thiry M, Herens C, Ades LC, Malfait F, Paepe AD, Franck P, Wolff G, Oosterwijk JC, Smitt JH, Lapiere CM, Nusgens BV. Novel types of mutation responsible for the dermatosparactic type of Ehlers-Danlos syndrome (Type VIIC) and common polymorphisms in the ADAMTS2 gene. J Invest Dermatol. 2004 Oct;123(4):656-63.\n*   Kelwick R, Desanlis I, Wheeler GN, Edwards DR. The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family. Genome Biol. 2015 May 30;16(1):113.\n*   Le Goff C, Cormier-Daire V. The ADAMTS(L) family and human genetic disorders. Hum Mol Genet. 2011 Oct 15;20(R2):R163-7.\n\n**Genomic Location**\n\nThe ADAMTS2 gene is found on chromosome 5.\n\n**Related Health Topics**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ADAMTSL2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/adamtsl2/",
    "content": "**ADAMTSL2 Gene**\n\nThe **ADAMTSL2** gene provides instructions for making a protein whose function is unknown. The **ADAMTSL2** protein is active in many different tissues and is found in the extracellular matrix, which is the intricate lattice of proteins and other molecules that forms in the spaces between cells.\n\nStudies suggest that the **ADAMTSL2** protein interacts with a protein called latent transforming growth factor beta binding protein 1 (LTBP1). The LTBP1 protein is involved in the storage of transforming growth factor beta (TGF-Î²), a critical growth factor that helps control the growth and division of cells, cell movement, and the self-destruction of cells. Through its interaction with the LTBP1 protein, researchers suspect that the **ADAMTSL2** protein may help regulate the availability of TGF-Î².\n\nThe interaction between the **ADAMTSL2** protein and the LTBP1 protein suggests that **ADAMTSL2** may also play a role in the microfibrillar network. This organized clustering of thread-like filaments (called microfibrils) in the extracellular matrix provides strength and flexibility to tissues throughout the body.\n\n**Health Conditions Related to Genetic Changes**\n\n*   Geleophysic dysplasia: At least five mutations in the **ADAMTSL2** gene have been identified in people with geleophysic dysplasia. Most of these mutations change single protein building blocks (amino acids) in the **ADAMTSL2** protein, which probably alters the protein's 3-dimensional shape. Through a process that is poorly understood, **ADAMTSL2** gene mutations alter the microfibrillar network in many different tissues. Impairment of this essential network disrupts the normal functions of cells, which likely contributes to the varied signs and symptoms of geleophysic dysplasia.\n\n---\n\n**ADAMTSL2 Gene**\n\n**Geleophysic Dysplasia**\n\nGeleophysic dysplasia is a rare genetic disorder caused by mutations in the ADAMTSL2 gene. The condition is characterized by short stature, heart disease, and other features.\n\n**How Mutations Affect the Body**\n\nMutations in the ADAMTSL2 gene alter the microfibrillar network in many different tissues. This impairment disrupts the normal functions of cells, leading to the varied signs and symptoms of geleophysic dysplasia.\n\n**Research on the Condition**\n\nResearchers are working to determine how mutations in the ADAMTSL2 gene lead to short stature, heart disease, and other features of the condition. At least five mutations in the ADAMTSL2 gene have been identified in people with geleophysic dysplasia.\n\n**Other Names for This Gene**\n\n* ADAMTS-like 2\n* ADAMTS-like 2 precursor\n* ATL2_HUMAN\n* FLJ45164\n* KIAA0605\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: Tests of ADAMTSL2\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM: ADAMTS-LIKE PROTEIN 2; ADAMTSL2\n* Gene and Variant Databases: NCBI Gene, ClinVar\n\n**References**\n\n* Koo BH, Le Goff C, Jungers KA, Vasanji A, O'Flaherty J, Weyman CM, Apte SS. ADAMTS-like 2 (ADAMTSL2) is a secreted glycoprotein that is widely expressed during mouse embryogenesis and is regulated during skeletal myogenesis. Matrix Biol. 2007 Jul;26(6):431-41.\n* Le Goff C, Morice-Picard F, Dagoneau N, Wang LW, Perrot C, Crow YJ, Bauer F, Flori E, Prost-Squarcioni C, Krakow D, Ge G, Greenspan DS, Bonnet D, Le Merrer M, Munnich A, Apte SS, Cormier-Daire V. ADAMTSL2 mutations in geleophysic dysplasia demonstrate a role for ADAMTS-like proteins in TGF-beta bioavailability regulation. Nat Genet. 2008 Sep;40(9):1119-23.\n* Marzin P, Cormier-Daire V. Geleophysic Dysplasia. 2009 Sep 22 [updated 2024 Mar 28]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025.\n\n**Genomic Location**\n\nThe ADAMTSL2 gene is found on chromosome 9.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ADAMTSL4 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/adamtsl4/",
    "content": "**ADAMTSL4 Gene**\n\nThe ADAMTSL4 gene provides instructions for making a protein that is found throughout the body. The ADAMTSL4 protein is released from cells into the extracellular matrix, which is an intricate lattice of proteins and other molecules that forms in the spaces between cells.\n\n*   **Normal Function:**\n    *   The ADAMTSL4 protein attaches (binds) to another protein called fibrillin-1.\n    *   Fibrillin-1 proteins bind to each other and other proteins to form threadlike filaments called microfibrils.\n    *   It is likely that the binding of ADAMTSL4 to fibrillin-1 promotes microfibril assembly.\n    *   Microfibrils provide support to many tissues, including the lenses of the eyes, which are held in their central position by these filaments.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Isolated Ectopia Lentis:**\n    *   At least 15 mutations in the ADAMTSL4 gene have been found to cause isolated ectopia lentis.\n    *   In this condition, the lens in one or both eyes is off-center (displaced), which leads to vision problems.\n    *   An ADAMTSL4 gene mutation that is frequently found in affected individuals of European ancestry deletes 20 DNA building blocks (nucleotides) from the gene (written as 767_787del20).\n    *   This mutation leads to the production of a protein that is abnormally short and nonfunctional.\n    *   A lack of functional ADAMTSL4 protein likely diminishes the ability of fibrillin-1 to effectively form microfibrils.\n    *   As a result, there is a reduction in filaments to anchor the lens in its central position at the front of the eye, leading to its displacement and the vision problems characteristic of isolated ectopia lentis.\n\n*   **Other Disorders:**\n    *   Some ADAMTSL4 gene mutations cause an eye condition called ectopia lentis et pupillae.\n    *   In this condition, both the lenses and the pupils are off-center; they are usually displaced in opposite directions.\n    *   People with ectopia lentis et pupillae have eye and vision problems similar to those with isolated ectopia lentis (described above), including nearsightedness (myopia), farsightedness (hyperopia), or an irregular curvature of the front of the eye (astigmatism).\n    *   They may also develop clouding of the lenses (cataracts) or increased pressure in the eyes (glaucoma) at an early age.\n\n---\n\n**ADAMTSL4 Gene**\n\nThe ADAMTSL4 gene provides instructions for making a protein called ADAMTSL4. This protein is abnormally short and nonfunctional due to mutations in the gene.\n\n**Production of Microfibrils**\n\nA lack of functional ADAMTSL4 protein diminishes the ability of fibrillin-1 to effectively form microfibrils. As a result, there is a reduction in filaments to anchor the lens in its central position at the front of the eye, leading to its displacement and the vision problems characteristic of isolated ectopia lentis.\n\n**Compensation by Other Proteins**\n\nWhile the ADAMTSL4 protein is found throughout the body, it is thought that other proteins can compensate for its function in tissues other than the eyes. This likely explains why only the eyes are affected in this condition.\n\n**Other Disorders**\n\nSome ADAMTSL4 gene mutations cause an eye condition called ectopia lentis et pupillae. In this condition, both the lenses and the pupils are off-center; they are usually displaced in opposite directions. People with ectopia lentis et pupillae have eye and vision problems similar to those with isolated ectopia lentis (described above), including nearsightedness (myopia), farsightedness (hyperopia), or an irregular curvature of the front of the eye (astigmatism). They may also develop clouding of the lenses (cataracts) or increased pressure in the eyes (glaucoma) at an early age.\n\n**Other Names for This Gene**\n\n* ADAMTS-like 4\n* ADAMTS-like protein 4\n* ADAMTSL-4\n* ATL4_HUMAN\n* ECTOL2\n* Thrombospondin repeat-containing protein 1\n* TSRC1\n\n**References**\n\n* Chandra A, Aragon-Martin JA, Hughes K, Gati S, Reddy MA, Deshpande C, Cormack G, Child AH, Charteris DG, Arno G. A genotype-phenotype comparison of ADAMTSL4 and FBN1 in isolated ectopia lentis. Invest Ophthalmol Vis Sci. 2012 Jul 24;53(8):4889-96.\n* Christensen AE, Fiskerstrand T, Knappskog PM, Boman H, Rodahl E. A novel ADAMTSL4 mutation in autosomal recessive ectopia lentis et pupillae. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6369-73.\n* Gabriel LA, Wang LW, Bader H, Ho JC, Majors AK, Hollyfield JG, Traboulsi EI, Apte SS. ADAMTSL4, a secreted glycoprotein widely distributed in the eye, binds fibrillin-1 microfibrils and accelerates microfibril biogenesis. Invest Ophthalmol Vis Sci. 2012 Jan 31;53(1):461-9.\n* Hubmacher D, Apte SS. Genetic and functional linkage between ADAMTS superfamily proteins and fibrillin-1: a novel mechanism influencing microfibril assembly and function. Cell Mol Life Sci. 2011 Oct;68(19):3137-48.\n\n---\n\n**ADAMTSL4 Gene**\n\nThe ADAMTSL4 gene is found on chromosome 1.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Genomic Location**\n\nThe ADAMTSL4 gene is found on chromosome 1.",
    "category": "general"
  },
  {
    "title": "ADAR gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/adar/",
    "content": "**ADAR Gene**\n\nThe ADAR gene provides instructions for making a protein called RNA-specific adenosine deaminase 1 (ADAR1). This protein is involved in making changes to (editing) RNA, a chemical cousin of DNA. Specifically, it attaches (binds) to RNA and changes an RNA building block (nucleotide) called adenosine to another nucleotide called inosine.\n\n**Normal Function**\n\nThe ADAR1 protein is involved in the control of the innate immune response, which is the immune system's early response to foreign invaders (pathogens). The immune system sometimes fails to recognize the bodyâs own RNA and may act as though it belongs to a pathogen that should be attacked. By changing adenosine to inosine, ADAR1 may prevent the immune system from targeting the body's own tissues.\n\nThe ADAR1 protein is also thought to inhibit the replication and spread of certain viruses, such as human immunodeficiency virus (HIV) and hepatitis C, by modifying their RNA. In addition, the ADAR1 protein controls the function of certain chemical messengers called neurotransmitters at particular sites in the body by modifying the RNA blueprint for the receptor proteins that interact with the neurotransmitters.\n\n**Health Conditions Related to Genetic Changes**\n\n*   Aicardi-GoutiÃ¨res syndrome: Variants (also called mutations) in the ADAR gene have been identified in people with Aicardi-GoutiÃ¨res syndrome, a disorder that typically involves severe brain dysfunction (encephalopathy), skin lesions, immune system abnormalities, and other health problems. Some of these variants lead to the production of an ADAR1 protein that is less able to bind to RNA; others impair the protein's RNA editing function. As a result, control of the immune response is impaired and the immune system attacks the body's own tissues and organs, leading to the signs and symptoms of Aicardi-GoutiÃ¨res syndrome.\n\n---\n\n**ADAR Gene: MedlinePlus Genetics (Part 2/4)**\n\n**Other Disorders**\n\n* ADAR gene variants have been identified in people with dyschromatosis symmetrica hereditaria. This disorder is characterized by freckle-like spots (macules) on the face, hands, and feet that are darker or lighter than the surrounding skin. These macules generally appear in infancy or early childhood.\n* Variants in the ADAR gene that lead to dyschromatosis symmetrica hereditaria cause cells to produce a version of the ADAR1 protein that does not function properly. While the function of this protein in the skin is unknown, researchers suggest that incorrect RNA editing may result in pigment-producing cells (melanocytes) that are more or less active than normal, causing the skin spots that occur in people with this disorder.\n\n**Aicardi-GoutiÃ¨res Syndrome**\n\n* Variants (also called mutations) in the ADAR gene have been identified in people with Aicardi-GoutiÃ¨res syndrome, a disorder that typically involves severe brain dysfunction (encephalopathy), skin lesions, immune system abnormalities, and other health problems. Some of these variants lead to the production of an ADAR1 protein that is less able to bind to RNA; others impair the protein's RNA editing function. As a result, control of the immune response is impaired and the immune system attacks the body's own tissues and organs, leading to the signs and symptoms of Aicardi-GoutiÃ¨res syndrome.\n\n**Other Names for This Gene**\n\n* ADAR1\n* adenosine deaminase acting on RNA 1-A\n* DRADA\n* DSH\n* DSRAD\n* dsRNA adenosine deaminase\n* dsRNA adeonosine deaminase\n* IFI-4\n* interferon-induced protein 4\n* interferon-inducible protein 4\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: Tests of ADAR\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM: DYSCHROMATOSIS SYMMETRICA HEREDITARIA; DSH, ADENOSINE DEAMINASE, RNA-SPECIFIC; ADAR\n\n---\n\n**ADAR Gene: MedlinePlus Genetics (Part 3/4)**\n\n\\n\\n\n\n**Catalog of Genes and Diseases from OMIM**\n\n*   **DYSCHROMATOSIS SYMMETRICA HEREDITARIA; DSH**\n*   **ADENOSINE DEAMINASE, RNA-SPECIFIC; ADAR**\n\n\\n\\n\n\n**Gene and Variant Databases**\n\n*   **NCBI Gene**\n*   **ClinVar**\n\n\\n\\n\n\n**Tests Listed in the Genetic Testing Registry**\n\n*   **Tests of ADAR**\n\n\\n\\n\n\n**Scientific Articles on PubMed**\n\n*   **PubMed**\n\n\\n\\n\n\n**References**\n\nExpand Section\n\n1.  Crow YJ. Aicardi-Goutieres Syndrome. 2005 Jun 29 [updated 2016 Nov 22]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from http://www.ncbi.nlm.nih.gov/books/NBK1475/. Citation on PubMed\n2.  Fisher AJ, Beal PA. Effects of Aicardi-Goutieres syndrome mutations predicted from ADAR-RNA structures. RNA Biol. 2017 Feb;14(2):164-170. doi: 10.1080/15476286.2016.1267097. Epub 2016 Dec 12. Citation on PubMed or Free article on PubMed Central\n3.  Hayashi M, Suzuki T. Dyschromatosis symmetrica hereditaria. J Dermatol. 2013 May;40(5):336-43. doi: 10.1111/j.1346-8138.2012.01661.x. Epub 2012 Sep 14. Citation on PubMed\n4.  Heraud-Farlow JE, Walkley CR. The role of RNA editing by ADAR1 in prevention of innate immune sensing of self-RNA. J Mol Med (Berl). 2016 Oct;94(10):1095-1102. doi: 10.1007/s00109-016-1416-1. Epub 2016 Apr 5. Citation on PubMed\n5.  Liddicoat BJ, Chalk AM, Walkley CR. ADAR1, inosine and the immune sensing system: distinguishing self from non-self. Wiley Interdiscip Rev RNA. 2016 Mar-Apr;7(2):157-72. doi: 10.1002/wrna.1322. Epub 2015 Dec 21. Citation on PubMed\n6.  Pestal K, Funk CC, Snyder JM, Price ND, Treuting PM, Stetson DB. Isoforms of RNA-Editing Enzyme ADAR1 Independently Control Nucleic Acid Sensor MDA5-Driven Autoimmunity and Multi-organ Development. Immunity. 2015 Nov 17;43(5):933-44. doi: 10.1016/j.immuni.2015.11.001. Citation on PubMed or Free article on PubMed Central\n7.  Rice GI, Kasher PR, Forte GM, Mannion NM, Greenwood SM, Szynkiewicz M, Dickerson JE, Bhaskar SS, Zampini M, Briggs TA, Jenkinson EM, Bacino CA, Battini R, Bertini E, Brogan PA, Brueton LA, Carpanelli M, De Laet C, de Lonlay P, del Toro M, Desguerre I, Fazzi E, Garcia-Cazorla A, Heiberg A, Kawaguchi M, Kumar R, Lin JP, Lourenco CM, Male AM, Marques W Jr, Mignot C, Olivieri I, Orcesi S, Prabhakar P, Rasmussen M, Robinson RA, Rozenberg F, Schmidt JL, Steindl K, Tan TY, van der Merwe WG, Vanderver A, Vassallo G, Wakeling EL, Wassmer E, Whittaker E, Livingston JH, Lebon P, Suzuki T, McLaughlin PJ, Keegan LP, O'Connell MA, Lovell SC, Crow YJ. Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a type I interferon signature. Nat Genet. 2012 Nov;44(11):1243-8. doi: 10.1038/ng.2414. Epub 2012 Sep 23. Citation on PubMed or Free article on PubMed Central\n8.  Rice GI, Kitabayashi N, Barth M, Briggs TA, Burton ACE, Carpanelli ML, Cerisola AM, Colson C, Dale RC, Danti FR, Darin N, De Azua B, De Giorgis V, De Goede CGL, Desguerre I, De Laet C, Eslahi A, Fahey MC, Fallon P, Fay A, Fazzi E, Gorman MP, Gowrinathan NR, Hully M, Kurian MA, Leboucq N, Lin JS, Lines MA, Mar SS, Maroofian R, Marti-Sanchez L, McCullagh G, Mojarrad M, Narayanan V, Orcesi S, Ortigoza-Escobar JD, Perez-Duenas B, Petit F, Ramsey KM, Rasmussen M, Rivier F, Rodriguez-Pombo P, Roubertie A, Stodberg TI, Toosi MB, Toutain A, Uettwiller F, Ulrick N, Vanderver A, Waldman A, Livingston JH, Crow YJ. Genetic, Phenotypic, and Interferon Biomarker Status in ADAR1-Related Neurological Disease. Neuropediatrics. 2017 Jun;48(3):166-184. doi: 10.1055/s-0037-1601449. Epub 2017 Apr 10. Citation on PubMed\n9.  Zipeto MA, Jiang Q, Melese E, Jamieson CH. RNA rewriting, recoding, and rewiring in human disease. Trends Mol Med. 2015 Sep;21(9):549-59. doi: 10.1016/j.molmed.2015.07.001. Epub 2015 Aug 7.\n\n---\n\n**ADAR Gene**\n\n\\n\\n\n\n**Genomic Location**\nThe ADAR gene is found on chromosome 1.\n\n\\n\\n\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders\n\n\\n\\n\n\n* **Understanding Genetics**\n\t+ What is DNA?\n\t+ What is a gene?\n\t+ What is a gene variant and how do variants occur?",
    "category": "general"
  },
  {
    "title": "ADCY5 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/adcy5/",
    "content": "**ADCY5 Gene**\n\nThe **ADCY5 gene** provides instructions for making an enzyme called adenylate cyclase 5. This enzyme helps convert a molecule called adenosine triphosphate (ATP) to another molecule called cyclic adenosine monophosphate (cAMP). ATP is a molecule that supplies energy for cells' activities, including muscle contraction, and cAMP is involved in signaling for many cellular functions.\n\n**Health Conditions Related to Genetic Changes**\n\n* **ADCY5-related dyskinesia**: At least six ADCY5 gene mutations have been identified in people with ADCY5-related dyskinesia, a disorder that causes abnormal involuntary movements. These mutations are thought to enhance adenylate cyclase 5 enzyme activity and lead to higher levels of cAMP within cells, so they are described as \"gain-of-function\" mutations. Other ADCY5 gene mutations prevent production of adenylate cyclase 5.\n* **Type 2 diabetes**: Certain normal variations (polymorphisms) in the ADCY5 gene have been associated with an increased risk of type 2 diabetes.\n\n**Other Names for This Gene**\n\n* AC5\n* Adenylate cyclase type 5\n* Adenylate cyclase type 5 isoform 1\n* Adenylate cyclase type 5 isoform 2\n* Adenylate cyclase type V\n* Adenylyl cyclase 5\n* ATP pyrophosphate-lyase 5\n* FDFM\n\n---\n\n**ADCY5 Gene**\n\nThe ADCY5 gene is located on chromosome 3.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Genomic Location**\n\nThe ADCY5 gene is found on chromosome 3.\n\n**Scientific Articles on PubMed**\n\n* Chen YZ, Friedman JR, Chen DH, Chan GC, Bloss CS, Hisama FM, Topol SE, Carson AR, Pham PH, Bonkowski ES, Scott ER, Lee JK, Zhang G, Oliveira G, Xu J, Scott-Van Zeeland AA, Chen Q, Levy S, Topol EJ, Storm D, Swanson PD, Bird TD, Schork NJ, Raskind WH, Torkamani A. Gain-of-function ADCY5 mutations in familial dyskinesia with facial myokymia. Ann Neurol. 2014 Apr;75(4):542-9.\n* Chen YZ, Matsushita MM, Robertson P, Rieder M, Girirajan S, Antonacci F, Lipe H, Eichler EE, Nickerson DA, Bird TD, Raskind WH. Autosomal dominant familial dyskinesia and facial myokymia: single exome sequencing identifies a mutation in adenylyl cyclase 5. Arch Neurol. 2012 May;69(5):630-5.\n* Hodson DJ, Mitchell RK, Marselli L, Pullen TJ, Gimeno Brias S, Semplici F, Everett KL, Cooper DM, Bugliani M, Marchetti P, Lavallard V, Bosco D, Piemonti L, Johnson PR, Hughes SJ, Li D, Li WH, Shapiro AM, Rutter GA. ADCY5 couples glucose to insulin secretion in human islets. Diabetes. 2014 Sep;63(9):3009-21.\n* Mencacci NE, Erro R, Wiethoff S, Hersheson J, Ryten M, Balint B, Ganos C, Stamelou M, Quinn N, Houlden H, Wood NW, Bhatia KP. ADCY5 mutations are another cause of benign hereditary chorea. Neurology. 2015 Jul 7;85(1):80-8.\n* Raskind WH, Matsushita M, Peter B, Biberston J, Wolff J, Lipe H, Burbank R, Bird TD. Familial dyskinesia and facial myokymia (FDFM): Follow-up of a large family and linkage to chromosome 3p21-3q21. Am J Med Genet B Neuropsychiatr Genet. 2009 Jun 5;150B(4):570-4.\n\n**References**\n\n* Carapito R, Paul N, Untrau M, Le Gentil M, Ott L, Alsaleh G, Jochem P, Radosavljevic M, Le Caignec C, David A, Damier P, Isidor B, Bahram S. A de novo ADCY5 mutation causes early-onset autosomal dominant chorea and dystonia. Mov Disord. 2015 Mar;30(3):423-7.\n* Chen DH, Meneret A, Friedman JR, Korvatska O, Gad A, Bonkowski ES, Stessman HA, Doummar D, Mignot C, Anheim M, Bernes S, Davis MY, Damon-Perriere N, Degos B, Grabli D, Gras D, Hisama FM, Mackenzie KM, Swanson PD, Tranchant C, Vidailhet M, Winesett S, Trouillard O, Amendola LM, Dorschner MO, Weiss M, Eichler EE, Torkamani A, Roze E, Bird TD, Raskind WH. ADCY5-related dyskinesia: Broader spectrum and genotype-phenotype correlations. Neurology. 2015 Dec;85(23):2026-35.\n* Chen YZ, Friedman JR, Chen DH, Chan GC, Bloss CS, Hisama FM, Topol SE, Carson AR, Pham PH, Bonkowski ES, Scott ER, Lee JK, Zhang G, Oliveira G, Xu J, Scott-Van Zeeland AA, Chen Q, Levy S, Topol EJ, Storm D, Swanson PD, Bird TD, Schork NJ, Raskind WH, Torkamani A. Gain-of-function ADCY5 mutations in familial dyskinesia with facial myokymia. Ann Neurol. 2014 Apr;75(4):542-9.\n* Chen YZ, Matsushita MM, Robertson P, Rieder M, Girirajan S, Antonacci F, Lipe H, Eichler EE, Nickerson DA, Bird TD, Raskind WH. Autosomal dominant familial dyskinesia and facial myokymia: single exome sequencing identifies a mutation in adenylyl cyclase 5. Arch Neurol. 2012 May;69(5):630-5.\n* Hodson DJ, Mitchell RK, Marselli L, Pullen TJ, Gimeno Brias S, Semplici F, Everett KL, Cooper DM, Bugliani M, Marchetti P, Lavallard V, Bosco D, Piemonti L, Johnson PR, Hughes SJ, Li D, Li WH, Shapiro AM, Rutter GA. ADCY5 couples glucose to insulin secretion in human islets. Diabetes. 2014 Sep;63(9):3009-21.\n* Mencacci NE, Erro R, Wiethoff S, Hersheson J, Ryten M, Balint B, Ganos C, Stamelou M, Quinn N, Houlden H, Wood NW, Bhatia KP. ADCY5 mutations are another cause of benign hereditary chorea. Neurology. 2015 Jul 7;85(1):80-8.\n* Raskind WH, Matsushita M, Peter B, Biberston J, Wolff J, Lipe H, Burbank R, Bird TD. Familial dyskinesia and facial myokymia (FDFM): Follow-up of a large family and linkage to chromosome 3p21-3q21. Am J Med Genet B Neuropsychiatr Genet. 2009 Jun 5;150B(4):570-4.\n\n**Catalog of Genes and Diseases from OMIM**\n\n* ADENYLATE CYCLASE 5; ADCY5\n\n---\n\n**ADCY5 Gene**\n\n**What is the ADCY5 gene?**\n\nThe ADCY5 gene provides instructions for making one part of an enzyme called adenylate cyclase 5. This enzyme plays a crucial role in the transmission of signals within cells, particularly in nerve cells.\n\n**How do changes in the ADCY5 gene affect health?**\n\nChanges in the ADCY5 gene have been associated with developmental delays and intellectual disability. The severity of these effects can vary widely among affected individuals, even within the same family.\n\n**Where can I find more information about the ADCY5 gene?**\n\nYou can find more information about the ADCY5 gene on MedlinePlus, a trusted source of health information from the National Institutes of Health and other federal government agencies.",
    "category": "general"
  },
  {
    "title": "ADCY5-related dyskinesia: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/condition/adcy5-related-dyskinesia/",
    "content": "**ADCY5-related Dyskinesia**\n\n**Description**\n\nADCY5-related dyskinesia is a movement disorder characterized by abnormal involuntary movements. These movements typically appear as sudden (paroxysmal) jerks, twitches, tremors, muscle tensing (dystonia), or writhing (choreiform) movements and can affect the limbs, neck, and face.\n\n**Symptoms**\n\nThe abnormal movements associated with ADCY5-related dyskinesia usually begin between infancy and late adolescence. They can occur continually during waking hours and frequently disturb sleep. The involuntary movements often occur when changing position or deliberately making other movements.\n\nSeverely affected infants may experience weak muscle tone (hypotonia) and delay in development of motor skills such as crawling and walking. Later, these individuals may have difficulties with activities of daily living and eventually require a wheelchair. In more mildly affected individuals, the condition has little impact on walking and other motor skills, although the abnormal movements can lead to clumsiness or difficulty with social acceptance.\n\n**Course of the Disorder**\n\nIn some people with ADCY5-related dyskinesia, the disorder is generally stable throughout their lifetime. In others, it slowly gets worse (progresses) in both frequency and severity before stabilizing or even improving in middle age. Anxiety, fatigue, and other stress can temporarily increase the severity of the signs and symptoms of ADCY5-related dyskinesia, while some affected individuals may experience remission periods of days or weeks without abnormal movements.\n\n**Life Expectancy and Intelligence**\n\nLife expectancy is not usually affected by ADCY5-related dyskinesia, and most people with this condition have normal intelligence.\n\n---\n\n**ADCY5-related Dyskinesia**\n\n**What is ADCY5-related Dyskinesia?**\n\nADCY5-related dyskinesia is a rare genetic disorder characterized by abnormal involuntary movements. The condition is caused by mutations in the ADCY5 gene, which provides instructions for making an enzyme called adenylate cyclase 5.\n\n**Symptoms and Signs**\n\nThe abnormal movements associated with ADCY5-related dyskinesia typically appear as sudden (paroxysmal) jerks, twitches, tremors, muscle tensing (dystonia), or writhing (choreiform) movements. These movements can affect the limbs, neck, and face.\n\n**Frequency**\n\nAt least 400 people have been diagnosed with ADCY5-related dyskinesia, but its prevalence is unknown. The disorder is thought to be underdiagnosed because its features can resemble those of other conditions such as cerebral palsy or epilepsy.\n\n**Causes**\n\nAs its name suggests, ADCY5-related dyskinesia is caused by mutations in the ADCY5 gene. This gene provides instructions for making an enzyme called adenylate cyclase 5. Some ADCY5 gene mutations that cause ADCY5-related dyskinesia are thought to increase adenylate cyclase 5 enzyme activity and the level of cAMP within cells. Others prevent production of adenylate cyclase 5.\n\n**Inheritance**\n\nThis condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. In some cases, an affected person inherits the mutation from one affected parent. Other cases result from new mutations in the gene and occur in people with no history of the disorder in their family.\n\n**Other Names for This Condition**\n\nFamilial dyskinesia with facial myokymia (FDFM)\n\n**Additional Information & Resources**\n\nGenetic Testing Registry: Dyskinesia with orofacial involvement, autosomal dominant\nGenetic and Rare Diseases Information Center: Familial dyskinesia and facial myokymia\n\n---\n\n**ADCY5-related dyskinesia**\n\n**What is ADCY5-related dyskinesia?**\n\nADCY5-related dyskinesia is a rare genetic disorder characterized by involuntary movements of the face, trunk, and limbs.\n\n**Causes and risk factors**\n\nThe condition is caused by mutations in the ADCY5 gene, which codes for an enzyme involved in signaling pathways that regulate muscle tone. The mutation leads to an overactive signaling pathway, resulting in excessive muscle contraction and relaxation.\n\n**Symptoms**\n\n* Involuntary movements of the face, trunk, and limbs\n* Facial myokymia (involuntary twitching of facial muscles)\n* Chorea (involuntary dance-like movements)\n\n**Diagnosis**\n\nDiagnosis is typically made through genetic testing, which identifies mutations in the ADCY5 gene.\n\n**Treatment and management**\n\nThere is no cure for ADCY5-related dyskinesia, but treatment options may include:\n\n* Medications to reduce muscle tone and alleviate symptoms\n* Physical therapy to improve mobility and balance\n* Lifestyle modifications to manage stress and prevent exacerbation of symptoms\n\n**Prognosis**\n\nThe prognosis for individuals with ADCY5-related dyskinesia varies depending on the severity of symptoms and response to treatment. Some individuals may experience a significant improvement in symptoms, while others may require ongoing management to maintain quality of life.\n\n**Genetic inheritance**\n\nADCY5-related dyskinesia is inherited in an autosomal dominant pattern, meaning that a single copy of the mutated gene is sufficient to cause the condition. Each child of an affected parent has a 50% chance of inheriting the mutation.\n\n**References**\n\n* Carapito R, et al. (2015). A de novo ADCY5 mutation causes early-onset autosomal dominant chorea and dystonia.\n* Chen DH, et al. (2015). ADCY5-related dyskinesia: Broader spectrum and genotype-phenotype correlations.\n* Chen YZ, et al. (2014). Gain-of-function ADCY5 mutations in familial dyskinesia with facial myokymia.\n* Mencacci NE, et al. (2015). ADCY5 mutations are another cause of benign hereditary chorea.\n\n**Related health topics**\n\n* Genetic Disorders\n* Movement Disorders\n\n---\n\n**ADCY5-related Dyskinesia**\n\n\\n\\n* **What is ADCY5-related dyskinesia?**\n\t+ A rare genetic disorder characterized by involuntary movements of the face, neck, and limbs.\n\t+ Caused by mutations in the ADCY5 gene, which codes for a protein involved in signaling pathways that regulate muscle tone.\n\n**MedlinePlus Links**\n\n\\n\\n* MedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\n**Important Note**\n\n\\n\\n* The information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ADGRE2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/adgre2/",
    "content": "**ADGRE2 Gene**\n\nThe ADGRE2 gene provides instructions for making a protein found in several types of immune system cells, including mast cells. Mast cells, which are found in many body tissues including the skin, are important for the normal protective functions of the immune system. They also play a role in allergic reactions, which occur when the immune system overreacts to stimuli that are not harmful.\n\n**Normal Function**\n\nThe ADGRE2 protein consists of two parts (subunits) that interact with each other: an alpha subunit that lies on the outside surface of the cell and a beta subunit that crosses the cell membrane and extends into the cell. The specific role of the ADGRE2 protein in mast cells is not well understood.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Vibratory Urticaria**: At least one mutation in the ADGRE2 gene has been identified in people with vibratory urticaria, a condition in which vibration, repetitive stretching, or friction on the skin results in allergy symptoms such as hives (urticaria), swelling (angioedema), redness (erythema), and itching (pruritus) in the affected area. The reaction can be brought on by towel drying, hand clapping, running, a bumpy ride in a vehicle, or other repetitive stimulation.\n*   The ADGRE2 gene mutation that causes vibratory urticaria, written as Cys492Tyr or C492Y, replaces the protein building block (amino acid) cysteine with the amino acid tyrosine at position 492 of the protein sequence. The substitution alters the protein structure and leads to a less stable interaction between the two subunits. This fragile connection can be more easily broken; vibration, friction, or stretching of the skin can disrupt the association between subunits in mast cells.\n\n---\n\n**ADGRE2 Gene**\n\n**What is ADGRE2?**\n\nThe ADGRE2 gene provides instructions for making a protein called F4/80, which plays a crucial role in the immune system. Specifically, it helps regulate the activity of certain white blood cells called macrophages.\n\n**Vibratory Urticaria and ADGRE2**\n\nAt least one mutation in the ADGRE2 gene has been identified in people with vibratory urticaria, a condition where vibration, repetitive stretching, or friction on the skin results in allergy symptoms such as hives (urticaria), swelling (angioedema), redness (erythema), and itching (pruritus) in the affected area.\n\n**The Cys492Tyr Mutation**\n\nThe ADGRE2 gene mutation that causes vibratory urticaria, written as Cys492Tyr or C492Y, replaces the protein building block (amino acid) cysteine with the amino acid tyrosine at position 492 of the protein sequence. This substitution alters the protein structure and leads to a less stable interaction between the two subunits.\n\n**How Does ADGRE2 Work?**\n\nThe fragile connection between the two subunits can be more easily broken; vibration, friction, or stretching of the skin can disrupt the association between subunits in mast cells. Researchers suggest that once the subunits are disconnected, the beta subunit signals the mast cells to react and produce the allergy symptoms in the skin that occur in vibratory urticaria.\n\n**Other Names for ADGRE2**\n\n* CD312\n* EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2)\n\n**Genomic Location**\n\nThe ADGRE2 gene is found on chromosome 19.",
    "category": "general"
  },
  {
    "title": "ADGRG1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/adgrg1/",
    "content": "**ADGRG1 Gene**\n\nThe ADGRG1 gene, formerly known as GPR56, provides instructions for making a protein that is critical for normal brain development.\n\n**Normal Function**\n\n* The ADGRG1 protein appears to be essential for the normal growth and movement (migration) of nerve cells (neurons) in a part of the brain called the cerebral cortex.\n* This outer layer of the brain carries out many important functions, such as sensation, voluntary muscle movement, thought, planning, and memory.\n* Although the ADGRG1 protein has been studied most extensively in the brain, it is active in many of the body's tissues.\n* This protein interacts with other proteins on the cell surface to trigger a series of chemical signals within the cell.\n* Studies suggest that ADGRG1 signaling may play an important role in attaching cells to one another (cell adhesion).\n\n**Health Conditions Related to Genetic Changes**\n\n* **Polymicrogyria**\n\t+ At least eleven mutations in the ADGRG1 gene have been identified in people with a severe form of polymicrogyria called bilateral frontoparietal polymicrogyria (BFPP).\n\t+ This disorder causes intellectual disability, delayed development, problems with speech and movement, and recurrent seizures (epilepsy).\n\t+ Most of the identified mutations change a single protein building block (amino acid) in the ADGRG1 protein.\n\t+ These mutations interfere with the normal processing of the protein.\n\t+ The abnormal protein becomes trapped within the cell, where it is unable to reach the cell surface to carry out its normal signaling functions.\n\t+ A loss of ADGRG1 protein function likely disrupts the normal migration of neurons in the developing brain.\n\t+ As a result, certain regions of the cerebral cortexâareas known as the frontal and parietal lobesâdevelop too many folds (called gyri), and the folds are unusually small.\n\n---\n\n**ADGRG1 Gene: MedlinePlus Genetics (Part 2/3)**\n\n**What is the ADGRG1 gene?**\n\nThe ADGRG1 gene provides instructions for making a protein called ADGRG1, which plays a crucial role in the development of the brain. Specifically, it helps regulate the migration and positioning of neurons during fetal development.\n\n**How does the ADGRG1 gene affect the brain?**\n\nMutations in the ADGRG1 gene have been linked to bilateral frontoparietal polymicrogyria (BFPP), a severe form of polymicrogyria that affects the frontal and parietal lobes of the cerebral cortex. This condition is characterized by an excessive number of folds in these regions, leading to intellectual disability, delayed development, problems with speech and movement, and recurrent seizures (epilepsy).\n\n**What are the symptoms associated with ADGRG1 gene mutations?**\n\nThe symptoms associated with ADGRG1 gene mutations include:\n\n* Intellectual disability\n* Delayed development\n* Problems with speech and movement\n* Recurrent seizures (epilepsy)\n\n**How do ADGRG1 gene mutations affect brain development?**\n\nADGRG1 gene mutations disrupt the normal migration of neurons in the developing brain, leading to an excessive number of folds in the frontal and parietal lobes. This abnormal brain development causes intellectual disability and other neurological problems associated with bilateral frontoparietal polymicrogyria.\n\n**Other Names for This Gene**\n\n* 7-transmembrane protein with no EGF-like N-terminal domains-1\n* DKFZp781L1398\n* EGF-TM7-like G protein-coupled receptor 56\n* GPR56\n* GPR56_HUMAN\n* TM7LN4\n* TM7XN1\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: Tests of ADGRG1\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM: ADHESION G PROTEIN-COUPLED RECEPTOR G1; ADGRG1\n* Gene and Variant Databases: NCBI Gene, ClinVar\n\n**References**\n\n* Iguchi T, Sakata K, Yoshizaki K, Tago K, Mizuno N, Itoh H. Orphan G protein-coupled receptor GPR56 regulates neural progenitor cell migration via a G alpha 12/13 and Rho pathway. J Biol Chem. 2008 May 23;283(21):14469-78.\n* Jin Z, Tietjen I, Bu L, Liu-Yesucevitz L, Gaur SK, Walsh CA, Piao X. Disease-associated mutations affect GPR56 protein trafficking and cell surface expression. Hum Mol Genet. 2007 Aug 15;16(16):1972-85.\n* Ke N, Ma H, Diedrich G, Chionis J, Liu G, Yu DH, Wong-Staal F, Li QX. Biochemical characterization of genetic mutations of GPR56 in patients with bilateral frontoparietal polymicrogyria (BFPP). Biochem Biophys Res Commun. 2008 Feb 8;366(2):314-20.\n* Ke N, Sundaram R, Liu G, Chionis J, Fan W, Rogers C, Awad T, Grifman M, Yu D, Wong-Staal F, Li QX. Orphan G protein-coupled receptor GPR56 plays a role in cell transformation and tumorigenesis involving the cell adhesion pathway. Mol Cancer Ther. 2007 Jun;6(6):1840-50.\n* Li S, Jin Z, Koirala S, Bu L, Xu L, Hynes RO, Walsh CA, Corfas G, Piao X. GPR56 regulates pial basement membrane integrity and cortical lamination. J Neurosci. 2008 May 28;28(22):5817-26.\n* Liu M, Parker RM, Darby K, Eyre HJ, Copeland NG, Crawford J, Gilbert DJ, Sutherland GR, Jenkins NA, Herzog H. GPR56, a novel secretin-like human G-protein-coupled receptor gene. Genomics. 1999 Feb 1;55(3):296-305.\n* Parrini E, Ferrari AR, Dorn T, Walsh CA, Guerrini R. Bilateral frontoparietal polymicrogyria, Lennox-Gastaut syndrome, and GPR56 gene mutations. Epilepsia. 2009 Jun;50(6):1344-53.\n\n---\n\n**ADGRG1 Gene**\n\n**Genomic Location**\nThe ADGRG1 gene is found on chromosome 16.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ADHD Screening: MedlinePlus Medical Test",
    "url": "https://medlineplus.gov/lab-tests/adhd-screening/",
    "content": "**ADHD Screening**\n\n**What is ADHD screening?**\n\nADHD screening, also called ADHD testing, helps find out if a child, teen, or adult has ADHD (attention deficit hyperactivity disorder). It's used to check for ADHD in people who have frequent, serious problems with attention, hyperactivity, and/or impulsive behavior.\n\n**Types of ADHD**\n\nThere are three types of ADHD:\n\n* Mostly Inattentive ADHD: trouble paying attention and being easily distracted\n* Mostly Hyperactive-Impulsive ADHD: symptoms of both hyperactivity and impulsivity (e.g., fidgeting, interrupting others)\n* Combined ADHD: a mix of inattention and hyperactive-impulsive symptoms\n\n**Why do I need ADHD screening?**\n\nYou may need screening if you or someone else notices symptoms of ADHD, such as:\n\n* Attention problems:\n\t+ Missing details or making careless mistakes\n\t+ Trouble staying focused on tasks\n\t+ Not seeming to listen when spoken to directly\n\t+ Difficulty following instructions or finishing tasks\n\t+ Avoiding tasks that require long periods of mental effort\n\t+ Losing important items\n\t+ Forgetting daily activities\n* Hyperactivity-impulsivity:\n\t+ Fidgeting and squirming while seated\n\t+ Getting up when staying seated is expected\n\t+ Running around or climbing (children) or feeling restless (teens and adults)\n\t+ Trouble doing quiet activities\n\t+ Constant movement or \"on the go\"\n\t+ Talking too much\n\t+ Blurring out answers before questions are completed\n\t+ Interrupting others\n\n**What happens during an ADHD screening?**\n\nThe general screening process involves several steps:\n\n1. Physical exam: checking for certain health conditions that can cause symptoms similar to ADHD.\n2. Review of medical history, family health history, and other records.\n3. Gathering information using standardized ADHD symptom checklists, questionnaires, and/or interview questions.\n4. Screening for other mental health disorders.\n\n**Will I need to do anything to prepare for ADHD screening?**\n\nYou usually don't need any special preparations for ADHD screening. Your provider will let you know what health and school records you may need to gather.\n\n**Are there any risks to screening?**\n\nThere is no risk to a physical exam, written test, or questionnaire.\n\n**What do the results mean?**\n\nThe provider will write up the results of an ADHD screening in a report that includes a diagnosis. To diagnose ADHD, the screening must find:\n\n* Several symptoms of ADHD that began before age 12.\n* Several symptoms of inattention and/or hyperactivity-impulsivity that have lasted for at least 6 months and cause serious problems.\n* Symptoms that happen in 2 or more settings (e.g., at home and at work or school).\n* Symptoms that clearly get in the way of functioning well at school, work, and/or in social situations.\n\nIf there is a diagnosis of ADHD, the report will include the type of ADHD (inattentive, hyperactive-impulsive, or combined) and whether it's mild, moderate, or severe. Any other disorders that may have been found will be included in the report.\n\n---\n\n**ADHD Screening**\n\nThere's no cure for ADHD, but treatment may help reduce symptoms. Treatment may include medicine, talk therapy, behavioral therapy, and lifestyle changes. Usually, two or more treatments are combined. Parents of children with ADHD may also receive training to help their children manage ADHD.\n\n**What is ADHD?**\n\nADHD stands for attention deficit hyperactivity disorder. It used to be called ADD (attention-deficit disorder). A person who has ADHD has a hard time paying attention and focusing on tasks. ADHD is a common developmental disorder that begins in childhood and often lasts into adulthood. Although it's usually diagnosed in childhood, some people with ADHD don't get diagnosed with ADHD until they are adults.\n\n**Types of ADHD**\n\nThere are three types of ADHD:\n\n* Mostly Inattentive ADHD: People have trouble paying attention and are easily distracted.\n* Mostly Hyperactive-Impulsive ADHD: People have symptoms of both hyperactivity and impulsivity, including a need to always be moving and trouble controlling their actions and words.\n* Combined ADHD: People have a mix of inattentive and hyperactive-impulsive symptoms.\n\n**Why is ADHD Screening Important?**\n\nADHD screening is used to check for ADHD in people who have frequent, serious problems with attention, hyperactivity, and/or impulsive behavior. The screening also checks for other mental disorders that often happen with ADHD. Sometimes symptoms of these other disorders are mistaken for ADHD.\n\n**Who Needs ADHD Screening?**\n\n* Children as young as age four\n* Adults who have had challenges since childhood (before age 12) with focusing, impulsive behavior, restlessness, and/or being organized\n\n**Symptoms of ADHD**\n\nPeople with symptoms of attention problems may often:\n\n* Miss details or make careless mistakes in schoolwork, at work, or in other activities\n* Have trouble staying focused on play activities or work tasks\n* Not seem to listen when spoken to directly\n* Find it hard to follow instructions or finish tasks, or may start but get easily sidetracked\n* Have trouble being organized, keeping belongings in order, and managing time\n* Avoid doing tasks that require long periods of mental effort\n* Lose important items, such as books, wallets, keys, eyeglasses, and cellphones\n* Forget about doing daily activities\n\nPeople with symptoms of hyperactivity-impulsivity may often:\n\n* Fidget and squirm while seated\n* Get up when staying seated is expected, such as at school or work\n* Run around or climb when it's not appropriate (children) or feel restless (teens and adults)\n* Have trouble doing quiet activities\n* Be constantly moving or \"on the go\"\n* Talk much more than is normal\n* Blurt out answers before questions are completed\n* Have trouble waiting for their turn\n* Interrupt others, for example during conversations or games\n\n**What Happens During an ADHD Screening?**\n\nThe general screening process involves several steps. A primary care provider may do the entire screening or refer the person to a mental health provider. A mental health provider is a health care professional who specializes in diagnosing and treating mental health problems.\n\nDuring an ADHD screening, the provider will:\n\n* Gather information about the person's symptoms and behavior\n* Do tests to help diagnose the cause of the person's symptoms\n* Follow a set of professional guidelines for gathering information, doing tests, and diagnosing the cause of a person's symptoms\n\n---\n\n**ADHD Screening**\n\nIf you suspect that you or your child has ADHD, it's essential to see a mental health provider. A mental health provider is a healthcare professional who specializes in diagnosing and treating mental health problems.\n\n**The Screening Process**\n\nDuring an ADHD screening, the provider will:\n\n* Do a physical exam. An exam by a primary care provider checks for certain health conditions that can cause symptoms similar to ADHD. The exam may include vision and hearing tests (for children and adults), thyroid tests, and other tests.\n* Review medical history, family health history, and other records. The cause of ADHD isn't known, but it often runs in families. So, family history is important. The results of any past tests and school reports provide valuable information, too. For adults, old school records can help a provider find out if symptoms began in childhood.\n* Gather information using standardized ADHD symptom checklists, questionnaires, and/or interview questions. A provider will use one or more tools to gather, organize, and evaluate information during an ADHD screening. These tools have rating scales (scoring systems) that help the provider see if a person's symptoms and history fit a diagnosis of ADHD.\n\n**The Screening Process for Children**\n\nFor children, the screening process involves:\n\n* Interviewing the child about their symptoms. Questions and activities are geared toward their age.\n* Gathering information from others, such as:\n\t+ Teachers\n\t+ Babysitters\n\t+ Coaches\n\t+ Other family members who spend time with the child\n\t+ Parents completing checklists and/or questionnaires\n\n**The Screening Process for Adults**\n\nFor adults, the screening process involves:\n\n* Interviewing the adult about their symptoms.\n* Gathering information from others, such as:\n\t+ Family members who know the person from childhood\n\t+ Spouses\n\t+ Friends\n\t+ Co-workers\n\n**Screening for Other Mental Health Disorders**\n\nPeople who have ADHD often have other mental health disorders. It's also possible that another disorder, and not ADHD, is causing symptoms. So, mental health screening tests are often done as needed to check for conditions such as anxiety, depression, and bipolar disorder.\n\n**Preparing for the Screening**\n\nYou usually don't need any special preparations for ADHD screening. Your provider will let you know what health and school records you may need to gather.\n\n**Risks of the Screening**\n\nThere is no risk to a physical exam, written test, or questionnaire.\n\n**Interpreting the Results**\n\nThe provider will usually write up the results of an ADHD screening in a report that includes a diagnosis. To diagnose ADHD, the screening must find all of these things:\n\n* Several symptoms of ADHD that began before age 12.\n* Several symptoms of inattention and/or hyperactivity-impulsivity that have lasted for at least 6 months and cause serious problems.\n* Symptoms that happen in 2 or more settings (e.g., at home and at work or school).\n* Symptoms that clearly get in the way of functioning well at school, work, and/or in social situations.\n\nIf there is a diagnosis of ADHD, the report will include the type of ADHD (inattentive, hyperactive-impulsive, or combined). It will also say whether ADHD is mild, moderate, or severe. Any other disorders that may have been found will be included in the report.\n\n**Treatment**\n\nThere's no cure for ADHD, but treatment may help reduce symptoms. Treatment may include medicine, talk therapy, behavioral therapy, and lifestyle changes. Usually, two or more treatments are combined. Parents of children with ADHD may also receive training to help their children manage ADHD.\n\n---\n\n**ADHD Screening**\n\n\\n\\n\n\n**What is ADHD?**\n\nAttention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity. It affects both children and adults, and its exact cause is still unknown.\n\n\\n\\n\n\n**Symptoms of ADHD**\n\nThe symptoms of ADHD can vary from person to person, but common ones include:\n\n*   Inattention: difficulty paying attention to details, following instructions, or completing tasks\n*   Hyperactivity: excessive fidgeting, running, or feeling constantly \"on the go\"\n*   Impulsivity: difficulty controlling impulses, leading to impulsive behaviors such as interrupting others or blurting out answers\n\n\\n\\n\n\n**Diagnosing ADHD**\n\nTo diagnose ADHD, healthcare providers typically use a combination of:\n\n*   Clinical evaluation: a thorough medical and psychological examination\n*   Behavioral observations: observing the child's behavior in different settings\n*   Rating scales: using standardized questionnaires to assess symptoms and their impact on daily life\n\n\\n\\n\n\n**Treatment Options for ADHD**\n\nWhile there is no cure for ADHD, various treatment options can help manage its symptoms. These include:\n\n*   Medications: stimulants, non-stimulants, or combination therapy\n*   Behavioral therapies: behavioral modification, cognitive-behavioral therapy (CBT), or parent training\n*   Lifestyle changes: regular exercise, balanced diet, sufficient sleep, and stress management\n\n\\n\\n\n\n**Screening Tools for ADHD**\n\nSeveral screening tools can help identify children at risk of developing ADHD. These include:\n\n*   Vanderbilt Assessment Scale (VAS)\n*   Conners' Rating Scales\n*   Behavior Assessment System for Children (BASC)\n\n\\n\\n\n\n**When to Seek Help**\n\nIf you suspect your child might have ADHD, don't hesitate to consult a healthcare provider. Early detection and intervention can make a significant difference in their quality of life.\n\n\\n\\n\n\n**Related Health Topics**\n\n*   Attention Deficit Hyperactivity Disorder\n*   Child Mental Health\n*   Mental Disorders\n*   Mental Health",
    "category": "health"
  },
  {
    "title": "ADNP gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/adnp/",
    "content": "**ADNP Gene**\n\nThe ADNP gene provides instructions for making a protein that helps control the activity (expression) of other genes through a process called chromatin remodeling. Chromatin is the network of DNA and protein that packages DNA into chromosomes.\n\n**Normal Function**\n\n* The ADNP protein attaches to DNA and interacts with groups of proteins called SWI/SNF complexes, which direct changes in the structure of chromatin.\n* By regulating gene expression, the ADNP protein is involved in many aspects of development, including normal brain development.\n* It likely controls the activity of genes that direct the development and function of other body systems.\n\n**Health Conditions Related to Genetic Changes**\n\n* **ADNP Syndrome**\n\t+ At least 22 ADNP gene mutations have been found to cause ADNP syndrome.\n\t+ This condition features intellectual disability and autism spectrum disorder, which is characterized by impaired communication and social interactions.\n\t+ Affected individuals can also have distinctive facial features and a wide variety of other signs and symptoms.\n\t+ Most ADNP gene mutations are thought to lead to the production of an abnormally short ADNP protein.\n\t+ Although it is unclear how these genetic changes cause ADNP syndrome, researchers speculate that the abnormally short protein can attach to DNA but cannot interact with SWI/SNF complexes.\n\t+ As a result, chromatin remodeling is impaired, leading to disturbance in the activity of many genes and disruption in the development or function of several body tissues and organs, including the brain.\n\n---\n\n**ADNP Gene**\n\n**Autism Spectrum Disorder**\n\nMedlinePlus Genetics provides information about Autism spectrum disorder.\n\n**ADNP Syndrome**\n\nAt least 22 ADNP gene mutations have been found to cause ADNP syndrome. This condition features intellectual disability and autism spectrum disorder, which is characterized by impaired communication and social interactions. Affected individuals can also have distinctive facial features and a wide variety of other signs and symptoms. Most ADNP gene mutations are thought to lead to the production of an abnormally short ADNP protein.\n\nAlthough it is unclear how these genetic changes cause ADNP syndrome, researchers speculate that the abnormally short protein can attach to DNA but cannot interact with SWI/SNF complexes. As a result, chromatin remodeling is impaired. Disturbance of this process alters the activity of many genes and disrupts the development or function of several of the body's tissues and organs, including the brain.\n\nThese changes likely explain the intellectual disability, autism spectrum disorder, and other diverse signs and symptoms of ADNP syndrome.\n\n**Other Names for This Gene**\n\n* Activity-dependent neuroprotective protein\n* Activity-dependent neuroprotector\n* Activity-dependent neuroprotector homeobox protein\n* ADNP homeobox 1\n* ADNP1\n* HVDAS\n* KIAA0784\n* MRD28\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry:\n\t+ Tests of ADNP\n* Scientific Articles on PubMed:\n\t+ PubMed\n* Catalog of Genes and Diseases from OMIM:\n\t+ ACTIVITY-DEPENDENT NEUROPROTECTOR HOMEOBOX; ADNP\n* Gene and Variant Databases:\n\t+ NCBI Gene\n\t+ ClinVar\n\n**References**\n\n* Helsmoortel C, Vulto-van Silfhout AT, Coe BP, Vandeweyer G, Rooms L, van den Ende J, Schuurs-Hoeijmakers JH, Marcelis CL, Willemsen MH, Vissers LE, Yntema HG, Bakshi M, Wilson M, Witherspoon KT, Malmgren H, Nordgren A, Anneren G, Fichera M, Bosco P, Romano C, de Vries BB, Kleefstra T, Kooy RF, Eichler EE, Van der Aa N. A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP. Nat Genet. 2014 Apr;46(4):380-4.\n* Malishkevich A, Leyk J, Goldbaum O, Richter-Landsberg C, Gozes I. ADNP/ADNP2 expression in oligodendrocytes: implication for myelin-related neurodevelopment. J Mol Neurosci. 2015 Oct;57(2):304-13.\n* Mandel S, Rechavi G, Gozes I. Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol. 2007 Mar 15;303(2):814-24.\n* Vandeweyer G, Helsmoortel C, Van Dijck A, Vulto-van Silfhout AT, Coe BP, Bernier R, Gerdts J, Rooms L, van den Ende J, Bakshi M, Wilson M, Nordgren A, Hendon LG, Abdulrahman OA, Romano C, de Vries BB, Kleefstra T, Eichler EE, Van der Aa N, Kooy RF. The transcriptional regulator ADNP links the BAF (SWI/SNF) complexes with autism. Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):315-26.\n\n---\n\n**ADNP Gene**\n\n**Genomic Location**\nThe ADNP gene is found on chromosome 20.\n\n*   **Related Health Topics**\n    *   Genes and Gene Therapy\n    *   Genetic Disorders\n\n**Citations**\n\n*   Mandel S, Spivak-Pohis I, Gozes I. ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. J Mol Neurosci. 2008 Jun;35(2):127-41. doi: 10.1007/s12031-007-9013-y. Epub 2008 Feb 20. Citation on PubMed\n*   Vandeweyer G, Helsmoortel C, Van Dijck A, Vulto-van Silfhout AT, Coe BP, Bernier R, Gerdts J, Rooms L, van den Ende J, Bakshi M, Wilson M, Nordgren A, Hendon LG, Abdulrahman OA, Romano C, de Vries BB, Kleefstra T, Eichler EE, Van der Aa N, Kooy RF. The transcriptional regulator ADNP links the BAF (SWI/SNF) complexes with autism. Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):315-26. doi: 10.1002/ajmg.c.31413. Epub 2014 Aug 28. Citation on PubMed or Free article on PubMed Central",
    "category": "general"
  },
  {
    "title": "ADNP syndrome: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/condition/adnp-syndrome/",
    "content": "**ADNP Syndrome**\n\nADNP syndrome is a condition that causes a wide variety of signs and symptoms. Its hallmark features are intellectual disability and autism spectrum disorder, which is characterized by impaired communication and social interaction. Affected individuals also have distinctive facial features and abnormalities of multiple body systems.\n\n* **Intellectual Disability**: Individuals with ADNP syndrome have mild to severe intellectual disability and delayed development of speech and motor skills such as sitting and walking.\n* **Autism Spectrum Disorder**: People with this disorder exhibit characteristics typical of autism spectrum disorder, including repetitive behaviors and difficulty with social interactions.\n* **Mood Disorders or Behavioral Problems**: ADNP syndrome is also associated with mood disorders or behavioral problems, such as anxiety, temper tantrums, attention-deficit/hyperactivity disorder (ADHD), obsessive-compulsive disorder, or sleep problems.\n\n**Distinctive Facial Features**\n\nMany people with ADNP syndrome have distinctive facial features, which most commonly include:\n\n* A prominent forehead\n* A high hairline\n* Outside corners of the eyes that point upward or downward (upslanting or downslanting palpebral fissures)\n* Droopy eyelids (ptosis)\n* A broad nasal bridge\n* A thin upper lip\n\nThese individuals may also have unusually shaped ears or hand and finger abnormalities.\n\n**Other Features**\n\nADNP syndrome is associated with various other features, including:\n\n* Eye and vision abnormalities, such as strabismus and farsightedness (hyperopia)\n* Early appearance (eruption) of primary (baby) teeth\n* Weak muscle tone (hypotonia) and feeding difficulties in infancy\n* Digestive system problems, such as gastroesophageal reflux, vomiting, and constipation\n* Obesity, seizures, and heart abnormalities\n\n---\n\n**ADNP Syndrome**\n\n**What is ADNP Syndrome?**\n\nADNP syndrome is a rare genetic disorder characterized by intellectual disability, autism spectrum disorder, and other diverse signs and symptoms.\n\n**Common Features**\n\n* Intellectual disability\n* Autism spectrum disorder\n* Distinctive facial features:\n\t+ Prominent forehead\n\t+ High hairline\n\t+ Upslanting or downslanting palpebral fissures (outside corners of the eyes)\n\t+ Droopy eyelids (ptosis)\n\t+ Broad nasal bridge\n\t+ Thin upper lip\n\t+ Unusually shaped ears or hand and finger abnormalities\n* Eye and vision abnormalities:\n\t+ Eyes that do not point in the same direction (strabismus)\n\t+ Farsightedness (hyperopia)\n\t+ Early appearance of primary (baby) teeth\n\n**Other Features**\n\n* Weak muscle tone (hypotonia)\n* Feeding difficulties in infancy\n* Digestive system problems:\n\t+ Backflow of stomach acids into the esophagus (gastroesophageal reflux)\n\t+ Vomiting\n\t+ Constipation\n* Obesity\n* Seizures\n* Heart abnormalities\n\n**Causes**\n\nADNP syndrome is caused by mutations in the ADNP gene. The protein produced from this gene helps control the activity of other genes through chromatin remodeling.\n\n**Inheritance**\n\nADNP syndrome is not inherited. It results from new (de novo) mutations in the ADNP gene that occur during the formation of reproductive cells or in early embryonic development.\n\n**Frequency**\n\nThe prevalence of ADNP syndrome is unknown, but it is estimated to account for 0.17 percent of all cases of autism spectrum disorder.\n\n---\n\n**ADNP Syndrome**\n\n**What is ADNP syndrome?**\n\nADNP syndrome is a rare genetic disorder caused by mutations in the ADNP gene. It affects various aspects of development, including reproductive cell formation and early embryonic development.\n\n**Is ADNP syndrome inherited?**\n\nNo, ADNP syndrome is not inherited. It results from new (de novo) mutations in the ADNP gene that occur during reproductive cell formation or early embryonic development.\n\n**Other names for this condition**\n\n* ADNP-related intellectual disability and autism spectrum disorder\n* ADNP-related multiple congenital anomalies-intellectual disability-autism spectrum disorder\n* Helsmoortel-van der Aa syndrome (HVDAS)\n* Mental retardation, autosomal dominant 28 (MRD28)\n\n**Additional information & resources**\n\n* Genetic Testing Information: Genetic Testing Registry: ADNP-related multiple congenital anomalies - intellectual disability - autism spectrum disorder\n* Genetic and Rare Diseases Information Center: ADNP syndrome\n* Patient Support and Advocacy Resources: National Organization for Rare Disorders (NORD)\n* Clinical Trials: ClinicalTrials.gov\n* Catalog of Genes and Diseases from OMIM: HELSMOORTEL-VAN DER AA SYNDROME; HVDAS\n* Scientific Articles on PubMed: PubMed\n\n**References**\n\n* Gozes I, Van Dijck A, Hacohen-Kleiman G, Grigg I, Karmon G, Giladi E, Eger M, Gabet Y, Pasmanik-Chor M, Cappuyns E, Elpeleg O, Kooy RF, Bedrosian-Sermone S. Premature primary tooth eruption in cognitive/motor-delayed ADNP-mutated children. Transl Psychiatry. 2017 Feb 21;7(2):e1043.\n* Helsmoortel C, Vulto-van Silfhout AT, Coe BP, Vandeweyer G, Rooms L, van den Ende J, Schuurs-Hoeijmakers JH, Marcelis CL, Willemsen MH, Vissers LE, Yntema HG, Bakshi M, Wilson M, Witherspoon KT, Malmgren H, Nordgren A, Anneren G, Fichera M, Bosco P, Romano C, de Vries BB, Kleefstra T, Kooy RF, Eichler EE, Van der Aa N. A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP. Nat Genet. 2014 Apr;46(4):380-4.\n* Krajewska-Walasek M, Jurkiewicz D, Piekutowska-Abramczuk D, Kucharczyk M, Chrzanowska KH, Jezela-Stanek A, Ciara E. Additional data on the clinical phenotype of Helsmoortel-Van der Aa syndrome associated with a novel truncating mutation in ADNP gene. Am J Med Genet A. 2016 Jun;170(6):1647-50.\n* Pescosolido MF, Schwede M, Johnson Harrison A, Schmidt M, Gamsiz ED, Chen WS, Donahue JP, Shur N, Jerskey BA, Phornphutkul C, Morrow EM. Expansion of the clinical phenotype associated with mutations in activity-dependent neuroprotective protein. J Med Genet. 2014 Sep;51(9):587-9.\n* Van Dijck A, Vandeweyer G, Kooy F. ADNP-Related Disorder. 2016 Apr 7 [updated 2022 Oct 6]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025.\n* Vandeweyer G, Helsmoortel C, Van Dijck A, Vulto-van Silfhout AT, Coe BP, Bernier R, Gerdts J, Rooms L, van den Ende J, Bakshi M, Wilson M, Nordgren A, Hendon LG, Abdulrahman OA, Romano C, de Vries BB, Kleefstra T, Eichler EE, Van der Aa N, Kooy RF. The transcriptional regulator ADNP links the BAF (SWI/SNF) complexes with autism. Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):315-26.\n\n---\n\n**ADNP Syndrome**\n\n\\n\\n\n\n*   **Article:** a N, Kooy RF. The transcriptional regulator ADNP links the BAF (SWI/SNF) complexes with autism. Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):315-26.\n    doi: 10.1002/ajmg.c.31413. Epub 2014 Aug 28. Citation on PubMed or Free article on PubMed Central\n\n\\n\\n\n\n**Understanding Genetics**\n\n*   **Prognosis of a genetic condition:** The prognosis of a genetic condition depends on various factors, including the severity of the disorder, the effectiveness of treatment, and the individual's overall health.\n*   **Gene variants and health:** Gene variants can affect health and development in numerous ways, such as influencing susceptibility to certain diseases or affecting physical characteristics.\n*   **Family history:** If a disorder seems to run in your family, it may indicate a genetic component. However, many factors contribute to the development of a genetic condition, including environmental influences and random chance.\n*   **Inheritance patterns:** Genetic conditions can be inherited through various mechanisms, such as autosomal dominant, autosomal recessive, X-linked, or mitochondrial inheritance.\n*   **Treatment and management:** Genetic conditions are often treated or managed through a combination of medical interventions, lifestyle modifications, and supportive care.\n\n\\n\\n\n\n**Related Health Topics**\n\n*   Autism Spectrum Disorder\n*   Developmental Disabilities\n*   Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ADSL gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/adsl/",
    "content": "**ADSL Gene**\n\nThe ADSL gene provides instructions for making an enzyme called adenylosuccinate lyase. This enzyme performs two steps in the process that produces (synthesizes) purine nucleotides. These nucleotides are building blocks of DNA, its chemical cousin RNA, and molecules such as ATP that serve as energy sources in the cell.\n\n**Normal Function**\n\nThe ADSL gene provides instructions for making an enzyme called adenylosuccinate lyase. This enzyme performs two steps in the process that produces (synthesizes) purine nucleotides. These nucleotides are building blocks of DNA, its chemical cousin RNA, and molecules such as ATP that serve as energy sources in the cell.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Adenylosuccinate Lyase Deficiency**\n    More than 50 mutations in the ADSL gene have been found to cause adenylosuccinate lyase deficiency. This condition causes brain dysfunction (encephalopathy) that leads to delayed development of mental and motor skills (psychomotor delay), autistic behaviors that affect communication and social interaction, and seizures.\n\n        Most of the mutations involved in this condition change single protein building blocks (amino acids) in the adenylosuccinate lyase enzyme. The altered enzymes have two to 20 percent of normal function, and studies suggest they are less able to form stable purinosomes.\n\n        A reduction of adenylosuccinate lyase function, possibly due to a shortage of purinosomes, leads to buildup of SAICAR and SAMP. These substances are converted through a different reaction to succinylaminoimidazole carboxamide riboside (SAICAr) and succinyladenosine (S-Ado). Detection of these substances in body fluids can help with diagnosis of adenylosuccinate lyase deficiency.\n\n        Researchers believe that SAICAr and S-Ado are toxic; damage to brain tissue caused by one or both of these substances likely underlies the neurological problems that occur in adenylosuccinate lyase deficiency.\n\n---\n\n**ADSL Gene: MedlinePlus Genetics (Part 2/3)**\n\n**Category:** general\n\n**Content:**\n\n*   The neurological problems that occur in adenylosuccinate lyase deficiency are explained.\n*   Studies suggest that the amount of SAICAr relative to S-Ado reflects the severity of adenylosuccinate lyase deficiency. Individuals with more SAICAr than S-Ado have more severe encephalopathy and psychomotor delay.\n\n**More Than 50 Mutations in the ADSL Gene Have Been Found to Cause Adenylosuccinate Lyase Deficiency**\n\n*   This condition causes brain dysfunction (encephalopathy) that leads to delayed development of mental and motor skills (psychomotor delay), autistic behaviors that affect communication and social interaction, and seizures.\n*   Most of the mutations involved in this condition change single protein building blocks (amino acids) in the adenylosuccinate lyase enzyme. The altered enzymes have two to 20 percent of normal function, and studies suggest they are less able to form stable purinosomes.\n\n**A Reduction of Adenylosuccinate Lyase Function Leads to Buildup of SAICAR and SAMP**\n\n*   These substances are converted through a different reaction to succinylaminoimidazole carboxamide riboside (SAICAr) and succinyladenosine (S-Ado). Detection of these substances in body fluids can help with diagnosis of adenylosuccinate lyase deficiency.\n*   Researchers believe that SAICAr and S-Ado are toxic; damage to brain tissue caused by one or both of these substances likely underlies the neurological problems that occur in adenylosuccinate lyase deficiency.\n\n**Studies Suggest That the Amount of SAICAr Relative to S-Ado Reflects the Severity of Adenylosuccinate Lyase Deficiency**\n\n*   Individuals with more SAICAr than S-Ado have more severe encephalopathy and psychomotor delay.\n\n**Other Names for This Gene**\n\n*   adenylosuccinase\n*   adenylosuccinate lyase isoform a\n*   adenylosuccinate lyase isoform b\n*   AMPS\n*   ASASE\n*   ASL\n\n**Additional Information & Resources**\n\n*   Tests Listed in the Genetic Testing Registry:\n    *   Tests of ADSL\n*   Scientific Articles on PubMed:\n    *   PubMed\n*   Catalog of Genes and Diseases from OMIM:\n    *   ADENYLOSUCCINATE LYASE; ADSL\n*   Gene and Variant Databases:\n    *   NCBI Gene\n    *   ClinVar\n\n**References**\n\n*   Ariyananda Lde Z, Lee P, Antonopoulos C, Colman RF. Biochemical and biophysical analysis of five disease-associated human adenylosuccinate lyase mutants. Biochemistry. 2009 Jun 16;48(23):5291-302. doi: 10.1021/bi802321m. Citation on PubMed or Free article on PubMed Central\n*   Baresova V, Skopova V, Sikora J, Patterson D, Sovova J, Zikanova M, Kmoch S. Mutations of ATIC and ADSL affect purinosome assembly in cultured skin fibroblasts from patients with AICA-ribosiduria and ADSL deficiency. Hum Mol Genet. 2012 Apr 1;21(7):1534-43. doi: 10.1093/hmg/ddr591. Epub 2011 Dec 16.\n*   Ray SP, Deaton MK, Capodagli GC, Calkins LA, Sawle L, Ghosh K, Patterson D, Pegan SD. Structural and biochemical characterization of human adenylosuccinate lyase (ADSL) and the R303C ADSL deficiency-associated mutation. Biochemistry. 2012 Aug 21;51(33):6701-13. doi: 10.1021/bi300796y. Epub 2012 Aug 7. Citation on PubMed or Free article on PubMed Central\n*   Zikanova M, Skopova V, Hnizda A, Krijt J, Kmoch S. Biochemical and structural analysis of 14 mutant adsl enzyme complexes and correlation to phenotypic heterogeneity of adenylosuccinate lyase deficiency. Hum Mutat. 2010 Apr;31(4):445-55. doi: 10.1002/humu.21212.\n\n**Genomic Location**\n\n*   The ADSL gene is found on chromosome 22.\n\n**Related Health Topics**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders\n\n---\n\n**ADSL Gene**\n\n**Genomic Location**\nThe ADSL gene is found on chromosome 22.\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n\\n\\n\n\n**Disclaimers**\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "AFF2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/aff2/",
    "content": "**AFF2 Gene**\n\nThe **AFF2 gene** provides instructions for making a protein that is found in the nucleus of cells but whose function is not well understood. Some studies suggest that it acts as a transcription factor, which means that it attaches (binds) to specific regions of DNA and helps control the activity of other genes, although the identity of these genes is unknown. Other studies show that the protein can attach to specific regions of messenger RNA (mRNA), which is a chemical cousin of DNA that serves as the genetic blueprint for protein production. It is thought that the AFF2 protein helps control the process by which the mRNA blueprint is cut and rearranged to produce different versions of proteins (alternative splicing).\n\nOne region of the **AFF2 gene** contains a particular DNA segment known as a CCG trinucleotide repeat, so called because this segment of three DNA building blocks (nucleotides) is repeated multiple times within the gene. In most people, the number of CCG repeats ranges from 6 to about 30.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Fragile XE syndrome**: Variants (also called mutations) in the AFF2 gene cause fragile XE syndrome, a condition characterized by mild intellectual disability and learning difficulties. Nearly all cases are caused by a variant called a CCG trinucleotide repeat expansion, in which the CCG trinucleotide is abnormally repeated more than 200 times, which makes this region of the gene unstable. As a result, the AFF2 gene is turned off (silenced), and no protein is produced from it. It is unclear how a shortage of this protein leads to problems with intellectual functioning.\n* **Rare deletions**: Rarely, small deletions of genetic material from the AFF2 gene are associated with fragile XE syndrome, although how these deletions affect the protein and lead to intellectual disability is unknown.\n\n**Additional Information & Resources**\n\n* More about fragile XE syndrome: [link]\n\n---\n\n**AFF2 Gene**\n\nThe AFF2 gene is located on the X chromosome.\n\n**Variants in the AFF2 Gene**\n\nVariants in the AFF2 gene cause fragile XE syndrome, a condition characterized by mild intellectual disability and learning difficulties. Nearly all cases are caused by a variant called a CCG trinucleotide repeat expansion, in which the CCG trinucleotide is abnormally repeated more than 200 times, making this region of the gene unstable. As a result, the AFF2 gene is turned off (silenced), and no protein is produced from it.\n\n**Rare Deletions**\n\nRarely, small deletions of genetic material from the AFF2 gene are associated with fragile XE syndrome, although how these deletions affect the protein and lead to intellectual disability is unknown.\n\n**Other Names for This Gene**\n\n* AFF2_HUMAN\n* FMR2\n* FMR2P\n* FRAXE\n* MRX2\n\n**Additional Information & Resources**\n\n* Scientific Articles on PubMed: [PubMed](link)\n* Catalog of Genes and Diseases from OMIM: ALF TRANSCRIPTION ELONGATION FACTOR 2; AFF2\n* Gene and Variant Databases:\n\t+ NCBI Gene (link)\n\t+ ClinVar (link)\n\n**References**\n\n* Bensaid M, Melko M, Bechara EG, Davidovic L, Berretta A, Catania MV, Gecz J, Lalli E, Bardoni B. FRAXE-associated mental retardation protein (FMR2) is an RNA-binding protein with high affinity for G-quartet RNA forming structure. Nucleic Acids Res. 2009 Mar;37(4):1269-79.\n* Gecz J, Gedeon AK, Sutherland GR, Mulley JC. Identification of the gene FMR2, associated with FRAXE mental retardation. Nat Genet. 1996 May;13(1):105-8.\n* Knight SJ, Flannery AV, Hirst MC, Campbell L, Christodoulou Z, Phelps SR, Pointon J, Middleton-Price HR, Barnicoat A, Pembrey ME, et al. Trinucleotide repeat amplification and hypermethylation of a CpG island in FRAXE mental retardation. Cell. 1993 Jul 16;74(1):127-34.\n* Melko M, Bardoni B. The role of G-quadruplex in RNA metabolism: involvement of FMRP and FMR2P. Biochimie. 2010 Aug;92(8):919-26.\n\n**Genomic Location**\n\nThe AFF2 gene is found on the X chromosome.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n---\n\n**AFF2 Gene**\n\n**Genomic Location**\nThe AFF2 gene is found on the X chromosome.\n\n\\n\\n\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders\n\n\\n\\n\n\n* **Understanding Genetics**\n\t+ What is DNA?\n\t+ What is a gene?\n\t+ What is a gene variant and how do variants occur?\n\n\\n\\n\n\n**Disclaimers**\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "AFF4 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/aff4/",
    "content": "**AFF4 Gene**\n\nThe AFF4 gene provides instructions for making part of a protein complex called the super elongation complex (SEC). During embryonic development, the SEC is involved in an activity called transcription, which is the first step in the production of proteins from genes. By re-starting the transcription of certain genes after pauses that normally occur during the process, the SEC helps ensure that development proceeds appropriately before birth.\n\n**Health Conditions Related to Genetic Changes**\n\n* **CHOPS Syndrome**: Mutations in the AFF4 gene cause CHOPS syndrome, a disorder involving multiple abnormalities that are present from birth (congenital). The name \"CHOPS\" is an abbreviation for a list of features of the disorder including cognitive impairment, coarse facial features, heart defects, obesity, lung (pulmonary) involvement, short stature, and skeletal abnormalities.\n* **Cancers**: The AFF4 gene is occasionally involved in chromosomal rearrangements (translocations) that are found in certain blood cancers called infant acute lymphoblastic leukemia and mixed lineage leukemia.\n\n---\n\n**AFF4 Gene**\n\nThe AFF4 gene is involved in chromosomal rearrangements (translocations) that are found in certain blood cancers called infant acute lymphoblastic leukemia and mixed lineage leukemia.\n\n**Cancers**\n\nThe translocations fuse the AFF4 gene with another gene called KMT2A (formerly known as MLL). The fusion gene provides instructions for making an abnormal protein that combines features of the proteins produced from AFF4 and KMT2A. The abnormal protein likely disrupts the transcription elongation function of the SEC, which alters normal gene activity (expression) and results in the uncontrolled growth of cells that occurs in leukemia.\n\n**Other Names for This Gene**\n\n* AF4/FMR2 family, member 4\n* AF5Q31\n* ALL1-fused gene from chromosome 5q31 protein major CDK9 elongation factor-associated protein MCEF\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: Tests of AFF4\n* Scientific Articles on PubMed:\n\t+ Luo Z, Lin C, Shilatifard A. The super elongation complex (SEC) family in transcriptional control. Nat Rev Mol Cell Biol. 2012 Sep;13(9):543-7.\n\t+ Scholz B, Kowarz E, Rossler T, Ahmad K, Steinhilber D, Marschalek R. AF4 and AF4N protein complexes: recruitment of P-TEFb kinase, their interactome and potential functions. Am J Blood Res. 2015 Jun 15;5(1):10-24.\n\t+ Smith E, Lin C, Shilatifard A. The super elongation complex (SEC) and MLL in development and disease. Genes Dev. 2011 Apr 1;25(7):661-72.\n* Catalog of Genes and Diseases from OMIM: ALF TRANSCRIPTION ELONGATION FACTOR 4; AFF4\n* Gene and Variant Databases:\n\t+ NCBI Gene\n\t+ ClinVar\n\n**Genomic Location**\n\nThe AFF4 gene is found on chromosome 5.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n---\n\n**AFF4 Gene**\n\n**Genomic Location**\nThe AFF4 gene is found on chromosome 5.\n\n\\n\\n\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders\n\n\\n\\n\n\n* **Understanding Genetics**\n\t+ What is DNA?\n\t+ What is a gene?\n\t+ What is a gene variant and how do variants occur?\n\n\\n\\n\n\n**Disclaimers**\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "AGA gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/aga/",
    "content": "**AGA Gene**\n\nThe AGA gene provides instructions for producing an enzyme called aspartylglucosaminidase. This enzyme is active in lysosomes, which are structures inside cells that act as recycling centers. Within lysosomes, the enzyme helps break down complex chains of sugar molecules (oligosaccharides) attached to certain proteins (glycoproteins). Specifically, this enzyme cuts (cleaves) glycoproteins between a protein building block (amino acid) called asparagine and a sugar molecule called N-acetylglucosamine. This cut is one of the last steps in breaking down a glycoprotein in the lysosome.\n\n**Health Conditions Related to Genetic Changes**\n\nMany variants (also known as mutations) in the AGA gene have been found to cause aspartylglucosaminuria. This condition primarily affects mental functioning and movement. Aspartylglucosaminuria worsens over time. Most AGA gene variants change one amino acid in aspartylglucosaminidase. One variant, found in 98 percent of people with this condition in Finland, replaces the amino acid cysteine with the amino acid serine at position 163 in the enzyme (written as Cys163Ser or C163S). Many AGA gene variants, including C163S, disrupt the structure of aspartylglucosaminidase, resulting in an enzyme that cannot effectively break down glycoproteins because it cannot make the cut between asparagine and N-acetylglucosamine. A buildup of glycoproteins seems to particularly affect nerve cells in the brain; loss of these cells causes a progressive decline in mental functioning and the other signs and symptoms of aspartylglucosaminuria.\n\n**Other Names for This Gene**\n\nASRG glycosylasparaginase N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase N4-(N-acetyl-beta-glucosaminyl)-L-asparagine amidase\n\n---\n\n**AGA Gene: MedlinePlus Genetics**\n\n**Scientific Articles on PubMed**\n\n*   Aronson NN Jr. Aspartylglycosaminuria: biochemistry and molecular biology. Biochim Biophys Acta. 1999 Oct 8;1455(2-3):139-54. doi: 10.1016/s0925-4439(99)00076-9.\n*   Arvio M, Mononen I. Aspartylglycosaminuria: a review. Orphanet J Rare Dis. 2016 Dec 1;11(1):162. doi: 10.1186/s13023-016-0544-6.\n*   Goodspeed K, Feng C, Laine M, Lund TC. Aspartylglucosaminuria: Clinical Presentation and Potential Therapies. J Child Neurol. 2021 Apr;36(5):403-414. doi: 10.1177/0883073820980904.\n*   Saarela J, Laine M, Oinonen C, von Schantz C, Jalanko A, Rouvinen J, Peltonen L. Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations. Hum Mol Genet. 2001 Apr 15;10(9):983-95. doi: 10.1093/hmg/10.9.983.\n*   Saarela J, Oinonen C, Jalanko A, Rouvinen J, Peltonen L. Autoproteolytic activation of human aspartylglucosaminidase. Biochem J. 2004 Mar 1;378(Pt 2):363-71. doi: 10.1042/BJ20031496.\n\n**Catalog of Genes and Diseases from OMIM**\n\n*   ASPARTYLGLUCOSAMINIDASE; AGA\n\n**Gene and Variant Databases**\n\n*   NCBI Gene\n*   ClinVar\n\n**Tests Listed in the Genetic Testing Registry**\n\n*   Tests of AGA\n\n**Genomic Location**\n\nThe AGA gene is found on chromosome 4.\n\n**Related Health Topics**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders",
    "category": "general"
  },
  {
    "title": "AGL gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/agl/",
    "content": "**AGL Gene**\n\nThe AGL gene provides instructions for making the glycogen debranching enzyme. This enzyme is involved in the breakdown of a complex sugar called glycogen, which is a major source of stored energy in the body.\n\n* **Normal Function**\n\t+ The AGL gene provides instructions for making several different versions (isoforms) of the glycogen debranching enzyme.\n\t+ These isoforms vary by size and are active (expressed) in different tissues.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Glycogen Storage Disease Type III**\n\t+ Approximately 100 variants (also called mutations) in the AGL gene have been found to cause glycogen storage disease type III (also called GSDIII or Cori disease).\n\t+ Most of these variants lead to a premature stop signal in the instructions for making the glycogen debranching enzyme, resulting in a nonfunctional enzyme.\n\t+ As a result, the side chains of glycogen molecules cannot be removed and abnormal, partially broken down glycogen molecules are stored within cells.\n\t+ A buildup of abnormal glycogen damages organs and tissues throughout the body, particularly the liver and muscles, leading to the signs and symptoms of GSDIII.\n\n---\n\n**AGL Gene**\n\n**What is the AGL gene?**\n\nThe AGL gene provides instructions for making an enzyme called glycogen debranching enzyme, which plays a crucial role in breaking down glycogen, a complex carbohydrate stored in cells. This enzyme helps to remove side chains from glycogen molecules, allowing them to be properly processed and utilized by the body.\n\n**Variants of the AGL Gene**\n\nApproximately 100 variants (also called mutations) in the AGL gene have been found to cause glycogen storage disease type III (GSDIII or Cori disease). Most of these variants lead to a premature stop signal in the instructions for making the glycogen debranching enzyme, resulting in a nonfunctional enzyme.\n\n**Effects of Variants on the Body**\n\nA buildup of abnormal glycogen damages organs and tissues throughout the body, particularly the liver and muscles, leading to the signs and symptoms of GSDIII. Variants in the AGL gene can affect different isoforms of the enzyme, depending on where the variants are located in the gene.\n\n**Other Names for This Gene**\n\n* amylo-1, 6-glucosidase\n* 4-alpha-glucanotransferase\n* GDE\n* glycogen debrancher\n* glycogen debranching enzyme\n\n**Genomic Location**\n\nThe AGL gene is found on chromosome 1.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  }
]